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Summary 
 
Chronic Obstructive Pulmonary Disease 
(COPD) is mainly caused by cigarette 
smoking and is characterized by an 
abnormal inflammatory reaction in the 
airways and lung parenchyma and 
destruction of lung parenchyma or 
emphysema. There is substantial evidence 
that this exaggerated accumulation of 
inflammatory cells is largely orchestrated 
by chemokines and their respective 
chemokine receptors. Additionally, the 
pulmonary inflammation in COPD may be 
initiated or even maintained by the 
signalling of pathogen recognition 
receptors (PRRs). Enhanced release of 
proteases by inflammatory cells may 
subsequently lead to an imbalance 
between proteolytic and antiproteolytic 
activity, contributing to the development of 
pulmonary emphysema. 
To unravel these hypotheses we used a 
murine COPD model. In this model, mice 
are exposed to cigarette smoke and 
display several hallmarks of human 
COPD. Subacute (1 month) exposure 
already leads to a significant increase in 
cells of both the innate and adaptive 
immune system in bronchoalveolar lavage 
and lung tissue. Upon chronic (6 months) 
exposure there is also significant 
development of pulmonary emphysema, 
lymphoid follicle formation and airway wall 
remodeling. 
Mice deficient for matrix metalloproteinase 
(MMP)-12 are protected against the 
development of emphysema upon chronic 
exposure to cigarette smoke. We showed 
that both subacute and chronic exposure 
to cigarette smoke leads to increased 
expression of MMP-12 in lung tissue of 
wild type mice. In addition, we 
demonstrated that MMP-12 (or 
macrophage metalloelastase) is not only 
produced by macrophages, but also by 
dendritic cells (DCs). Since these cells 
constantly migrate from the circulation to 
the lungs and subsequently to the lymph 
nodes, they are capable of damaging the 
lung structures by releasing MMP-12. 
By using Toll-like receptor (TLR) 4 
defective mice, we proved that pulmonary 
inflammation upon subacute cigarette 
smoke exposure is partly dependent on 
TLR4 signalling. However, upon chronic 
exposure the involvement of TLR4 is less 
pronounced. 
To study the role of chemokine receptors 
in the accumulation of inflammatory cells, 
we exposed both CCR5 and CCR6 
deficient mice to cigarette smoke. In both 
mice strains the inflammatory response 
was significantly impaired, compared to 
wild type control mice. Moreover, both 
strains were partially protected against the 
development of pulmonary emphysema. In 
CCR6 mice, this partial protection 
correlated with a decreased release of 
9
MMP-12. Interestingly, while the deletion 
of CCR5 or CCR6 had clear effects on 
inflammation, it had no effect on airway 
wall remodeling, suggesting (at least) 
partially independent mechanisms for both 
processes. 
These results confirm the role of MMP-12 
in the development of pulmonary 
emphysema, and show a clear 
involvement of TLR4 and the chemokine 
receptors CCR5 and CCR6 in the 
inflammatory  process in COPD. 
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Samenvatting 
 
Chronisch obstructief longlijden (COPD) 
wordt voornamelijk veroorzaakt door het 
roken van sigaretten en is gekenmerkt 
door enerzijds een abnormale inflammatie 
ter hoogte van de kleine luchtwegen en 
het longparenchym, en anderzijds 
destructie van het longparenchym of 
emfyseem. Er zijn vele aanwijzingen dat 
de verhoogde accumulatie van 
inflammatoire cellen in COPD grotendeels 
wordt georkestreerd door chemokines en 
hun respectievelijke receptoren. 
Bovendien is het mogelijk dat de 
pulmonale inflammatie wordt geïnitieerd 
en zelfs onderhouden door signalisatie via 
zogenaamde ‘pathogen recognition 
receptors’ (PRRs). Een verhoogde 
vrijstelling van proteinasen door 
inflammatoire cellen geeft dan weer 
aanleiding tot een onevenwicht tussen 
proteinasen en anti-proteinasen, dat 
bijdraagt tot de ontwikkeling van 
pulmonaal emfyseem. 
Om voorgaande hypothesen verder op te 
helderen, maakten we gebruik van een 
muis COPD model. In dit model worden 
muizen blootgesteld aan sigarettenrook, 
waarna ze kenmerken van humaan COPD 
vertonen. Reeds na subacute blootstelling 
(1 maand) is er een significante toename 
in cellen van het aangeboren en adaptief 
immuunsysteem in zowel bronchoalveolair 
lavage vocht als longweefsel. Na 
chronische blootstelling (6 maand) is er 
tevens duidelijke ontwikkeling van 
emfyseem, vorming van lymfoïde follikels 
en luchtwegwand ‘remodeling’. 
Muizen die deficiënt zijn voor matrix 
metalloproteinase-12 (MMP-12) ont-
wikkelen geen emfyseem na langdurige 
blootstelling aan sigarettenrook. Wij 
hebben zowel na subacute als chronische 
blootstelling aan sigarettenrook een 
verhoogde expressie van MMP-12 in het 
longweefsel van wild type muizen 
waargenomen. Bovendien hebben we 
aangetoond dat MMP-12 (of macrofaag 
metalloelastase) niet enkel door 
macrofagen, maar ook door dendritische 
cellen (DCs) wordt aangemaakt. Dit kan 
van belang zijn in de ontwikkeling van 
emfyseem, aangezien DCs migrerende 
cellen zijn die tijdens hun continue 
migratie tussen de circulatie, de longen en 
de lymfeknopen het omliggende weefsel 
kunnen beschadigen via de vrijstelling van 
MMP-12. 
Gebruik makend van Toll-like receptor 
(TLR) 4 defectieve muizen hebben we 
aangetoond dat de pulmonale inflammatie 
ten gevolge van subacute  rook-
blootstelling deels afhankelijk is van TLR4 
signalisatie. Bij chronische expositie is de 
betrokkenheid van TLR4 evenwel veel 
minder uitgesproken. 
Om de rol van chemokine receptoren in de 
rekrutering van inflammatoire cellen te 
onderzoeken, hebben we zowel CCR5 als 
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CCR6 deficiënte muizen blootgesteld aan 
sigarettenrook. In beide muizenstammen 
was de inflammatoire respons significant 
afgenomen ten opzichte van de wild type 
controles. Daarenboven bleken beide 
stammen gedeeltelijk beschermd tegen de 
ontwikkeling van emfyseem. In CCR6 
knock-out muizen correleerde deze 
partiële bescherming bovendien met een 
verminderde vrijstelling van MMP-12. 
Opmerkelijk is dat deletie van CCR5 of 
CCR6 een duidelijke invloed heeft op de 
inflammatie, doch niet op luchtwegwand 
‘remodeling’. Dit veronderstelt (ten minste) 
partieel onafhankelijke mechanismen voor 
beide processen. 
Deze resultaten bevestigen de rol van 
MMP-12 in de ontwikkeling van pulmonair 
emfyseem, en tonen een duidelijke 
betrokkenheid van TLR4 en de chemokine 
receptoren CCR5 en CCR6 in het 
inflammatoire proces in COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12
PART I: INTRODUCTION 
 
Chapter 1. Chronic Obstructive Pulmonary Disease (COPD) 
 
1.1. Introduction and definition 
 
Chronic obstructive pulmonary disease is 
the fifth leading cause of death worldwide 
and a major burden on healthcare 
systems. Importantly, COPD is the only 
common cause of death that has 
increased over the last 30 years and its 
prevalence and mortality are expected to 
escalate even further in the coming 
decades1;2.  The most recent definition that 
was issued by the Global initiative for 
chronic Obstructive Lung Disease (GOLD) 
describes COPD as: “A preventable and 
treatable disease with some significant 
extrapulmonary effects that may contribute 
to the severity in individual patients. Its 
pulmonary component is characterized by 
airflow limitation that is not fully reversible. 
The airflow limitation is usually progressive 
and associated with an abnormal 
inflammatory response of the lung to 
noxious particles and gases” 
(www.goldcopd.com)3. The pathology of 
COPD includes chronic obstructive 
bronchiolitis with fibrosis and obstruction 
of the small airways and emphysema with 
destruction of the lung parenchyma and 
Figure 1. Mechanisms of airflow limitation in COPD. During expiration normal airways are held open by 
alveolar attachments, allowing the air to flow out of the alveoli. In COPD lungs, the alveolar attachments are 
disrupted because of emphysema, contributing to airway closure and trapping of air in the alveoli during 
expiration. The small airways in COPD are also obstructed by airway inflammation, fibrosis and mucus 
hypersecretion. (Figure by K. Bracke, adapted from references 4 and 5) 
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enlargement of airspaces4;5 (Figure 1). 
The airflow limitation in COPD results from 
both the emphysematous lung destruction, 
causing an increase in lung compliance, 
and the narrowing of small airways (often 
combined with luminal obstruction by 
mucus hypersecretion), causing an 
increase in the resistance of the 
conducting airways. However, the relative 
proportion of each mechanism can differ 
between patients. Importantly, a recent 
study by Hogg and colleagues found a 
significant association between the 
severity of airway obstruction and the 
thickness of the walls of the small 
airways6. This increased airway wall 
thickness results from infiltration by 
inflammatory cells, indicating the 
importance of chronic inflammation in 
COPD, as well as from structural 
alterations of the small airways, often 
referred to as airway wall remodeling. The 
latter includes increases in smooth muscle 
and fibrosis under the epithelium and in 
the outer part of the wall. 
Airflow limitation is measured by 
spirometry, as this is the most widely 
available and reproducible test of lung 
function. The classification of severity of 
COPD, as issued by GOLD, is based upon 
FEV1 and FEV1/FVC (Table 1).  
COPD is characterized by an acceleration 
in the normal decline of lung function seen 
with age7 (Figure 2). The slowly 
progressive airflow limitation leads to 
disability and eventually death and is 
Table 1. Classification of COPD by severity  
Stage Characteristics 
Stage I:  Mild COPD Mild airflow limitation (FEV1/FVC < 70% but FEV1 ≥ 80% 
predicted) and usually, but not always, chronic cough and 
sputum production. 
Stage II:  Moderate COPD Worsening airflow limitation (FEV1/FVC < 70% and 50% ≤ FEV1 
< 80% predicted), and usually the progression of symptoms, with 
shortness of breath typically developing on exertion. 
Stage III:  Severe COPD Further worsening of airflow limitation (FEV1/FVC < 70% and 
30% ≤ FEV1 < 50% predicted), increased shortness of breath 
and repeated exacerbations which have an impact on patients’ 
quality of life. 
Stage IV:  Very Severe COPD Severe airflow limitation (FEV1/FVC < 70% and FEV1 < 30% 
predicted) or FEV1 < 50% predicted plus chronic respiratory 
failure or cor pulmonale. Patients may have very severe (Stage 
IV) COPD even if the FEV1 > 30% predicted, whenever these 
complications are present. 
FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity 
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 different from asthma, where the airway 
obstruction and symptoms rarely progress 
in severity. 
The progressive course of COPD is 
complicated by acute exacerbations that 
are characterized by an acute worsening 
of the airway inflammation, with even 
development of airway eosinophilia8. 
These exacerbations are triggered by a 
variety of factors including viruses, 
bacteria and air pollutants. 
Cigarette smoking is by far the major risk 
factor for the development of COPD, 
especially in developed countries. Other 
risk factors include air pollution 
(particularly indoor air pollution from 
burning fuels), passive smoking, poor diet 
and occupational dusts. Not all smokers 
develop COPD, making it likely that 
genetic factors determine the susceptibility 
to develop COPD. However, the only well-
established genetic risk factor is the rare 
hereditary deficiency of α1-antitrypsin (α1-
AT), a major circulating inhibitor of serine 
proteases. Patients with this deficiency 
show a rapid decline in FEV1, even without 
smoking9. 
Aside from smoking cessation, current 
pharmacologic therapy for COPD is limited 
to bronchodilatation and/or treatment with 
inhaled corticosteroids. This treatment is 
directed against the clinical symptoms. 
However, these drugs neither affect the 
natural history of the disease (e.g. 
accelerated decline in lung function) nor 
prevent the underlying inflammatory 
process. Effective treatment depends on 
elucidation of the molecular and cellular 
mechanisms that are responsible for the 
development of COPD. 
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Figure 2. Natural history of 
COPD. Annual decline in lung 
function shows accelerated 
decline in susceptible smokers 
and effects of smoking 
cessation. Patients with COPD 
often show a decline in FEV1 
greater than 50 ml/year, 
compared with the normal 
decline of approximately 20 
ml/year.  
 
(Figure by K. Bracke, adapted from 
reference 7) 
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1.2. Inflammation in COPD 
 
The chronic inflammation in COPD is 
characterized by an excessive 
accumulation of inflammatory cells of both 
the innate and the adaptive immune 
system.  
 
 
Macrophages 
 
Macrophages appear to play a central role 
in the pathogenesis of COPD as they can 
be linked to most features of the disease 
(Figure 3)10-12.  
Increased numbers of macrophages have 
been described in airways, lung 
parenchyma, BAL fluid and sputum of 
COPD patients. Morphometric analysis of 
lung parenchyma revealed a 25-fold 
increase in macrophages in patients with 
emphysema13. Moreover, these 
macrophages are localised in sites of 
alveolar wall destruction14;15.  Importantly, 
the numbers of macrophages in the 
airways correlate with severity of COPD16. 
Macrophages provide a link between 
smoking and inflammation, as activation of 
Figure 3. Macrophages play a pivotal role in COPD. Once activated by cigarette smoke they release several 
inflammatory mediators that may orchestrate the inflammatory process in COPD. Neutrophils may be 
attracted by IL-8 and GRO-α, monocytes by MCP-1 and CD8+ T-cells by IP-10, Mig and I-TAC. Release of 
proteases including MMPs and cathepsins may contribute to the development of emphysema and release of 
TGF-β can lead to airway wall remodeling. (Figure by K. Bracke, adapted from reference 11) 
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macrophages by cigarette smoke leads to 
excessive release of inflammatory 
mediators (Figure 3), most likely triggered 
by an increased expression of the 
transcription factor nuclear factor-κB (NF-
κB)17. Macrophages are also capable of 
releasing a wide variety of proteolytic 
enzymes, including matrix 
metalloproteinase (MMP)-2, MMP-9, 
MMP-12, cathepsins K, S and L, and even 
neutrophil elastase taken up from 
neutrophils18-23, which can all contribute to 
alveolar wall destruction. Moreover, 
macrophages from patients with COPD 
secrete more proteases and have greater 
proteolytic activity than those from normal 
smokers19;20;24. 
 
 
Neutrophils 
 
Significantly increased numbers of 
activated neutrophils are found in sputum 
and BAL fluid of COPD patients25;26. On 
the other hand, only small increases in 
neutrophil numbers are documented in 
airways and lung parenchyma of patients 
with COPD, suggesting a rapid transit 
through these parts of the lung14. Despite 
this increase and a positive correlation 
between neutrophil numbers and decline 
in lung function, the role of neutrophils in 
COPD is not yet clear.  Neutrophils 
release several serine proteases like 
neutrophil elastase, cathepsin G and 
proteinase-3, which may contribute to 
parenchymal destruction. However, it 
seems unlikely that this is the major role of 
neutrophilia in COPD, as neutrophils are 
not a prominent feature of parenchymal 
inflammation. Moreover, a negative 
correlation has been observed between 
neutrophil numbers and the amount of 
parenchymal destruction14. The serine 
proteases released by neutrophils do have 
the capacity to stimulate mucus 
hypersecretion27;28, another contibutor to 
airflow limitation in COPD. 
 
 
T-lymphocytes 
 
Increased numbers of T-lymphocytes have 
been found throughout the lungs of 
patients with COPD, with a greater 
increase in CD8+ than in CD4+ T-cells14;29-
31. Moreover, there is a correlation 
between the number of T-lymphocytes, the 
amount of alveolar destruction and the 
severity of airflow obstruction. The role of 
T-lymphocytes in COPD is not yet 
completely understood, but CD8+ 
(cytotoxic) T-cells have the ability to 
contribute to cytolysis and apoptosis of 
alveolar cells by releasing perforins, 
granzyme B and TNF-α32. Indeed, there is 
an association between CD8+ T-cells and 
apoptosis of alveolar cells in 
emphysema31. 
COPD is generally regarded as a Th1-
driven disease, with high levels of Th1-
cytokines like IFN-γ33-35. However, Th2 
responses may also be present in COPD, 
as enhanced levels of Th2-cytokines are 
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well documented in COPD36;37. Recently, it 
has been described that IL-18, a cytokine 
that can act as a co-factor for both Th1 
and Th2 responses38, plays a role in 
pulmonary inflammation and emphysema 
in COPD39;40. 
 
 
Dendritic cells 
 
Dendritic cells are specialised antigen 
presenting cells and play a central role in 
initiating both the innate and adaptive 
immune response41. Since both 
components of the immune system are 
augmented in COPD and dendritic cells 
are ideally located in the airways and lung 
parenchyma at the interface between the 
inhaled air and the lung42, it seems likely 
that they play an important role in the 
pulmonary response to cigarette smoke. 
Increased numbers of dendritic cells have 
been observed in the airways and alveolar 
walls of smokers43;44. Moreover, pulmonary 
histiocytosis, a disease caused by 
dendritic cell granulomata, is characterized 
by emphysema-like destruction of lung 
parenchyma45;46. Aside from the role of 
dendritic cells in initiating the inflammatory 
response in COPD, they are also a source 
of proteolytic enzymes like MMP-1247;48. 
 
 
Epithelial cells 
 
Both airway and alveolar epithelial cells 
are important for initiating and maintaining 
the pulmonary inflammation in COPD. 
Upon activation by cigarette smoke they 
have the ability to release a wide variety of 
inflammatory mediators, including 
cytokines or chemokines like IL-849 and 
CCL20/MIP-3α50. Epithelial cells in small 
airways may also be an important source 
of TGF-β51, which can induce airway wall 
remodeling52. 
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1.3. Pulmonary Emphysema 
 
Pulmonary emphysema is the destruction 
of the lung parenchyma, which includes 
the gas exchanging surface of the lung 
(respiratory bronchioles and alveoli), as 
well as the pulmonary capillary system 
(Figure 4). Emphysema is defined as 
enlargement of airspaces, caused by 
destruction of the airway walls and 
reduces maximal expiratory airflow by 
decreasing the elastic recoil force that 
drives air out of the lungs.  
The most common type of emphysema in 
COPD patients is centrilobular or 
centriacinar emphysema, which involves 
dilatation or destruction of the respiratory 
bronchioles (Figure 5A). These lesions 
occur mostly in the upper regions of the 
lung, but may appear diffusely throughout 
the entire lung in advanced disease. 
Panlobular or panacinar emphysema, 
which is usually associated with α1-AT 
deficiency, results in a more uniform 
dilatation and destruction of the entire 
acinus (Figure 5B). Both types of 
pulmonary emphysema are thought to be 
the result of an imbalance between 
proteases and antiproteases, although 
oxidative stress and apoptosis could also 
play a role53. 
 
 
 
Figure 5. Photomicrographs of human 
centrilobular or centriacinar emphysema (A) and 
panlobular or panacinar emphysema (B). 
 
A B 
Figure 4. Photomicrographs of normal human lung 
parenchyma (A) and emphysematous human lung 
parenchyma (B). 
 
A
B
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1.4. Airway wall remodeling 
 
Remodeling is an alteration in the size, 
mass or number of tissue structural 
components and occurs during growth or 
in response to injury and/or inflammation. 
It may be an appropriate process during 
normal lung development, but can lead to 
abnormally altered tissue structure or 
function when it is associated with chronic 
inflammatory diseases like COPD. 
Airway wall remodeling in COPD occurs in 
the small airways and is a combination of 
several structural changes, including 
subepithelial fibrosis with increased 
deposition of connective tissue, 
augmentation of airway smooth muscle, 
mucous gland hypertrophy and 
squamaous and goblet cell metaplasia6;54 
(Figure 6).  
This results in thickening of the airway wall 
and a narrowed and/or distorted lumen, 
leading to an increased resistance to 
airflow in the small airways. Importantly, 
the progression of COPD from GOLD 
stage I to GOLD stage IV correlates with 
the thickening of the airway wall and with 
the degree to which the lumen is filled with 
mucous exudates6. 
It is still open to debate whether the 
excessive deposition of connective tissue 
that leads to fibrosis in COPD occurs as a 
consequence of inflammation or rather 
through direct induction of growth factors 
by cigarette smoke, and thus 
independently of inflammation55. 
Interestingly, cultured epithelial cells from 
smokers and COPD patients release more 
transforming growth factor (TGF)-β than 
those from control patients51. TGF-β may 
play an important role in airway wall 
remodeling by stimulating the production 
of extracellular matrix components such as 
collagen and fibronectin. Moreover, it 
reduces matrix degradation by altering the 
balance between collagenase and 
collagenase inhibitor. 
 
Figure 6. Photomicrograph of a normal human 
airway (A) and a human airway that has been 
extensively remodeled by connective tissue 
deposition in the subepithelial and adventitial 
compartments of the airway wall (B). 
 
(Figure adapted from reference 6) 
 
A 
B 
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Chapter 2. Pathogenesis of COPD 
 
2.1. Role of proteases in COPD 
 
An imbalance between proteases and their 
inhibitors is believed to play an essential 
role in the development of pulmonary 
emphysema. This imbalance may occur 
either by an excessive release of 
proteases by inflammatory cells and lung 
resident cells, or by a reduced synthesis or 
increased breakdown of antiproteases. 
The protease/antiprotease hypothesis of 
emphysema was first proposed 40 years 
ago, based on the observations that 
smokers with a deficiency of α-1 
antitrypsin (α1-AT) were at increased risk 
for pulmonary emphysema56, and that 
intratracheal administration of papain, a 
plant protease, leads to emphysema in 
experimental animals57. Since these initial 
experiments, a lot of proteases have been 
implicated in COPD. 
 
 
Serine proteases 
 
Neutrophil elastase (NE) is the serine 
protease that has received the most 
attention, since a deficiency of its inhibitor 
α1-AT leads to the development of 
pulmonary emphysema. NE is produced 
by neutrophils and stored in azurophilic 
granules. The role of NE in development 
of emphysema was further supported by 
the neutrophilia in COPD and the fact that 
intratracheal instillation of NE in animal 
models induces emphysema58;59. There is 
an increased amount of NE/α1-AT 
complexes in BAL fluid of COPD 
patients60, and this correlates with the 
decline in FEV161. The initial idea that NE 
is the main protease in the development of 
emphysema has been challenged, mainly 
because of the inability to correlate 
neutrophil numbers in the lung 
parenchyma with the amount of alveolar 
destruction14. This shifted the attention to 
other proteases, especially matrix 
metalloproteinases (MMPs). However, 
recently there is renewed interest in NE as 
a mediator of emphysema. Not only are 
NE deficient mice significantly protected 
from the development of emphysema after 
cigarette smoke-exposure62, it seems that 
there are many interactions between NE 
and MMPs, with each augmenting the 
other’s destructive capacity. Indeed, 
MMPs degrade α1-AT, whereas NE 
degrades tissue inhibitors of 
metalloproteinases (TIMPs) (Figure 7). NE 
also mediates monocyte migration, 
whereas MMP-12 may influence neutrophil 
accumulation by activation of TNF-α63. 
Other serine proteases that have similar 
properties to NE and are also produced by 
neutrophils are proteinase-3 and cathepsin 
G. The importance of neutrophils and 
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neutrophil-derived serine proteases has 
been reemphasized by the finding that 
levels of α1-AT affect the response to 
cigarette smoke in mice64;65. Indeed, pallid 
mice, which are deficient for α1-AT, are 
more susceptible for the development of 
emphysema. Moreover, parallel to the 
human situation, they develop the 
panlobular form of emphysema. 
Besides α1-AT, serine proteases are also 
inhibited by secretory leukoprotease 
inhibitor (SLPI), an inhibitor that is 
inactivated by cathepsins B, L and S66. 
 
 
Cysteine proteases 
 
Lysosomal cysteine proteases (or 
cathepsins) may also be involved in 
COPD. Cathepsin L is significantly 
increased in alveolar macrophages and 
BAL fluid from smokers with 
emphysema22;67. Overexpression of IFN-γ 
or IL-13 in the lungs of mice induces 
emphysema and is accompanied by an 
increased expression of cathepsins B, H, 
K, S, D and L34;68. Cathepsin inhibitors 
significantly reduce the development of 
emphysema in IL-13 transgenic mice, 
indicating the elastolytic potential of 
cathepsins68. Cathepsins are inhibited by 
cystatins and stefins, but little is known 
about their role in COPD. Cystatin C is 
increased in BAL fluid from smokers with 
emphysema67. 
 
 
Matrix Metalloproteinases (MMPs) 
 
MMPs are a large family of zinc-dependent 
proteases that have the ability to degrade 
several components of the extracellular 
matrix and thus are likely to play a role in 
cell migration and tissue destruction. They 
are produced as inactive pro-enzymes by 
both inflammatory and structural cells and 
become activated by proteolytic cleavage 
of an N-terminal domain. MMPs are 
counteracted by four tissue inhibitors of 
metalloproteinases (TIMPs), which bind to 
the catalytic site of MMPs. There is 
increasing evidence for a role of MMPs in 
the pathogenesis of COPD69. Interestingly, 
MMPs can activate cytokines and 
chemokines, thereby further contributing to 
the inflammatory reaction in COPD. The 
Figure 7. Neutrophil elastase (NE) and matrix 
metalloproteinase (MMP)-12 augment each other’s 
destructive capacity. MMP-12 has the ability to 
degrade α1-antitrypsin (α1-AT) and NE degrades 
tissue inhibitors of metalloproteinases (TIMPs).  
 
(Figure by K. Bracke) 
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most important MMPs in the pathogenesis 
of pulmonary diseases are summarised in 
Table 2. 
In sputum of patients with COPD there is 
increased concentration and activity of the 
gelatinases MMP-2 and MMP-9 and the 
collagenases MMP-1 and MMP-870-73. 
Recently our group described increased 
concentration and activity of MMP-12 or 
macrophage metalloelastase in induced 
sputum from smokers with COPD, 
compared to ‘healthy’ smokers and non-
smokers74. 
In BAL of patients with emphysema there 
Table 2. List of most important MMPs involved in the pathogenesis of pulmonary diseases 
Name Common name Substrates Cellular source 
MMP-1 Collagenase-1 Type I and II fibrillar collagens Macrophages, fibroblasts, 
epithelial cells, endothelial cells 
MMP-2 Gelatinase A Denatured collagen (i.e. gelatine), 
CCL7, CXCL12 
Neutrophils, macrophages, T-
cells, fibroblast, endothelial cells 
MMP-3 Stromelysin-1 Laminin, E-cadherin, latent TGF-β, 
type IV collagen 
Macrophages, fibroblasts, 
epithelial cells, endothelial cells 
MMP-7 Matrilysin Elastin, E-cadherin, pro-α-defensins, 
FAS ligand, membrane-bound pro-
TNF-α 
Macrophages, epithelial cells, 
mesangial cells 
MMP-8 Collagenase-2 Type I and II fibrillar collagens, 
mouse CXCL5 
Neutrophils, fibroblasts, 
endothelial cells 
MMP-9 Gelatinase B Denatured collagen (i.e. gelatine), 
fibrin,  latent TGF-β, latent VEGF, 
α1-antiproteinase, NG2 
proteoglycan 
Neutrophils, eosinophils, 
macrophages, dendritic cells, T-
cells, fibroblasts, epithelial cells, 
endothelial cells 
MMP-10 Stromelysin-2 Unknown T-cells, fibroblasts, epithelial cells 
MMP-11 Stromelysin-3 Unknown Fibroblasts, epithelial cells, 
mesenchymal cells 
MMP-12 Macrophage 
metalloelastase 
Membrane-bound pro-TNF-α, 
elastin 
Macrophages 
MMP-13 Collagenase-3 Type I and II fibrillar collagens Fibroblasts 
MMP-14 Membrane-type MMP Fibrillar collagens, fibrin, pro-MMP2, 
Syndecan-1 
Macrophages, epithelial cells, 
fibroblasts 
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are increased concentrations of the 
collagenases MMP-1 and MMP-8 and the 
gelatinase MMP-970;71. In vitro cultured 
alveolar macrophages from COPD 
patients released greater amounts of 
MMP-9 with greater enzymatic activity 
than those from ‘healthy’ smokers and 
non-smokers19;20;24. In recent studies both 
Montaño and Molet found increased 
expression of MMP-12 in alveolar 
macrophages from COPD patients75;76. 
Studies on human lung parenchyma 
showed increases in MMP-1, -2, -8 and -9 
in patients with COPD77-79. Moreover, 
MMP-9 concentrations were inversely 
correlated with FEV1, suggesting a role of 
MMP-9 in the development of airflow 
limitation79. 
The interest in MMPs has also been 
heightened by experiments with animal 
models of COPD. Hautamaki and 
colleagues demonstrated that induction of 
emphysema by exposure to cigarette 
smoke is prevented in MMP-12 deficient 
mice80. Emphysema induced by 
overexpression of IL-13 or IFN-γ is also 
reduced in MMP-12 knockout mice34;68, 
and is accompanied by a reduction in the 
recruitment of monocytes in the lung. This 
may be because MMPs generate 
chemotactic peptides that promote 
macrophage recruitment to the 
parenchyma and airways81;82. MMP-9 
deficient mice are not protected from the 
development of cigarette smoke-induced 
emphysema, but they are protected from 
small airway fibrosis83. This protection 
could be the result of impaired MMP-9 
mediated release of TGF-β in MMP-9 
knockout mice84. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24
2.2. Role of pathogen recognition receptors (PRRs) in COPD 
 
PRRs and pathogen-associated 
molecular patterns (PAMPs) 
 
Innate immunity has, in contrast to 
adaptive immunity, been regarded as a 
relative non-specific system. However, 
recent studies have shown that the innate 
immune system has a higher degree of 
specificity than was previously thought and 
that it is able to discriminate between self 
and foreign pathogens85. These abilities 
rely to a great extent on the existence of 
pathogen recognition receptors (PRRs) 
that recognise molecular signatures that 
are unique to the microbial world and 
invariant among pathogens of a given 
class. These constitutive and conserved 
products, such as for example endotoxin, 
flagellin or double stranded RNA, are 
called pathogen-associated molecular 
patterns (PAMPs). The recognition of 
PAMPs by PRRs triggers an intracellular 
signalling pathway which culminates in 
initiation of a whole range of host defense 
mechanisms, including induction of 
proinflammatory cytokines and 
chemokines, induction of apoptosis, 
opsonisation, phagocytosis  and activation 
of complement86;87. PRRs are expressed 
on the cell surface, in intracellular 
compartments or secreted into the blood 
stream and tissue fluids. PRRs include 
pentraxins like C-reactive protein (CRP) 
and serum amyloid protein (SAP) or C-
type lectins like macrophage mannose 
receptor and mannan-binding lectin (MBL). 
The largest and most interesting group of 
PRRs are the Toll-like receptors88 
(TLRs). TLRs were first described in 
Drosophila and can initiate adequate 
immune responses against almost any 
threatening microorganism. For example, 
TRL2 is able to detect the presence of 
gram-positive bacteria by recognising 
peptidoglycan from their cell wall, while 
TLR4 can detect gram-negative bacteria 
by recognising lipopolysaccharide (LPS) 
from their outer membrane. The PAMP 
specificity of TLRs is given in Figure 8. 
Interestingly, in addition to the detection of 
PAMPs, TLRs also recognise endogenous 
ligands such as heat shock proteins89;90 
and  extracellular matrix breakdown 
products91;92. 
 
 
TLR4 and lipopolysaccharide (LPS) 
 
TLR4 was originally identified as the 
receptor for LPS, a gram-negative 
bacterial cell wall component, and is 
mainly expressed on myeloid cells such as 
monocytes, macrophages, dendritic cells, 
mast cells and granulocytes93;94. TLR4 
expression was also reported on structural 
cells of the lung, such as alveolar type II 
cells, bronchial epithelial cells and 
endothelial cells95-97. 
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Recently, several researchers have 
reported on the importance of TLR4 in 
several inflammatory pulmonary 
diseases98-101 and it is likely that TLR4 
signaling is also involved in the cigarette 
smoke-induced pulmonary inflammation in 
COPD. Indeed, bioactive LPS is present in 
both mainstream and sidestream cigarette 
smoke102;103 and it has been demonstrated 
in healthy human subjects that 
experimental inhalation of LPS induces a 
dose-dependent pulmonary inflammation 
which is accompanied by clinical COPD 
symptoms like sputum production and 
airflow decline104;105. Similar data have 
been obtained using a chronic LPS mouse 
model in which mice are exposed to LPS 
by repetitive intratracheal instillation. After 
12 weeks these mice show several 
hallmarks of COPD, including pulmonary 
inflammation, airway wall remodeling and 
development of emphysema106;107.  
In addition to LPS, exposure to cigarette 
smoke could also lead to the presence of 
several endogenous ligands that can bind 
TLR4 and subsequently activate the TLR4 
pathway. Indeed, tissue stress and 
damage by cigarette smoke could release 
heat shock proteins, β-defensins or 
breakdown products of the extracellular 
matrix108-111. Moreover, the lower airways 
of patients with severe COPD are often 
colonized by gram-negative bacteria, 
which can also activate the TLR4 pathway. 
 
 
 
Figure 8. PAMP specificities of Toll-like receptors (TLRs). TLR2 recognizes gram-positive bacteria and 
functions in combination with several (but not all) other TLRs, including TLR1 and TLR6. TLR4 recognizes 
lipopolysaccharide (LPS) from gram-negative bacteria. TLR5 is specific for bacterial flagellin. TLR3 is involved 
in recognition of double stranded (ds) RNA, whereas TLR7 and TLR8 recognise single stranded (ss) RNA. 
TLR9 is a receptor for unmethylated CpG motifs, which are present in bacterial and viral DNA.  
 
(Figure by K. Bracke, adapted from reference 80)  
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2.3. Role of chemokines and chemokine receptors in COPD 
 
There is growing evidence that the 
recruitment of inflammatory cells in COPD 
is largely orchestrated by chemokines 
binding to their respective chemokine 
receptors. 
Chemokines are a family of small, 
structurally related peptides that regulate 
trafficking of various types of leukocytes, 
both under physiological and inflammatory 
conditions112. In addition, they have broad-
reaching effects on other fundamental 
aspects of immunology, including the 
development, homeostasis and function of 
the immune system. Chemokines have 
been divided into four subfamilies based 
on the arrangement of amino acids 
surrounding conserved cysteine residues 
(CXC, CC, C and CX3C), with most of the 
chemokines belonging to the CXC- and 
CC-families. Generally, chemokines exert 
their biological functions by interactions 
with specific receptors on the surface of 
their target cells113. These chemokine 
receptors are members of a large 
subfamily within the 7-transmembrane, G-
protein coupled receptors and are 
classified according to their affinity for one 
of the chemokine subfamilies: CXCR, 
CCR, XCR and CX3CR. There is 
extensive redundancy in this receptor-
ligand binding, as an individual chemokine 
receptor may have an affinity for several 
chemokines, and a single chemokine may 
bind to multiple receptors. Several CXC- 
and CC-chemokine receptors are found to 
be expressed on inflammatory cells 
associated with COPD. 
 
 
CXC-chemokines and receptors 
 
The CXC-chemokine receptors with their 
respective ligands are listed in Table 3. 
We will focus this discussion on those 
receptors that have been implicated in the 
pathogenesis of COPD. 
The chemokine receptors CXCR1 and 
CXCR2 are highly expressed on 
neutrophils and macrophages, and there is 
evidence demonstrating expression on T-
lymphocytes and dendritic cells. Hence, 
there has been considerable interest in the 
involvement of these receptors in COPD. 
The chemokine interleukin-8 (IL-8)/CXCL8 
is a strong attractant of neutrophils and 
has an affinity for both CXCR1 and 
CXCR2. IL-8 is increased in sputum and 
BAL of COPD patients and correlates with 
the numbers of neutrophils26;114-116. 
Moreover, concentrations of IL-8/CXCL8 
are significantly higher in BAL of smokers 
with emphysema compared to ‘healthy’ 
smokers, whereas  concentrations of other 
CXC chemokines do not discriminate 
between these groups117. IL-8/CXCL8 is 
predominantly produced by epithelial cells, 
macrophages and neutrophils, and it has 
been shown that airway and bronchial 
27
epithelial cells as well as alveolar 
macrophages from COPD patients have 
an increased secretion of IL-8/CXCL8118-
120. During acute exacerbations of COPD 
there is marked upregulation of CXCR2, 
correlating with the increased numbers of 
neutrophils during these exacerbations121. 
GRO-α/CXCL1 is another chemokine that 
acts via CXCR2 and is chemotactic for 
neutrophils and monocytes. GRO-
α/CXCL1 is produced in greater amounts 
by epithelial cells of COPD patients, 
compared to ‘healthy’ smokers119 and 
there are higher concentrations of GRO-
α/CXCL1 in sputum of these patients122. 
Traves and colleagues recently reported 
higher monocyte chemotactic response to 
GRO-α/CXCL1 in COPD patients, which 
may be one of the mechanisms leading to 
increased numbers of alveolar 
macrophages in the lungs of these 
patients123. 
The chemokine receptor CXCR3 is 
expressed on T-lymphocytes, especially 
on the CD8+ subtype. T-cells infiltrating the 
lungs of COPD patients have a higher 
expression of CXCR3124. This receptor is 
activated by monokine induced by 
interferon-γ (Mig)/CXCL9, interferon-γ 
inducible protein of 10 kDa (IP-
10)/CXCL10 and interferon-inducible T 
cell-α chemoattractant (I-TAC)/CXCL11, 
leading to recruitment of T-lymphocytes.  
There is increased expression of IP-
10/CXCL10 in bronchial epithelial cells 
and smooth muscle cells of COPD 
patients, which could contribute to the 
accumulation of CD8+ cells in their 
lungs125-127. Interestingly, IFN-γ stimulates 
dendritic cells to produce IP-10/CXC10, 
thereby enhancing their ability to attract 
CD8+ T-lymphocytes128. Other cell types, 
including macrophages and neutrophils 
produce the CXCR3 ligands upon 
activation by IFN-γ, thereby perpetuating 
the recruitment of CD8+ T-lymphocytes to 
the lungs of COPD patients129;130. Since 
these CD8+ T-cells produce IFN-γ, this 
Table 3. CXC-Chemokine Receptors 
Name Cell-type expression Chemokine ligands 
CXCR1 neutrophils, monocytes, endothelial cells ENA-78/CXCL5, GCP-2/CXCL6, IL-8/CXCL8 
CXCR2 neutrophils, monocytes, eosinophils, 
endothelial cells 
GRO-α/CXCL1, GRO-β/CXCL2, GRO-γ/CXCL3, 
ENA-78/CXCL5, NAP-2/CXCL7, IL-8/CXCL8 
CXCR3 T-lymphocytes, B-lymphocytes, smooth 
muscle cells, mesengial cells 
Mig/CXCL9, IP-10/CXCL10, I-TAC/CXCL11 
CXCR4 T-lymphocytes, dendritic cells, monocytes, 
B-lymphocytes, neutrophils 
SDF-1/CXCL12 
CXCR5 B-lymphocytes, T-lymphocytes BCA-1/CXCL13 
CXCR6 T-lymphocytes PSOX/CXCL16 
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provides a positive feedback loop for their 
recruitment. Interestingly, on bronchial 
epithelial cells of COPD patients there is 
an upregulation of both CXCR3 and its 
ligand IP-10/CXCL10125. Activation of 
CXCR3 with IP-10/CXCL10 induces 
epithelial cell proliferation, suggesting a 
potential role for chemokine receptors in 
airway wall remodeling131. 
 
 
CC-chemokines and receptors 
 
The CC-chemokine receptors with their 
respective ligands are listed in Table 4. 
We will focus this discussion on those 
receptors that have been implicated in the 
pathogenesis of COPD. 
CCR2 is the only chemokine receptor for 
monocyte chemoattractant protein-1 
(MCP-1) and is involved in recruitment of 
monocytes/macrophages and immature 
dendritic cells to sites of inflammation132. It 
has also been demonstrated that activated 
neutrophils can migrate in response to 
MCP-1/CCL2133. These cell types are all 
implicated in the pathology of COPD, 
making the CCR2/MCP-1 axis an 
interesting target. Indeed, Capelli et al. 
reported increased concentrations of 
MCP-1/CCL2 in BAL fluid from smokers134. 
On the other hand, Traves et al. could not 
confirm the elevated MCP-1/CCL2 levels 
in BAL, but found increased MCP-1/CCL2 
concentrations in induced sputum of 
patients with COPD122. Moreover, they 
reported a negative correlation between 
sputum MCP-1/CCL2 levels and FEV1 % 
predicted and a positive correlation 
between sputum MCP-1/CCL2 levels and  
sputum neutrophil numbers. The latter 
could be the result of enhanced monocyte 
recruitment, followed by secretion of 
neutrophil chemoattractants like IL-8 or 
GROα. In addition, elevated levels of both 
CCR2 and MCP-1/CCL2 mRNA were 
observed in bronchial epithelium of COPD 
patients120. Increased MCP-1/CCL2 
production upon cigarette smoke exposure 
has also been described in a mouse 
model of COPD135, further underscribing 
the role of CCR2 in the inflammatory 
process of COPD. 
 
CCR3 is mainly involved in eosinophil 
recruitment, and has therefore been 
strongly implicated in allergic airway 
inflammation136;137. Although eosinophils 
are not elevated in stable COPD, patients 
with mild to moderate COPD 
exacerbations show increased numbers of 
eosinophils in their bronchial mucosa8;37. 
Exacerbations of COPD are characterized 
by an acute worsening of the airway 
inflammation and are triggered by a variety 
of factors including viruses, bacteria and 
air pollutants. The eosinophilia during 
these exacerbations is paralleled by an 
up-regulation of both CCR3 and its ligands 
eotaxin-1/CCL11 and RANTES/CCL5 
37;138. Moreover, a positive correlation 
between CCR3+ cells and eosinophils has 
been described, further supporting the role 
29
of CCR3 in the recruitment of eosinophils 
during COPD exacerbations. 
CCR5 is a receptor for macrophage 
inflammatory protein (MIP)-1α/CCL3, MIP-
1β/CCL4 and RANTES/CCL5, and is 
expressed on granulocytes, macrophages, 
immature dendritic cells, CD8+ T-
lymphocytes and memory CD4+ T-
lymphocytes139;140. CCR5 is known to 
influence the recruitment of 
monocytes/macrophages, dendritic cells 
and T-lymphocytes140, and also acts as a 
co-receptor for HIV 141. In bronchial 
biopsies from COPD patients with mild to 
moderate disease, increased levels of 
CCR5+ T-lymphocytes have been 
reported142, and Grumelli et al. associated 
high percentages of CCR5-expressing T-
Table 4. CC-Chemokine Receptors 
Name Cell-type expression Chemokine ligands 
CCR1 NK cells, T-lymphocytes, macrophages, 
immature dendritic cells, basophils, 
eosinophils, neutrophils 
MIP-1α/CCL3, RANTES/CCL5, MCP-2/CCL8, MCP-
3/CCL7, MCP-4/CCL13 
CCR2 monocytes, immature dendritic cells, T-
lymphocytes, B-lymphocytes, basophils, 
neutrophils 
MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-
4/CCL13 
CCR3 eosinophils, Th2 lymphocytes, dendritic 
cells, basophils, mast cells,  
Eotaxin-1/CCL11, Eotaxin-2/CCL24, Eotaxin-
3/CCL26, RANTES/CCL5, MCP-2/CCL8, MCP-
3/CCL7, MCP-4/CCL13, MIP-1δ/CCL15 
CCR4 Th2 lymphocytes, NK cells, epithelial cells, 
dendritic cells 
TARC/CCL17, MDC/CCL22 
CCR5 monocytes, immature dendritic cells, 
granulocytes, CD8+ T-lymphocytes, 
memory CD4+ T-lymphocytes 
MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, MCP-
2/CCL8 
CCR6 immature dendritic cells, B-lymphocytes, 
memory T-lymphocytes, neutrophils, 
endothelial cells 
MIP-3α/CCL20 
CCR7 mature dendritic cells, T-lymphocytes, B-
lymphocytes, NK cells 
MIP-3β/CCL19, SLC/CCL21 
CCR8 Th2 lymphocytes, monocytes, B-
lymphocytes, NK cells, endothelial cells 
TCA3/CCL1, HCC4/CCL16 
CCR9 T-lymphocytes TECK/CCL25 
CCR10 T-lymphocytes, Langerhans cells, 
melanocytes 
CTACK/CCL27, MEC/CCL28 
CCR11 astrocytes MIP-3β/CCL19, SLC/CCL21, TECK/CCL25 
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lymphocytes with loss of lung function and 
pulmonary emphysema143. Moreover, the 
CCR5 ligands MIP-1α/CCL3, MIP-
1β/CCL4 and RANTES/CCL5 are all 
significantly elevated in the lungs of COPD 
patients 134;144;145. These data suggest a 
prominent role of CCR5 in the 
pathogenesis of COPD. 
CCR6 has, unlike most of its family 
members, only one chemokine ligand, 
namely MIP-3α/CCL20. However, certain 
members of the β-defensin family also 
bind CCR6, but with a lower affinity 146. 
This receptor is expressed on immature 
DCs147, B-lymphocytes148, memory T-
lymphocytes149, cytokine activated 
neutrophils150 and endothelial cells151. The 
interaction of CCR6 with MIP-3α/CCL20 is 
described as one of the most potent 
mechanisms for recruitment of immature 
dendritic cells152;153 and is also known to 
be chemotactic for T-lymphocytes154, 
making CCR6 another possible player in 
the inflammatory process of COPD. Its 
chemokine ligand MIP-3α/CCL20 is 
expressed predominantly in inflamed 
epithelial surfaces, including the airway 
epithelium, and can be upregulated by a 
broad spectrum of pro-inflammatory 
cytokines that are released in the ongoing 
process of COPD50. 
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Chapter 3. Murine models of COPD 
 
Animal models act as a bridge between in 
vitro studies in the laboratory and studies 
in humans. In COPD they enable basic 
research to investigate in vivo the cellular 
and molecular mechanisms of 
inflammatory cell recruitment and alveolar 
destruction. They also allow the testing of 
potential new treatments.  
Mice provide the best choice for an animal 
model, mainly because the mouse 
genome has been entirely sequenced and 
bares close similarity to the human 
genome. Another major advantage is the 
ability to alter the genetic constitution of 
the mouse, either by removing or altering 
genes, or by inserting new genes or 
increasing the gene expression levels. In 
addition complementary antibodies and 
probes exist for many mouse gene 
products, enabling them to be studied 
directly for quantification and localisation. 
However, when using murine models of 
COPD certain limitations need to be taken 
into account. Firstly, there are certain 
anatomical and physiological differences 
between the respiratory tract of mice and 
humans. For example, mice are obligate 
nasal breathers that filter tobacco smoke 
inefficiently, and have less branching of 
the bronchial tree without respiratory 
bronchioles. Secondly, the profile of 
inflammatory mediators is also slightly 
different in the mouse. And lastly, there is 
no mouse model that mimics all the 
hallmarks of COPD pathology. 
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Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, that is not fully reversible, and that is associated
with an abnormal inflammatory response of the airways and lungs to noxious particles and gases. The airflow limitation is caused by
increased resistance of the small conducting airways and by decreased elastic recoil forces of the lung due to emphysematous destruction of
the lung parenchyma. In vivo animal models can help to unravel the molecular and cellular mechanisms underlying the pathogenesis of
COPD. Mice represent the most favored animal species with regard to the study of (both innate and adaptive) immune mechanisms, since
they offer the opportunity to manipulate gene expression. Several experimental approaches are applied in order to mimic the different traits of
COPD in these murine models. Firstly, the tracheal instillation of tissue-degrading enzymes induces emphysema-like lesions in the lung
parenchyma, adding further proof to the protease-antiprotease imbalance hypothesis. Secondly, the inhalation of noxious stimuli, including
tobacco smoke, sulfur dioxide, nitrogen dioxide, or oxidants such as ozone, may also lead to COPD-like lesions in mice, depending on
concentration, duration of exposure and strainspecific genetic susceptibility. Thirdly, in transgenic mice, a specific gene is either
overexpressed (non-specific or organ-specific) or selectively depleted (constitutively or conditionally). The study of these transgenic mice,
either per se or in combination with the above mentioned experimental approaches (e.g. the inhalation of tobacco smoke), can offer valuable
information on both the physiological function of the gene of interest as well as the pathophysiological mechanisms of diseases with complex
traits such as COPD.
Keywords: COPD; Emphysema; Murine; Cigarette smoke; Inflammation; Apoptosis1. Why do we need murine models of COPD/pulmonary
emphysema?
Chronic obstructive pulmonary disease (COPD) is a
major cause of chronic morbidity and mortality throughout
the world [1]. Since COPD is currently listed as the fifth1094-5539/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.pupt.2005.06.001
Abbreviations BAL, bronchoalveolar lavage; COPD, chronic obstruc-
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33leading cause of death in the world, and is also an important
cause of chronic disability and permanent impairment,
COPD represents a major economic and social burden
worldwide [2]. COPD is defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) as ‘a disease
state characterized by airflow limitation that is not fully
reversible, and that is usually both progressive and
associated with an abnormal inflammatory response of the
lungs to noxious particles or gases’ [3,4]. Cigarette smoking
is by far the most important risk factor for COPD. Pipe and
cigar smokers also have greater COPD morbidity and
mortality rates than nonsmokers, although their rates are
lower than those for cigarette smokers. Passive exposure to
cigarette smoke (i.e. environmental tobacco smoke) may
also contribute to respiratory symptoms and COPD.
However, only a susceptible minority (approximately
15–20%) of tobacco smokers develop clinically significant
COPD, suggesting that genetic factors must modify each
individual’s risk [5]. COPD is characterized by an
accelerated decline in lung function, expressed as the forced
expiratory volume in one second (FEV1) and its ratio to thePulmonary Pharmacology & Therapeutics 19 (2006) 155–165www.elsevier.com/locate/ypupt
Table 1
Similarities and differences between asthma and COPD
Asthma COPD
Etiology Sensitizing agent Noxious agent
Most frequent
cause
House dust mite Cigarette smoke
Onset Early in life (often
childhood)
In mid-life
Symptoms Variable (from day to
day)
Slowly progressive
Airway inflammation
Leukocytes Eosinophils Neutrophils and
macrophages
T lymphocytes CD4C Th2 cells CD8CT cells
Inflammatory mediators
Cytokines IL-4, IL-5, IL-13 IL-8, TNF-a
Leukotrienes LTC4, LTD4 LTB4
Airway wall remodeling
Epithelium Thickening of base-
ment membrane
Squamous metaplasia
of epithelium
Mucus glands Glandular enlarge-
ment
Glandular enlarge-
ment
Smooth muscle Muscle hypertrophy Muscle hypertrophy
Lung parenchymal- Absent Present (i.e. emphy-
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why only a minority of smokers experiences this excessive
decline in FEV1 over time is unknown. Therefore, although
the major environmental risk factor for COPD—tobacco
smoke—is well known since many years, the host factors
that are involved in the pathogenesis of COPD have not yet
been identified (besides the rare hereditary deficiency of a-1
antitrypsin) [6].
Since COPD arises from an interaction between genetic
host factors and environmental exposures, the study of these
gene-environment interactions is of critical importance in
order to elucidate the pathogenesis of this abundant and
devastating disease. Mice are the experimental tool of
choice in mammalian research for the following reasons:
(1) recently, both the human and mice genomes have been
sequenced, revealing that only approximately 300 genes
appear to be unique to one species or the other [7];
(2) more than 10,000 genetic markers are mapped in the
mouse, providing useful landmarks for genetic studies;
(3) the ability to alter the genetic constitution of the mouse,
either by inserting new genes or increasing the gene
expression levels by transgenesis, or by removing
or altering genes through gene replacement techniques
(e.g. knock-out mice);
(4) many hundreds of inbred strains and specialized stocks
(e.g. mutants) are available;
(5) thorough knowledge of anatomy, biology and physi-
ology of the mouse, especially with regard to the
immunological system; and
fast breading at relatively low cost.
The extensive knowledge of the mouse biology and the
huge genetic resources, including the ability to genetically
manipulate the mouse, offer thus an unprecedented capacity
to explore biological systems under physiological and
pathological conditions [8]. The mouse has become our
experimental surrogate, when experiments in human
subjects are either technically impossible or morally
inconceivable. The major goals of this research, using
murine models of COPD, are twofold: first, to understand
the cellular and molecular mechanisms involved, and from
this knowledge derive benefit for both the quality of life and
the prevention and treatment of this disease; secondly, to
develop new specific drugs for COPD, in order to improve
the clinical and functional status of patients with COPD,
and—most importantly—in order to prevent the accelerated
decline in lung function and the ensuing morbidity and
mortality.
destruction sema)
Lung function
Airflow limitation Completely reversible Largely irreversible
airway hyperre-
sponsiveness (AHR)
Moderate to severe
increase in AHR
No AHR or only mild
increase in AHR
Response to treatment Glucocorticoids
inhibit inflammation
Glucocorticoids have
little or no effect on
chronic inflammation2. Different experimental models of COPD/pulmonary
emphysema in mice: introduction
Several experimental models of COPD and emphysema
exist in mice, based upon different approaches [9,10].34Firstly, the tracheal instillation of tissue-degrading enzymes
has been used since a long time to study the development of
emphysematous lung lesions [11,12]. Secondly, inhalation
of tobacco smoke and other noxious stimuli in mice induces
lung tissue destruction, although the development of
emphysema-like lesions appears to be strain-dependent
[13,14]. Thirdly, several mouse strains with naturally
occurring genetic mutations develop emphysema spon-
taneously without external stimuli, although a number of
these mutations lead to multisystem defects and are thus not
restricted to pathology of the lung [15]. Gene targeted mice
can also show signs of airspace enlargement, but it is crucial
to distinguish airspace enlargement due to developmental
abnormal lung morphogenesis from adult emphysema,
which is characterized by the destruction of mature alveoli
[16]. Of course, these different approaches can be combined
(e.g. exposure of gene targeted mice to tobacco smoke). As
far as models of exposure to cigarette smoke are discussed
in this review, we will focus on the effects of chronic
exposure of different mice strains to cigarette smoke, since
an excellent review of the acute effects of smoking in both
human and animal studies has been published recently [17].
Before describing the different murine models of COPD
in greater detail, it is important to underline the differences
between COPD and asthma in humans, and by consequence
also in animal models which aim to mimic these chronic
airway diseases (see Table 1). Asthma is defined as a
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causes an associated increase in airway hyperresponsive-
ness that leads to recurrent episodes of wheezing, breath-
lessness and coughing [18]. These episodes are usually
associated with widespread, but variable airflow obstruction
that is often reversible. In contrast, COPD is characterized
by airflow limitation that is usually both progressive and not
fully reversible. The airflow limitation in COPD is
associated with an abnormal inflammatory response of the
airways and the lungs to noxious particles or gases [3].
Although asthma and COPD are thus both characterized by
chronic inflammation of the lower airways, there are
important differences between asthma and COPD in risk
factors, onset of the disease, symptoms, inflammatory
mediators and leukocytes, airway wall remodeling, lung
function and response to treatment with inhaled corticoster-
oids (Table 1) [19]. Moreover, pulmonary emphysema,
which is defined anatomically as ‘abnormal, permanent
enlargement of air spaces distal to the terminal bronchiole,
accompanied by destruction of the alveolar walls’, is a
crucial part of the clinical complex of COPD, but is absent
in asthma [9,20].3. COPD/pulmonary emphysema and the protease/
antiprotease imbalance
An imbalance between proteases and their inhibitors is
believed to play an essential role in the development of
pulmonary emphysema. This imbalance may occur either
by an excessive release of proteases by inflammatory cells
and lung resident cells, or by a reduced synthesis or
increased breakdown of antiproteases. The protease/anti-
protease hypothesis of emphysema was first proposed 40
years ago, based on the observations that smokers with a
deficiency of a1-antitrypsin were at increased risk for
pulmonary emphysema [6], and that intratracheal admin-
istration of papain, a plant protease, leads to emphysema
in experimental animals [21]. Since the initial experiments
of Gross, a variety of proteases have been instilled into
the lungs of animals. In mice, the most consistent and
impressive airspace enlargement has been accomplished
by the intratracheal instillation of porcine pancreatic
elastase [22]. Development of emphysema after instilla-
tion of human neutrophil elastase has also been described
in mice [23]. These rather crude and acute instillation
models can be useful to determine the capacity of a
protease to cause emphysema, and to study downstream
events such as alveolar repair. However, these instillation
models have at least three major drawbacks: they cannot
be used to explore any upstream events; they cannot give
any information about which proteases are involved in the
pathogenesis of emphysema, and lastly, it is difficult to
extrapolate the findings on the acute effects of elastase
instillation to the slowly progressive chronic onset disease
in humans.35Transgenic mice have artificially introduced alterations
in their genome, resulting in expression or overexpression of
the gene product of interest. These transgenic ‘gain-of-
function’ models have added further proof to the protea-
se/antiprotease imbalance hypothesis. Mice that over-
expressed human interstitial collagenase (MMP-1) in their
lungs spontaneously developed pulmonary emphysema
[24]. Recently, it has been shown that MMP-1 generated
this emphysematous phenotype via the degradation of type
III collagen [25,26]. A major disadvantage of this kind of
model is that the gene of interest is also expressed
throughout organ development and growth, which makes
it impossible to separate developmental abnormalities from
the structural injury in adult lungs that defines emphysema.
This problem of constitutive expression of transgenes can be
overcome by the construction of inducible transgenic
expression models. Induced overexpression of interleukin
13 (IL-13) or interferon-g (IFN-g) into the lungs of mice
causes a phenotype that mirrors human COPD [27,28]. In
both models, the overexpression of these inflammatory
cytokines was associated with an increased expression of
matrix metalloproteinases (MMPs) and cysteine proteases
(cathepsins). The emphysematous changes were partly
inhibited after treatment with MMP-inhibitors or cysteine
protease inhibitors. These data thus further establish the role
of proteases in lung tissue destruction, a hallmark of
pulmonary emphysema.
In contrast to transgenic ‘gain-of-function’ models,
targeted mutagenesis of genes has allowed investigators to
generate strains of mice that lack individual proteins, and
thus study the (patho)physiology of several diseases in
gene-targeted ‘loss-of-function’ models. Combination of
gene targeting with the cigarette smoke-exposure model can
provide useful information whether a specific proteinase
contributes to the pathogenesis of emphysema (Table 2).
Hautamaki et al. [29] elegantly demonstrated that MMP-12
deficient mice do not develop airspace enlargement in
response to long term exposure to cigarette smoke, in
contrast to the wild-type animals. MMP-12 deficient mice
also failed to recruit macrophages into their lungs in
response to cigarette smoke. This may be related to the
abrogated generation of elastin fragments, that are chemo-
tactic for monocytes, by MMP-12 [30,31]. Given the fact
that MMP-12 is expressed in human alveolar macrophages
[32], these data suggested a role for MMP-12 not only in the
pathogenesis of mouse but also of human emphysema.
Neutrophil elastase deficient mice were significantly
protected from the development of pulmonary emphysema
after cigarette smoke exposure [33]. It would seem that there
are many interactions between neutrophil elastase and
MMPs, with each augmenting the other’s destructive
capacity. Indeed, MMPs degrade a 1-antitrypsin, whereas
neutrophil elastase degrades tissue inhibitors of metallopro-
teinases (TIMPs). Neutrophil elastase also mediates mono-
cyte migration, whereas MMP-12 may influence neutrophil
accumulation by activation of TNF-a [34]. Interestingly,
Table 2
Gene targeted ‘loss-of-function’ models in selected knock-out (KO) mice
Gene Phenotype References
Macrophage Elastase (MMP-12) KO No emphysema after long term CS-exposure 29, 34
Impaired recruitment of macrophages into the lungs
Neutrophil Elastase (NE) KO Significant protection from CS-induced emphysema 33
Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) KO Spontaneous airspace enlargement evident at 2 weeks 37
[ degradation of collagen
[ MMP activity
Surfactant Protein D (SP-D) KO Spontaneous development of emphysema and fibrosis 38, 39
[ oxidant production in macrophages activates
[ NF-kB and MMP-expression
Integrin avb6 KO Spontaneous development of emphysema 41
Macrophage accumulation in the lungs
[ MMP-12 activation
Nuclear factor erythroid-derived 2 (Nrf2) KO [ extensive CS-induced emphysema 73
[ apoptotic alveolar septal cells
[ markers of oxidative stress
[ BAL inflammation
TNFa receptor double KO Y acute CS-induced inflammation 35, 36
Y acute CS-induced connective tissue breakdown
70% less emphysema after long term CS-exposure
Retinoic acid receptor KO Spontaneous development of emphysema 82
[ static compliance of the lung at postnatal week 4
Y, decreased; [, increased; KO, knock-out; CS, cigarette smoke.
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have demonstrated that TNFa and its receptors are central to
acute cigarette smoke-induced inflammation and connective
tissue breakdown. When these TNFa receptor double
knockout mice were exposed chronically to smoke for 6
months, the ensuing airspace enlargement was reduced by
70% compared to wild type animals [36]. These studies
indicate that TNFa is a critical mediator in the pathogenesis
of COPD/pulmonary emphysema.
Knockout of a specific gene can also lead to the
development of spontaneous, age-related emphysema
(Table 2). TIMP-3 deficient mice demonstrate a progressive
enlargement of alveolar airspaces with increasing age [37].
Next to the possible developmental abnormalities, these mice
display an increased MMP activity. Spontaneous emphy-
sema has also been observed in mice deficient for surfactant
protein D (SP-D) [38,39]. Macrophages of SP-D deficient
mice have increased oxidant production, activating NF-kB
with consequent MMP expression [40]. Finally, mice lacking
the integrin avb6, an activator of latent TGF-b, accumulate
macrophages in the lungs, show increased MMP-12
activation and develop airspace enlargement with age [41].
Interestingly, the phenotypic effects of the avb6 deletion are
overcome by crossing with MMP-12 deficient mice. This
suggests that under normal conditions TGF-b inhibits
MMP-12 production and that in the absence of the avb6
integrin, there is diminished TGF-b activity, leading to
increased production of MMP-12 and emphysema.
Mahadeva and Shapiro [16] excellently reviewed the
data on several naturally occurring mutant mice that
spontaneously develop emphysema due to genetic abnorm-
alities. In some of these strains of mice, the airspace36enlargement is thought to be the result of a disturbance in
the balance between proteases and their inhibitors. For
example, the pallid mice have a deficiency in a 1-antitrypsin
and thus reduced elastase inhibitory capacity, and spon-
taneously develop emphysema late in life [42]. These
histological changes are paralleled with a decrease in lung
elastin content, but there is no alteration in the BAL cell
population [43]. Chronic exposure to cigarette smoke
significantly accelerated parenchymal destruction in pallid
mice [44,45]. This is probably related to the diminished
antiprotease capacity in these mice, and correlates with the
enhanced risk for pulmonary emphysema in humans with a
1-antitrypsin deficiency. Low levels of a 1-antitrypsin have
also been shown in tight skin mice [46], who develop
emphysematous lesions at 2–4 weeks of age [47]. Finally,
also beige mice spontaneously develop emphysema at 2–4
weeks of age [47,48]. These mice were long considered
defective in neutrophil elastase and cathepsin G [49,50], but
recent studies have shown that beige mice are capable of
releasing these enzymes at normal levels [46,51,52].4. Innate immunity and murine models of COPD/
pulmonary emphysema
Lipopolysaccharide (LPS or endotoxin) is a strong
proinflammatory compound present in the cell wall of
Gram-negative bacteria. LPS contains two parts: a
polysaccharide part, that is characteristic and unique for
each bacterial strain and a lipid part (lipid A), which is the
least variable portion of the molecule and is responsible for
the endotoxic activity [53].
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high concentrations in tobacco (approximately 20 mg/
cigarette) and bioactive LPS could be detected in both
mainstream and sidestream cigarette smoke (approximately
0.12–0.2 mg/cigarette) [54,55]. The pulmonary inflam-
mation and airway obstruction observed in smokers and
patients with COPD could thus partially be attributed to the
responses to LPS. Moreover, in healthy human subjects it
was demonstrated that experimental inhalation of LPS
results in chest tightness, cough, dyspnea, sputum pro-
duction and an acute decline in FEV1. LPS inhalation
induces a pulmonary inflammation in a dose-dependent
manner, with increased numbers of neutrophils in bronch-
oalveolar lavage (BAL) and increased concentrations of
TNF-a, IL-1b, IL-6 and IL-8 in BAL fluid [56].
Several mouse models have been described in which
acute pulmonary inflammation was evaluated after a
single LPS exposure, but these models will not be
described here since they study acute LPS lung injury
instead of COPD. Perhaps more relevant to the human
disease is a chronic LPS model in which mice are
exposed to LPS by repetitive intratracheal instillation
during 12 weeks [57,58]. This mouse model mimics
several important pathological changes that are observed
in COPD patients, including goblet cell metaplasia in the
larger airways, thickening of the airway walls (increased
smooth muscle layer) and irreversible alveolar enlarge-
ments (emphysema). The inflammation is characterized
by peribronchial and perivascular lymphocytic aggregates
(CD4C and CD8CT-lymphocytes, and CD19CB-cells),
accumulation of macrophages and CD8CT cells in the
parenchyma and altered cytokine expression (increased
levels of Th1 cytokines TNF-a, IFN-g and IL-18,
measured by RT-PCR). The pulmonary inflammation-
induced by chronic LPS exposure persisted up to 8
weeks after the final LPS exposure, which is comparable
to the persisting airway inflammation in patients with
COPD despite smoking cessation. However, LPS is only
one single component of tobacco, which contains more
than 4.500 compounds in the particulate and vapour
phases, including many other toxic agents such as carbon
monoxide, nitrogen oxides, ammonia, acrolein, benzopyr-
enes, hydroquinone and nicotine [59]. Obviously, the
chronic administration of one single component of
cigarette smoke (i.e. LPS) in animals cannot mimic all
the different aspects of COPD—a complex disease
caused by cigarette smoke—in humans.
In another model, C3H/HeJ mice which are deficient
in TLR4 (the major LPS receptor), showed a reduced
pulmonary accumulation of dendritic cells, neutrophils
and lymphocytes upon cigarette smoke exposure
compared to control mice with a functional TLR4,
suggesting that LPS signaling is important in the
pulmonary inflammation in COPD [60]. Importantly,
despite their defective TLR4-signalling, these C3H/HeJ37mice still developed emphysema upon chronic cigarette
smoke exposure.5. COPD/pulmonary emphysema and the oxidant/
antioxidant imbalance
Cigarette smoke contains high concentrations of reactive
oxygen species (ROS) [61,62]. Increased levels of ROS in
airways and lungs upon cigarette smoking originate not only
directly from the oxidants in cigarette smoke, but also
indirectly from the release of ROS by infiltrating macro-
phages and neutrophils [61,63]. This excess of ROS disturbs
the balance between oxidants and antioxidants, resulting in
oxidative stress [64]. Oxidative stress may be important in
different aspects of the pathology of COPD, since it could
amplify the inflammatory responses, induce apoptosis,
impair the function of protective antiproteases and reduce
the activity of corticosteroids in the treatment of COPD
[65].
In different mouse models, it was demonstrated that
cigarette smoke induces oxidative stress. Mice exposed to
acute cigarette smoke showed a transient, but significant
decrease in antioxidant capacity (TEAC: Trolox Equivalent
Antioxidant Capacity) with a decrease in protein thiols and
in ascorbic acid in BAL [44]. Cigarette smoke strongly
affects the glutathione metabolism, which is an important
feature of the antioxidant defence in the lung [66,67].
Cigarette smoke exposure also increases the concentrations
of compounds resulting from lipid peroxidation, such as
8-isoprostane and 4-hydroxy-2-nonenal in plasma, BAL and
lung [44,68]. Immunohistological analysis after cigarette
smoke exposure demonstrated increased amounts of
8-hydroxy-2 0-deoxyguanosine (indicator of oxidative DNA
damage) in bronchiolar and alveolar epithelial cells [68].
Moreover, the cigarette smoke-induced oxidative stress was
also detected systemically, e.g. in heart and liver [69,70].
Many of the observations made in cigarette smoke-exposed
mice are similar to those obtained in human studies (see
reviews by Barnes [65] and MacNee [61]).
Cavarra and coworkers [14,44] have demonstrated that
the response towards the oxidative effects of cigarette
smoke in mice is strain-specific. The oxidant-sensitive
strains DBA/2 and C57Bl/6J showed a significant drop of
the antioxidant capacity in their BAL fluid in response to
acute cigarette smoke exposure [44]. In contrast, in the ICR
mice that are not oxidant-sensitive, the antioxidant capacity
in the BAL fluid increased. Interestingly, both the DBA/2
and C57Bl/6J mice developed emphysema upon chronic
smoke exposure, whereas the ICR mice were largely
protected from the deleterious effects of cigarette smoke
[14,44]. Another study demonstrated that the oral admin-
istration of an antioxidant (a-tocopherol) could reduce the
cigarette smoke-induced oxidative stress [71]. An in vivo
mouse model was also used to evaluate the effect of
oxidative stress on the activity of human trypsin inhibitors
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smoke exposure—reduced the antitrypsin activity of
intratracheally instilled human recombinant secretory
leucoprotease inhibitor (hrSLPI), suggesting that this
could be an important mechanism in the impaired
antiproteolytic activity in COPD. Finally, the crucial
protective role of antioxidant systems has been demon-
strated in mice with a targeted disruption of the Nuclear
factor, erythroid-derived 2, like 2 (Nrf2), a redox-sensitive
transcription factor that is involved in the regulation of
many detoxification and antioxidant genes [73] (see
Table 2). Disruption of the Nrf2 gene in mice led to
earlier-onset and more extensive cigarette smoke-induced
emphysema compared with wild type animals. Moreover,
emphysema in Nrf2-deficient mice exposed to cigarette
smoke for 6 months was associated not only with increased
levels of markers of oxidative stress, but also with more
pronounced BAL inflammation and with an increased
number of apoptotic alveolar septal cells [73]. This
experimental emphysema model in Nrf2-deficient mice
provides a clear link between excessive oxidative stress due
to an impaired antioxidant system, and increased inflam-
mation, apoptosis and worsened emphysema (see infra).6. Pulmonary repair processes and airway remodeling
in COPD/pulmonary emphysema
Long-term exposure to toxic gases and particles, mostly
cigarette smoke, is the primary cause of COPD. Host
defenses against these stimuli include innate immune
responses (mucociliary clearance, epithelial repair and the
acute inflammatory response) and adaptive immune
responses (humoral and cellular components). Both types
of response are associated with a repair process that
remodels damaged tissue by restoring the epithelium and
microvasculature and by adding connective-tissue matrix in
an attempt to return the tissue to its previous state [74,75].
Unfortunately, this repair process often contributes—in
concert with the chronic inflammation—to the complex
pathological changes leading to COPD [76]. Cigarette
smoke is known to inhibit human bronchial epithelial cell
repair processes [77], though normally the epithelium has a
tremendous capacity to repair itself following injury [78].
Several groups have shown that transforming growth
factor-b (TGF-b), an anti-inflammatory cytokine, is
involved in airway repair [79–81]. In an elastase-induced
murine model of pulmonary emphysema, the lesions
stabilize after the acute phase of tissue damage and repair.
Indeed, following endotracheal administration of elastase,
expression of the elastin gene was induced and synthesis of
elastin in the lungs was increased, resulting in lung elastin
levels which were 30% higher than controls 8 weeks after
challenge [22]. More recently, McGowan reported that
retinoic acid receptor-g knockout mice develop character-
istics of emphysema, suggesting a role for retinoic acid in38the generation and repair of the pulmonary alveolus [82]
(see Table 2). Although Fujita et al. reported that
exogenous applied retinoic acid fails to reverse emphy-
sema in adult mouse models [83], Ishizawa et al. [84]
showed the opposite. In addition, they demonstrated that
besides all-trans-retinoic acid also granulocyte colony-
stimulating factor (G-CSF) is able to promote lung tissue
regeneration in this mouse model of pulmonary emphy-
sema [84]. Mao et al. [85] concluded that all-trans-retinoic
acid could modulate the protease/antiprotease balance in a
manner that may impact on emphysema pathogenesis.
These results raise the possibility that repair mechanisms
following injury may be manipulated by exogenous agents,
and thus might be important in the search for therapeutic
agents for COPD.
Importantly, not only local structural cells of the lungs
are involved in the repair processes, also stem/progenitor
cells derived from the circulation contribute to the repair of
lung injury [86]. Using parabiotic mice that were joined
surgically and developed a common circulation, Rennard
and associates very elegantly demonstrated that after
acute lung injury, induced by intratracheal instillation of
elastase and/or irradiation, stem/progenitor cells in the
blood contributed not only to cells of hematopoietic origin
(e.g. interstitial monocytes/macrophages), but also to
structural lung cells (e.g. subepithelial fibroblasts and type
I alveolar epithelial cells) [86].
The term ‘remodeling’ originates from asthma
research and includes all chronic structural alterations
in the airway, excluding acute changes due to the
recruitment of inflammatory cells or to edema [87,88]. It
comprises most changes in anatomy that are not rapidly
reversible such as thickening of the airway wall,
subepithelial fibrosis, smooth muscle hypertrophy/hyper-
plasia and hyperplasia of fibroblasts, myofibroblasts and
goblet cells.
Some murine models of COPD describe such changes
indicative of airway remodeling. Transmission electron
microscopy demonstrated all the morphological stages of
epithelial injury and repair in the bronchi of oxidant-
sensitive strains of mice after 3 months of cigarette smoke
exposure [14]. In particular, areas of deciliation were
observed, as well as basal cells that accumulate after
epithelial cell detachment and poorly differentiated
epithelial cells with short microvilli covering denuded
areas. In the chronic LPS-model of COPD and emphysema,
airway walls of LPS-exposed mice were thickened when
compared with controls, as indicated by an increased width
of the smooth muscle layer [58]. Moreover, emphysematous
changes and goblet cell metaplasia were observed, whilst
the mRNA expression of the Th1 cytokines TNF-a, IFN-g
and IL-18 was increased in the lungs of LPS-exposed
animals [58].
Some transgenic mice strains with targeted expression
of cytokines in the airways under the control of the Clara
Cell protein 10 (CC10) promotor (e.g. CC10-IL-11 and
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ment, thickening of airway walls and subepithelial
fibrosis without exposure to a specific agent [89,90].
Interestingly, when IL-13 was overexpressed in the
murine lung, an asthma-like eosinophil—and lympho-
cyte-rich inflammation, goblet cell hyperplasia and
airway fibrosis was noted [91]. However, in contrast to
what was expected, the CC10-IL-13 transgenic mice also
had manifest alveolar enlargement, even if the transgene
was only induced in the fully formed lung (to exclude
effects of lung-specific overexpression of IL-13 on lung
development) [27]. IL-13 thus generates on the one hand
airway fibrosis—by inducing and activating TGF-b [92]
and on the other hand causes pulmonary emphysema, by
inducing the expression of a variety of cathepsins and
MMPs [27].
In humans, COPD is characterized by increased mucus
production in large airways (mucous gland enlargement)
as well as in bronchioles (goblet cell metaplasia) [74]. In
mice, submucosal glands were found only in the
proximal regions of the trachea at the same density as
in humans, but unlike in humans, these glands did not
extend below the trachea. Epithelial mucous cells (i.e.
goblet cells) in mice are mainly found in the proximal
airways, but not in smaller airways such as terminal
bronchioles [93]. Recently, goblet cell metaplasia/hyper-
plasia has been described in a murine model of COPD-
based upon chronic cigarette smoke exposure [14].
Comparing two strains of mice sensitive to oxidants,
Bartalesi et al. [14] demonstrated that 75% of the
animals in the C57Bl/6J group showed a positive
periodic acid-Schiff (PAS) reaction of their large or
middle size bronchi at 3 and 6 months smoke exposure;
in contrast, in the DBA/2 group there were no PAS-
positive animals at these timepoints. In C57Bl/6J mice,
the goblet cell metaplasia correlated with a positive
reaction in the airway epithelium on immunohistochem-
ical staining for IL-4, IL-13 and MUC5AC. However,
goblet cell metaplasia is a nonspecific phenomenon and
can be induced by several other stimuli including
ovalbumin challenge [94], LPS exposure [58,95] and
intratracheal instillation of neutrophil elastase [96]. These
in vivo models are valuable tools to further unravel the
mechanisms involved in goblet cell metaplasia (both in
asthma and COPD).7. Apoptosis of lung structural cells: development
of pulmonary emphysema without inflammation
Retamales et al. [97] showed that smokers who
developed severe emphysema had a severalfold increase
in the numbers of macrophages, T-lymphocytes, neutrophils
and eosinophils in their lungs, compared with persons who
smoked similar amounts of cigarettes, but maintained
normal lung function. This suggests that people who39develop emphysema have an amplified inflammatory
response to cigarette smoke, as explicitly mentioned in the
definition of COPD by GOLD [4]. Also in murine models of
chronic cigarette smoke exposure, there is a clear
correlation between the magnitude of the pulmonary
inflammation, comprising macrophages, neutrophils and
T-cells, and the development of emphysema [13,98,99] (see
Fig. 1). Thus both in humans and in mice, the traditional
hypothesis for the pathogenesis of emphysema is that
cigarette smoke induces an (exaggerated) influx into the
lungs of inflammatory cells that release ROS and proteases,
causing the degradation of matrix with subsequent loss of
attachment and death of structural cells. However, at least
three recent studies in mice demonstrated the development
of emphysema, despite a remarkable lack of inflammation
[68,100,101].
The first model used a single intratracheal injection of
active caspase-3 (in Chariot as a protein transfection
reagent) to induce emphysematous changes [68]. This
study provides direct evidence that alveolar wall apoptosis
suffice to cause pulmonary emphysema, even without the
accumulation of inflammatory cells [102]. In the second
model, the intravascular administration of a vascular
endothelial cell growth factor receptor-2 (VEGFR-2)
blocker also generated non-inflammatory emphysema
[100]. Vascular endothelial cell growth factor (VEGF) is
indeed a growth factor required for endothelial cell survival,
and blocking VEGF leads to apoptosis of endothelial cells
[103]. Chronic VEGFR-2 blockade caused thus alveolar
septal cell apoptosis, and airspace enlargement. Petrache
et al. [101] very recently reported that ceramide, a second
messenger lipid, appears to be a crucial mediator of alveolar
destruction in emphysema. Indeed, intratracheal instillation
of ceramide in naı¨ve mice induced emphysema, while
inhibition of enzymes controlling de novo ceramide
synthesis prevented alveolar cell apoptosis and emphysema
caused by blockade of the VEGF receptors in both mice and
rats [101].
These experimental observations in mice are in agree-
ment with recent studies showing that smokers with
emphysema have high levels of apoptosis compared to
smokers without emphysema [104–106]. Also in smoke-
exposed mouse lungs, an increase in apoptotic cells
(epithelial cells and macrophages) has been demonstrated,
and this was associated with enhanced expression of FasL
and caspases, suggesting that cigarette smoke-induced
apoptosis is mediated by a Fas/FasL death receptor
apoptosis pathway [107,108]. Both models put forward a
new concept in the pathogenesis of emphysema, in which
apoptosis and initial loss of epithelial or endothelial cells
can trigger matrix destruction and alveolar space enlarge-
ment. This contrasts with the traditional hypothesis of
cigarette-smoke induced pulmonary inflammation leading
to protease-mediated destruction of alveolar walls. Of
course, both hypotheses on the pathogenesis of emphysema
are not mutually exclusive, and it is becoming progressively
Fig. 1. highlights the different cellular and molecular mechanisms which may be involved in the pathogenesis of chronic obstructive pulmonary disease
(COPD) and pulmonary emphysema. Cigarette smoke can induce chronic inflammation of the airways and lung parenchyma, either directly or indirectly via the
bronchial or alveolar epithelium. Several chemokines such as Interleukin-8 (IL-8) and Macrophage Inflammatory Protein-3a (MIP-3a) are released by
epithelial cells upon exposure to cigarette smoke, inducing the recruitment of neutrophils and monocytes/macrophages, respectively. (1) These inflammatory
cells release various proteases, including neutrophil elastase (NE), cysteine proteases (cathepsins) and matrix metalloproteinases (MMPs), such as macrophage
metalloelastase (MMP-12), causing an imbalance between proteases and anti-proteases such as a1-antitrypsin (a1-AT) and Tissue Inhibitor of Matrix
metalloproteinase (TIMP). Besides these elastolytic proteases, macrophages can secrete many inflammatory proteins upon activation by cigarette smoke,
including Tumor Necrosis Factor-a (TNF-a) and several chemokines such as CXCL9, CXCL10 and CXCL11, which could contribute to the accumulation of
CD8CT-lymphocytes, since they preferentially express the chemokine receptor CXCR3. (2) These CD8CT-cells are able to cause further destruction of
alveolar epithelial cells, by cytolysis and apoptosis, through the release of granzymes and perforins. (3) Many inflammatory and structural cells in the airways
produce reactive oxygen species (ROS) upon activation, leading to oxidative stress when these ROS are generated in excess of the antioxidant defence
mechanisms, such as glutathione, superoxide dismutase and surfactant protein-D (SP-D). Of course, these different cellular and molecular pathogenetic
mechanisms interact, since oxidative stress may inactivate anti-proteases and may amplify apoptosis as well as the chronic inflammation.
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protease/antiprotease imbalance) and apoptosis of epithelial
and endothelial cells in the lungs interact and enforce each
others destructive potential (see Fig. 1).8. Limitations of murine models of human
COPD/pulmonary emphysema
In vivo murine models can offer valuable information on
several aspects of the pathogenesis and treatment of COPD
and emphysema. However, as for other animal species,
murine models of COPD/emphysema also have several
limitations. Firstly, no model mimics the entire COPD
phenotype, since many models specifically mimic only one
trait of the disease, eg the enlargement of the pulmonary
alveoli due to injury to the lung parenchyma (i.e. pulmonary
emphysema). However, the pathogenesis of the progressive
and fixed airflow limitation due to chronic (small) airway
obstruction [74,75], which defines COPD, has not yet been
thoroughly addressed in mice. Moreover, each murine
model of emphysema has its own specific disadvantages.
The most important disadvantages of the protease-induced40emphysema is the lack of significant inflammation and the
near absence of airway changes such as mucous cell
metaplasia. Although there is a significant inflammatory
reaction in the cigarette smoke-induced emphysema, this
murine model has also several specific limitations, since
there is a lack of standardized exposures and of standardized
morphometric analyses [9]. Various smoking machines and
various exposure regimens are used, but the choice of the
smoking regimen is often made arbitrarily [109]. Moreover,
breathing smoke generated by a machine resembles passive
smoking rather than active smoking.
Secondly, there are considerable differences in respirat-
ory physiology and anatomy between mice and humans. In
contrast to humans, mice are obligate nose breathers and
the submucosal glands in mice are restricted to the trachea.
Already during the embryonic stage of lung development,
there are important species differences between murine and
human lung morphogenesis including pulmonary lobation
and bronchial branching (at completion: six airway
generations in mice versus 23 airway generations in
humans) [110]. Importantly, pulmonary emphysema in
humans is classified according to the distribution of the
airspace enlargement within the acinus: in the panacinar
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deficiency—enlargement and destruction of airspaces of
the acinar unit are uniform, whereas in centriacinar
emphysema—as seen in cigarette smokers—the airspace
enlargement occurs primarily in the three generations of
respiratory bronchioles [74]. Rodents however do not have
clearly defined respiratory bronchioles nor distinct lobular
architecture [9]. These distinctions in anatomy have to be
taken into account when extrapolating experimental data
from murine models to human disease.
Lastly, there are also known discrepancies in both innate
and adaptive immunity between the human and murine
immune system [111]. The discrepancies in innate
immunity include the balance of leukocyte subsets,
defensins, Toll-like receptors, chemokines and chemokine
receptor expression. The differences in adaptive immunity
include among other things immunoglobulin subsets,
Th1/Th2 differentiation, and costimulatory molecule
expression and function [111]. All these physiological,
anatomical and immunological differences should be taken
into account when using mice as preclinical models of
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 3.2. Murine ‘cigarette-smoke’ model of COPD 
 
A cigarette smoke-driven murine model of 
COPD was developed in our lab by D’hulst 
and co-workers155. Using a smoking 
apparatus and a smoke chamber (Figure 
9), mice are exposed whole body to the 
tobacco smoke of 5 cigarettes (Kentucky 
Reference Cigarette 2R4F, without filters). 
This exposure is repeated 4 times a day, 
with 30 minute smoke-free intervals, 5 
days a week for 4 weeks (subacute 
exposure) up to 24 weeks (chronic 
exposure).  
 
 
Figure 9. Smoking apparatus and chamber. 
(Picture by A. D’hulst) 
 
The smoke chambers also have an air 
supply, obtaining an optimal smoke/air 
ratio of 1:6. Control groups are exposed to 
air. Carboxyhemoglobin levels in serum of 
CS-exposed mice reached 8.3 ± 1.4 % vs. 
1.0 ± 0.2 % in air-exposed mice. 
Mice exposed to this smoke protocol 
exhibit several hallmarks of COPD 
pathology. Both subacute and chronic 
exposure lead to inflammation in BAL and 
lung parenchyma, with increased 
accumulation of macrophages, 
neutrophils, T-lymphocytes and dendritic 
cells155.  
 
 
Figure 10. Photomicrographs of murine lung tissue 
exposed for 6 months to air (A) or CS (B). 
Magnification, X 200. (Pictures by K. Bracke) 
 
Upon chronic exposure there is also 
formation of peribronchial lymphoid 
follicles135, significant development of 
pulmonary emphysema155 (Figure 10) and 
airway wall remodeling (Figure 11). 
 
 
 
A
B
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This murine cigarette smoke model allows 
us to study inflammatory mediators and 
proteases that could be involved in the 
pathogenesis of COPD. This can assist in 
unravelling the cellular and molecular 
mechanisms that lead to the ongoing 
inflammation and the development of 
pulmonary emphysema. Moreover, by 
using gene targeted mice in this model, we 
can determine the effect of knocking out a 
specific gene on inflammation and alveolar 
destruction, which is a useful tool in 
pinpointing the role of a certain gene 
product in the mechanisms that lead to 
COPD. 
 
 
Measuring pulmonary inflammation 
 
The accumulation of inflammatory cells in 
the lungs of CS-exposured mice is 
measured in both BAL and lung 
parenchyma. Differential cell counts of 
BAL macrophage/monocytes, neutrophils 
and lymphocytes are performed on 
cytocentrifuged preparations using 
standard morphologic criteria after May-
Grünwald-Giemsa staining. Flow 
cytometric analysis is performed to 
enumerate BAL and lung macrophages, 
dendritic cells, CD4+ and CD8+ 
lymphocytes and granulocytes. 
Inflammatory mediators like cytokines or 
chemokines are measured on the RNA 
level by RT-PCR using RNA extracted 
from total lung tissue or BAL-cells. 
Analysis of protein levels of inflammatory 
mediators is performed on BAL 
supernatant using ELISA or the multiplex 
Cytometric Bead Array (CBA). 
 
 
Isolation of CD11c+ cell subsets 
 
CD11c+ cells subsets are isolated using 
the methodology described in our lab by 
Vermaelen et al156. Lung single cell 
suspension are first incubated with anti-
CD11c microbeads. CD11c+ lung cells are 
enriched after one passage through a 
VarioMACS magnetic cell separator. 
Subsequently the CD11c- fraction is kept 
on ice until RNA extraction, while the 
CD11c+ fraction is labelled with anti-
CD11c and anti-MHCII antibodies. With a 
dual-laser FACS Vantage™ flow 
cytometer running Cellquest™ software, 
macrophages and dendritic cells are then 
isolated by fluorescence-activated cell 
sorting using the following gating strategy 
A B 
C D 
Figure 11. Photomicrographs of peribronchial 
deposition of fibronectin (A: air, B: smoke) and 
collagen (C: air, D: smoke) upon chronic exposure 
in mice. Magnification, X 100. (Pictures by K. Bracke) 
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 (Figure 12). After gating on the CD11c-
bright population, two peaks of 
autofluorescence can be distinguished. 
Macrophages are identified as the CD11c-
bright, high autofluorescent population, 
and do not express MHCII. Dendritic cells 
are identified as CD11c-bright, low 
autofluorescent cells, which strongly 
express MHCII. Dendritic cells isolated by 
these criteria correspond with myeloid 
dendritic cells. 
As a last step, RNA is extracted from both 
macrophage and dendritic cell 
populations, as well as from the CD11c- 
population. RT-PCR now allows us to 
study the cell-specific expression levels of 
several proteases or inflammatory 
mediators. 
 
 
 
 
 
 
Figure 12. Gating strategy for flow 
cytometric cell sorting of 
macrophages and dendritic cells. 
Within the CD11c-bight population, 
two peaks of autofluorescence (AF) 
can be distinguished. Only CD11c-
bright/low-AF cells express MHCII 
and are identified as myeloid 
dendritic cells. CD11c-bright/high-
AF cells do not express MHCII, and 
are identified as macrophages. 
(transparent histogram: isotype 
control staining; grey histogram: 
antibody staining). 
 
(Figure by K. Bracke, adapted from reference 
150) 
 
46
 Quantification of Emphysema 
 
Emphysema is a structural disorder 
characterized by destruction of the 
alveolar walls and enlargement of the 
alveolar spaces. We determine destruction 
of alveolar walls by measuring the 
destructive index (DI)157 and 
enlargement of alveolar spaces by 
quantifying the mean linear intercept 
(Lm)158.  
Quantification of airspace enlargement is 
determined after chronic (24 weeks) air or 
CS-exposure by measuring the Lm using 
image analysis software (Image J 1.33). 
The Lm is measured by placing a 100 x 
100 µm grid over each field. The total 
length of each line of the grid divided by 
the number of alveolar intercepts gives the 
average distance between alveolated 
surfaces or the Lm (Figure 13). 
The destruction of alveolar walls is 
quantified by the DI. A grid with 42 points 
that are at the center of hairline crosses is 
superimposed on the lung field. Structures 
lying under these points are classified as 
normal (N) or destroyed (D) alveolar 
and/or duct spaces. Points falling over 
other structures, such as ducts walls, 
alveolar walls, etc., do not enter into the 
calculations. The DI is calculated from the 
formula: DI = D / (D + N) x 100. 
 
 
Figure 13. Quantification of pulmonary emphysema. The mean linear intercept (Lm) is measured by placing a 
100 x 100 µm grid over each field (blue lines). The total length of each line of the grid divided by the number of 
alveolar intercepts (colored dots) gives the average distance between alveolated surfaces or the Lm. 
Magnification, X 200. (Figure by K. Bracke) 
 
47
 Quantification of airway remodeling 
 
To determine the degree of airway 
remodeling, the deposition of collagen and 
fibronectin, as well as airway wall 
thickening is measured. 
After chronic exposure to air or CS, 
morphometrical parameters are marked 
manually on digital representations of the 
airways159: the length of the basement 
membrane (Pbm), the area defined by the 
basement membrane (Abm) and the area 
defined by the total adventitial perimeter 
(Ao). The total bronchial wall area (WAt) is 
calculated (WAt = Ao – Abm) and 
normalized to the squared Pbm. 
Collagen in the airway wall is stained 
using Sirius Red, and the amount of 
fibronectin with an anti-fibronectin 
antibody160. For the quantification of 
collagen or fibronectin deposition, the area 
in the wall covered by the stain is 
determined by a computerized image 
analysis system using the KS400 software 
(Zeiss) (Figure 14). Subsequently, the 
area of collagen or fibronectin is 
normalized to Pbm. Only airways with a 
Pbm smaller than 2000 µm and cut in 
reasonable cross sections (defined by a 
ratio of minimal to maximal internal 
diameter > 0.5) are included.
 
 
 
 
 
 
 
 
Figure 14. Assessment of 
extracellular matrix deposition in 
the airway wall. The small insert 
shows the area covered by Sirius 
Red stained collagen fibers for a 
part of the airway wall. This area 
was determined for the complete 
airway wall by the KS400 software 
(Zeiss) using an image analysis 
system. (Sirius Red stained 
section, magnification 200x). 
 
(Figure by K. Bracke) 
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PART II: RESEARCH WORK 
 
Chapter 4. Research objectives 
 
COPD is mainly caused by cigarette 
smoking and is characterized by an 
abnormal inflammatory reaction in the 
airways and lung parenchyma. There is 
substantial evidence in the literature that 
this exaggerated accumulation of 
inflammatory cells is largely orchestrated 
by chemokines and their respective 
chemokine receptors. Interestingly, the 
inflammation in COPD may be initiated or 
even maintained by the signalling of 
pathogen recognition receptors (PRRs). 
Subsequently, an enhanced release of 
proteases by inflammatory cells may lead 
to an imbalance between proteolytic and 
antiproteolytic activity, contributing to the 
development of pulmonary emphysema.  
As a first step, we attempted to further 
unravel this last hypothesis by studying 
which proteases are upregulated upon 
both sub acute and chronic exposure to 
CS, using a murine CS-driven model of 
COPD. Importantly, we specifically aimed 
at determining the cellular sources of 
these proteases. Our interest was 
particularly in the levels of MMP-12, as 
mice deficient for this protease are 
protected against the development of CS-
induced emphysema1. We wondered 
whether MMP-12 (or macrophage 
metalloelastase) is not only produced by 
macrophages, but also by dendritic cells. 
Since these cells constantly migrate from 
the circulation to the lungs and 
subsequently to the lymph nodes, they are 
capable of damaging the lung structures 
by releasing proteases. 
As a second step, we tried to elucidate 
whether Toll-like receptor (TLR) 4, a PRR 
that recognizes mainly lipopolysaccharide 
but also heat shock proteins, β-defensins 
and breakdown products of the 
extracellular matrix, is implicated in the 
pulmonary inflammation in COPD. 
Therefore, we subjected TLR4 defective 
mice to both sub acute and chronic CS-
exposure, before analysing inflammatory 
cell accumulation and levels of 
proinflammatory cytokines and 
chemokines in the lungs. 
In a third step we aimed at getting some 
more insight into which mechanisms lead 
to the enhanced accumulation of 
macrophages, dendritic cells, neutrophils 
and T-lymphocytes in the lungs of CS-
exposed mice. The possible involvement 
of chemokine receptors was studied by 
using both CCR5 and CCR6 deficient 
mice. We subjected these mice to our CS-
driven model of COPD in order to answer 
the following questions. (1) What is the 
effect of the CCR5 or CCR6 deletion on 
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the inflammatory reaction in CS-exposed 
mice? (2) Do these effects lead to a 
certain degree of protection against the 
development of pulmonary emphysema? 
(3) Is there a correlation between the 
effects on inflammation and the 
remodeling of airway walls? 
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Chapter 5. Publications 
 
5.1. ‘Matrix metalloproteinase-12 and cathepsin D expression in pulmonary 
macrophages and dendritic cells of cigarette smoke-exposed mice’ 
 
Ken Bracke, Didier Cataldo, Tania Maes, Maud Gueders, Agnes Noël, Jean-Michel Foidart,    
Guy Brusselle and Romain A. Pauwels 
 
International Archives of Allergy and Immunology 2005;138(2):169-179. 
 
It is believed that the tissue destruction that leads to pulmonary emphysema originates mainly 
from an imbalance between proteinases and their inhibitors. In this first study we screened lung 
tissue and bronchoalveolar lavage fluid of smoking mice for the expression of several 
proteinases and antiproteinases. Subsequently, we attempted at determining their cellular 
sources within the lung.  
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smoke-exposed mice, in contrast to air-exposed litter-
mates. Western blots on lung tissue demonstrated an 
increase of MMP-12 protein in cigarette smoke-exposed 
animals. These results indicate that cigarette smoke in-
creases the expression of MMP-12 and Cathepsin D in 
the lungs of mice, and that not only macrophages but 
also DCs produce MMP-12. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Cigarette smoking is the major risk factor for the de-
velopment of chronic obstructive pulmonary disease 
(COPD). COPD is one of the leading causes of mortality 
and morbidity and its prevalence is increasing worldwide 
 [1, 2] . The disease is characterized by slowly progressive 
development of airﬂ ow limitation that is poorly revers-
ible. The airﬂ ow limitation is due to chronic obstructive 
bronchiolitis and loss of elastic recoil caused by destruc-
tion of lung parenchyma (emphysema). The molecular 
and cellular mechanisms that are responsible for the de-
velopment of COPD are not well understood. It has been 
shown that chronic exposure to cigarette smoke leads to 
lung inﬂ ammation with recruitment of inﬂ ammatory 
 Key Words 
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 Abstract 
 An imbalance between proteinases and their inhibitors 
is believed to play an essential role in the development 
of chronic obstructive pulmonary disease (COPD) and 
pulmonary emphysema. COPD is mainly caused by cig-
arette smoking, and is characterized by an increase in 
infl ammatory cells in small airways and lung parenchy-
ma. We examined the mRNA expression of several pro-
teinases in lungs of mice exposed to cigarette smoke or 
control air. After 1, 3 and 6 months’ smoke exposure 
there was a signifi cant increase of matrix metalloprotein-
ase (MMP)-12 and Cathepsin D mRNA, compared to air-
exposed mice. To determine the cellular origin of MMP-
12 and Cathepsin D, we isolated dendritic cells (DCs) and 
macrophages from the lungs of mice. There was an in-
crease in MMP-12 mRNA after smoke exposure in both 
macrophage and DC populations, whereas Cathepsin D 
was predominantly expressed in macrophages. Immu-
nohistochemistry clearly revealed the expression of Ca-
thepsin D protein in alveolar macrophages of cigarette 
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cells such as macrophages  [3, 4] , neutrophils  [5, 6] and 
dendritic cells (DCs)  [7, 8] to the airways and pulmonary 
tissue. These cells are all capable of releasing proteinases 
in excess of their inhibitors, causing damage to the extra-
cellular matrix (ECM) of the lung. Ineffective repair of 
elastin and other ECM components results in air space 
enlargement that deﬁ nes pulmonary emphysema. This 
‘proteinase/antiproteinase imbalance’ hypothesis was 
ﬁ rst proposed 40 years ago, based on the observations that 
smokers with a deﬁ ciency of   1 -antitrypsin were at in-
creased risk for pulmonary emphysema  [9] , and that in-
tratracheal administration of papain (a plant proteinase) 
resulted in emphysema in experimental animals  [10] . 
Later, it was described that instillation of neutrophil elas-
tase causes pulmonary emphysema in animal experi-
ments  [11, 12] . Since then, many other proteinases, in-
cluding serine proteinases, cysteine proteinases and ma-
trix metalloproteinases (MMPs) have been linked in one 
way or another to COPD or emphysema. 
 We have previously demonstrated that MMP-9 and its 
active form are present in increased amounts in COPD 
sputum   [13] .   Other authors showed higher levels of 
 MMP-1, -2, -9 and -14 in lungs of COPD patients  [14–
16] . Animal models also afford strong arguments for a 
signiﬁ cant role of proteinases such as MMPs in emphy-
sema. Tissue inhibitor of matrix metalloproteinases 
(TIMP)-3-deﬁ cient mice demonstrate a slowly progres-
sive spontaneous enlargement of alveolar air spaces with 
increasing age  [17] and MMP-12-deﬁ cient mice do not 
develop air space enlargement in response to long-term 
exposure to cigarette smoke, in contrast to their wild-type 
littermates  [18] . Inducible targeting of IL-13 or IFN-  to 
the lungs of mice causes emphysema and is associated 
with an increased expression of MMPs and cathepsins 
 [19, 20] . 
 To further elucidate which are the key proteinases in 
the development of pulmonary emphysema, we exam-
ined the mRNA expression of several proteinases and 
antiproteinases in vivo in the lungs of mice either exposed 
to cigarette smoke or to control air for 1, 3 and 6 months. 
Secondly, to determine the cellular sources of these pro-
teinases, we examined the mRNA expression in DCs and 
macrophages isolated from lung tissue of mice exposed 
to cigarette smoke or control air. Thirdly, we studied the 
inﬂ uence of cigarette smoke extract (CSE) on bone mar-
row-derived DCs in vitro, to elucidate whether the ob-
served effects of cigarette smoke exposure on proteinase 
expression in DCs were due to a direct effect (by cigarette 
smoke itself) or due to an indirect mechanism (e.g. via 
lung inﬂ ammation). 
 Materials and Methods 
 Animals 
 Male C57BL/6 mice, 6–8 weeks old, were purchased from Har-
lan (Zeist, The Netherlands). The local Ethics Committee approved 
all in vivo manipulations. 
 Cigarette Smoke Exposure 
 Mice were exposed to the whole smoke of 5 cigarettes (Standard 
Cigarette 1R3, Kentucky University) using a standard smoking ap-
paratus  [21] with the chamber adapted for a group of mice (cham-
ber dimensions: 24  ! 14  ! 14 cm = 4,700 cm 3 ). An optimal smoke:
air ratio of 1:  12 was obtained. Smoke exposure is repeated 4 times/
day, with a smoke-free interval of 30 min, 5 days/week for 1, 3 or 
6 months. Control mice were air-exposed. 
 Preparation of CSE 
 To prepare CSE, the smoke of 10 cigarettes (Standard Cigarette 
2R4F without ﬁ lter, University of Kentucky) was bubbled through 
30 ml of culture medium. This treatment did not alter the pH of the 
medium. The resulting suspension was ﬁ lter-sterilized. This solu-
tion, considered to be 100% CSE, was diluted to a 5% concentration 
and applied to the DC cultures within 30 min of preparation. 
 Tissue Processing and Cellular Recovery 
 Twenty-four hours after the last smoke exposure, mice were 
anesthetized using an intraperitoneal pentobarbital injection. To 
obtain bronchoalveolar lavage (BAL) ﬂ uid, the trachea are cannu-
lated and 1 ml of HBSS without Ca 2+  or Mg 2+ , supplemented with 
0.5 m M EDTA, was instilled 4 times via the tracheal cannula and 
recovered by gentle manual aspiration. This BAL ﬂ uid was centri-
fuged, and the cell pellet was subjected to red blood cell lysis (am-
monium chloride) and kept on ice until RNA extraction. To obtain 
lung tissue, right heart catheterization and perfusion with saline-
EDTA was performed to remove the pulmonary intravascular pool 
of cells. Lungs were removed and collected in ice-cold tissue culture 
medium for preparation of single-cell suspensions, or in RNA later 
stabilization ﬂ uid (Qiagen) for RNA extraction. For protein analy-
sis, lungs were frozen in liquid nitrogen until further processing. 
 Morphometric Quantiﬁ cation of Emphysema 
 Lungs were ﬁ xated by gentle infusion of ﬁ xative (4% parafor-
maldehyde) through the tracheal cannula by a continuous-release 
pump under constant pressure for 10 min. The lungs were resected 
and ﬁ xed for an additional 4 h. After routine parafﬁ n embedding, 
3-  m sections were stained with hematoxylin and eosin (Klinipath, 
Geel, Belgium). 
 Quantiﬁ cation of emphysema was determined by mean linear 
intercept (L m ). For each animal, 10 ﬁ elds at a magniﬁ cation of 
200 ! were captured in a blinded fashion and studied via a com-
puterized image analysis system (KS400, Zeiss, Oberkochen, Ger-
many) with a custom-made macro-command. A 100  ! 100   m 
grid was drawn on the image and the L m  was measured  [22, 23] . 
 Buffers and Media for Preparation of Single-Cell Suspensions 
and Flow Cytometry 
 Tissue culture medium was prepared using RPMI-1640 supple-
mented with 5% FCS, penicillin/streptomycin,  L -glutamine and 
2-mercaptoethanol (all from GibcoBRL). Digestion medium con-
sisted of tissue culture medium supplemented with 1 mg/ml colla-
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genase type 2 (Worthington Biochemical Corp., Lakewood N.J., 
USA) and 0.02 mg/ml DNase I (grade II from bovine pancreas, 
Boehringer Mannheim, Brussels, Belgium). FACS-EDTA buffer 
contained PBS without Ca 2+  or Mg 2+ , 0.1% azide, 1% bovine serum 
albumin (Sigma) and 5 m M EDTA. 
 Preparation of Lung Single-Cell Suspensions 
 Lungs were minced using ﬁ ne scissors and incubated in diges-
tion medium in a humidiﬁ ed incubator at 37  °  C and 5% CO 2 . After 
30 min incubation, samples were vigorously agitated using glass 
pipettes, fresh digestion medium was added and incubation pro-
longed for another 15 min. Subsequently, the samples were agi-
tated, centrifuged and incubated in calcium and magnesium-free 
PBS containing 10 m M EDTA. Finally, the cells were subjected to 
red   blood   cell   lysis,   washed   in   FACS-EDTA,   passed   through a 
 50-  m cell strainer and kept on ice until ﬂ uorescent labeling. 
 Labeling of Single-Cell Suspensions for Flow Cytometry 
 Cells were preincubated with Fc-receptor blocking antibody 
(anti-CD16/CD32, clone 2.4G2) to reduce non-speciﬁ c binding. 
Monoclonal antibodies used to identify mouse DC and macrophage 
populations were: biotinylated anti-CD11c (N418), followed by 
streptavidin-APC, and PE-conjugated anti-MHCII/I-A b  (AF6-
120.1). All reagents were obtained from BD-Pharmingen (Erembo-
degem, Belgium) except clone N418 (kindly provided by M. Moser, 
ULB, Brussels, Belgium). Flow cytometry data acquisition was per-
formed on a FACS Vantage SE equipped with 488- and 633-nm 
lasers and running Cellquest 3.3 software (Becton Dickinson, 
Franklin Lakes, Calif., USA). Lung DCs were deﬁ ned as CD11c + /
low-autoﬂ uorescent/MHCII +  cells. Lung macrophages were de-
ﬁ ned as CD11c + /high-autoﬂ uorescent cells  [24] . 
 Puriﬁ cation and Separation of Pulmonary CD11c +  Cell 
Subsets 
 CD11c +  cell subsets were isolated according to Vermaelen and 
Pauwels  [24] . To obtain sufﬁ cient amounts of DCs and macro-
phages for RNA preparation, the single-cell suspensions of 8–12 
mice were pooled. Pulmonary single-cell suspensions were ﬁ rst in-
cubated with Fc-receptor block, followed by anti-CD11c micro-
beads (Miltenyi Biotec, Bergisch Gladbach, Germany). CD11c +  
lung cells were enriched after one passage through a VarioMACS 
magnetic cell separator according to manufacturer’s instructions. 
Subsequently, the CD11c –  fraction was kept on ice until RNA ex-
traction. The CD11c +  fraction was labelled with biotinylated anti-
CD11c, followed by streptavidin-APC, and PE-conjugated anti-
MHCII. On the FACS Vantage SE, the CD11c + /low-autoﬂ uores-
cent/MHCII +  and CD11c + /high-autoﬂ uorescent cells, representing 
DC and macrophage populations respectively, were separated by 
ﬂ uorescence-activated cell sorting with a 70-nm nozzle. 
 Generation of Bone Marrow-Derived DCs 
 The procedure used for the generation of DCs was that de-
scribed by Lutz et al.  [25] . Brieﬂ y, single-cell suspensions were ob-
tained from bone marrow by ﬂ ushing the femurs of mice. At day 0 
the cells were seeded at 2  ! 10 6  per 100 mm 2  Petri dish in 10 ml 
medium (RPMI-1640, 10% FCS, 100 U/ml penicillin, 100   g/ml 
streptomycin, 2 m M  L -glutamine and 50   M 2-mercaptoethanol 
(all from GibcoBRL)), supplemented by 20 ng/ml GM-CSF. At day 
3, an equal volume of fresh medium and GM-CSF was added to 
the plate. At day 6, half of the culture supernatant was collected, 
centrifuged, and the cell pellet was resuspended in an equal volume 
of fresh medium containing GM-CSF. At day 8, the DCs were har-
vested and depleted of GR1 +  cells to remove contamination of 
granulocytes (using puriﬁ ed anti-GR1 and Dynabeads m450). Part 
of the DCs were kept on ice until RNA extraction, and part of the 
cells were stimulated with LPS (1   g/ml culture medium) or 5% 
CSE and incubated overnight in a humidiﬁ ed incubator at 37  °  C 
and 5% CO 2 . On day 9 these LPS- or CSE-stimulated cells were 
harvested and kept on ice until RNA extraction. 
 RNA Extraction 
 RNA from lung tissue was extracted with the Qiagen RNeasy 
Midi Kit. RNA from cultured cells, BAL cells or sorted cells was 
extracted with the Qiagen RNeasy Mini Kit. All RNA extractions 
included an additional DNase step. 
 RT-PCR 
 RT-PCR for different proteinases and antiproteinases was per-
formed by means of in-house designed primer combinations or the 
Assays-on-Demand™ Gene Expression Products (Applied Biosys-
tems, Bedford, Mass., USA). All reactions were performed starting 
from 10 ng of total RNA. 
 For MMP-2, -9 and TIMP-1 and -2, a known copy number of 
external control RNA template (synthetic RNA) was introduced in 
each sample to monitor the RT-PCR reaction and to allow the 
quantitation of each endogenous mRNA  [26] . RT-PCR was per-
formed using the GeneAmp Thermostable rTth reverse transcrip-
tase RNA PCR kit (PerkinElmer, Branchburg, N.J., USA) and two 
pairs of primers (GibcoBRL-Life Technologies) ( table 1 ). Reverse 
transcription was performed at 70  °  C for 15 min followed by 2 min 
incubation at 95  °  C for denaturation of RNA-DNA heteroduplexes. 
Ampliﬁ cation started at 94  °  C for 15 s, 68  °  C for 30 s and 72  °  C for 
10 s and RT-PCR terminated by 2 min at 72  °  C. RT-PCR products 
were    resolved    on    10%    acrylamide    gels   and   analyzed   using   a  
 Fluor-S MultImager (Bio-Rad, Hercules, Calif., USA) after staining 
with Gelstar dye (FMC Bioproducts, Rockland, Me., USA). Quan-
titative RT-PCR results are expressed as a ratio between the inten-
sities of the bands corresponding to the endogenous RNA and to a 
synthetic RNA added in the RT-PCR reaction in known amounts 
 [26, 27] . For normalization of the samples, this ratio calculated for 
a given MMP is further divided by the same ratio calculated for 
28S rRNA in the same sample. The results shown are a mean of 
duplicates. 
 Expression of MMP-8 and -12, Cathepsins B, D and L and Cy-
statin C mRNA, relative to hypoxanthine guanine phosphoribo-
syltransferase (hprt) mRNA or transferrin receptor (tfrc) mRNA, 
was analyzed with the Assays-on-Demand™ Gene Expression 
Products (Applied Biosystems). RT-PCR was performed on an ABI 
PRISM 7700 Sequence Detection System with MuLV RTase (Ap-
plied Biosystems). Reverse transcription was performed at 48  °  C 
for 30 min followed by 12 min incubation at 95  °  C for denaturation 
of RNA-DNA heteroduplexes, and 50 cycles of 95  °  C for 15 s and 
60  °  C for 60 s. Monitoring of the RT-PCR occurred in real-time 
using a FAM/TAMRA probe. 
 Western Blotting for MMP-12 
 Proteins were isolated from lung tissue crushed in liquid nitro-
gen using a urea solution  [28] . Samples were electrophoretically 
separated in SDS-12% polyacrylamide gels in the presence of 5% 
  -mercaptoethanol. Proteins were transferred to a PVDF mem-
71
 Bracke/Cataldo/Maes/Gueders/Noël/
Foidart/Brusselle/Pauwels 
 
 Int Arch Allergy Immunol 2005;138:169–179 172
brane (NEN Life Science Products, Downers Grove, Ill., USA) 
which was subsequently incubated for 1 h at room temperature in 
Tris-buffered saline (TBS) containing 5% skimmed milk. The blots 
were then incubated for 1 h at room temperature with a rabbit poly-
clonal anti-MMP-12 antibody (Biomol, Plymouth Meeting, Pa., 
USA) diluted 1:  100 in TBS, washed 3 times in TBS-Tween (0.1%) 
and ﬁ nally incubated for 1 h with peroxidase-conjugated swine-
anti-rabbit IgG (DAKO, Glostrup, Denmark) diluted 1:  1,000. Ac-
cording to the manufacturer’s data, this antibody showed no cross-
reactivity with other MMPs. The peroxidase activity was assessed 
using an enhanced chemiluminescence kit (NEN Life Science Prod-
ucts). 
 Immunohistochemistry for Cathepsin D 
 Sections obtained from formalin-ﬁ xed, parafﬁ n-embedded lung 
lobes were subjected to the following immunohistological staining 
sequence: blocking reagent (Boehringer Mannheim, Germany) plus 
Triton X-100, goat-anti-mouse Cathepsin D (R&D Systems Eu-
rope, Abingdon, UK) or goat IgG isotype control, rabbit-anti-goat 
biotin (DAKO), streptavidin HRP (DAKO) and DAB substrate 
(DAKO). Sections were counterstained with hematoxylin. 
 Statistical Analysis 
 Reported values are expressed as means  8 SD. The different 
experimental groups were compared by Kruskal-Wallis test for 
multiple comparisons. Pairwise comparisons were made by means 
of a Mann-Whitney U test with the Bonferroni correction. A p 
value  ! 0.05 was considered signiﬁ cant. 
 Results 
 Morphometric Quantiﬁ cation of Emphysema 
 Microscopic analysis of lung tissue sections revealed a 
signiﬁ cant degree of emphysema after 6 months of smoke 
exposure. The L m  value was signiﬁ cantly higher in smoke-
exposed   mice   as   compared   to air-exposed animals (L m  
at 6 months’ smoke 42.44   8 0.69    m vs. air 38.21  8 
0.87   m; p  ! 0.01) ( ﬁ g. 1 ). 
 Proteinase mRNA Expression in Lung Tissue 
 Mice were exposed to cigarette smoke or control air 
for 1, 3 and 6 months. Expression of proteinase mRNA 
in total non-lavaged lung tissue was examined by quan-
titative RT-PCR at the three different time intervals. For 
MMP-12, there was a 6- to 7-fold increase in mRNA ex-
pression after 1, 3 and 6 months’ smoke exposure, com-
pared to air-exposed mice ( ﬁ g. 2 A). The Cathepsin D 
mRNA expression increased 2-fold after 1, 3 and 6 
months’ smoke exposure, compared to air-exposed mice 
( ﬁ g. 2 B). After 6 months of smoke exposure there was also 
a slight increase in MMP-2 expression (data not 
shown). 
 No differences in the expression of MMP-8 and -9 and 
Cathepsins B and L could be detected (data not shown). 
Importantly, there were no differences in the mRNA ex-
pression of the proteinase inhibitors TIMP-1, TIMP-2 
and Cystatin C after smoke exposure (data not shown). 
 Proteinase mRNA Expression in BAL Cells 
 Mice were exposed to cigarette smoke or control air 
for 1 month. Expression of proteinase mRNA in BAL 
cells was examined by quantitative RT-PCR. There was 
a 30-fold increase in MMP-12 mRNA after smoke expo-
sure, compared to air-exposed mice ( ﬁ g. 3 A). Smoke ex-
posure induced a 2-fold increase in Cathepsin D mRNA 
levels ( ﬁ g. 3 B). 
 Western Blotting for MMP-12 Protein in Lung Tissue 
 The presence of MMP-12 protein was examined by 
Western blotting on total, non-lavaged lung tissue. The 
used antibody recognized mainly the 54-kDa latent form 
of MMP-12. There was a signiﬁ cant increase in MMP-12 
protein in the lungs of mice exposed to cigarette smoke 
for 1 month, compared to air-exposed mice ( ﬁ g. 4 ). 
 Table 1. Primers and cycling conditions for RT-PCR 
Oligonucleotide sense Oligonucleotide antisense Number of 
PCR cycles
Expected RNA size, bp
control endogenous
MMP-2 5-AGATCTTCTTCTTCAAGGACCGGTT-3 5-GGCTGGTCAGTGGCTTGGGGTA-3 36 271 225
MMP-9 5-CCCACATTTGACGTCCAGAGAAGAA-3 5-GTTTTTGATGCTATTGCTGAGATCCA-3 36 266 208
TIMP-1 5-GGCATCCTCTTGTTGCTATCACTG-3 5-GTCATCTTGATCTCATAACGCTGG-3 35 295 168
TIMP-2 5-CTCGCTGGACGTTGGAGGAAAGAA-3 5-AGCCCATCTGGTACCTGTGGTTCA-3 30 269 155
28S 5-GTTCACCCACTAATAGGGAACGTGA-3 5-GATTCTGACTTAGAGGCGTTCAGT-3 19 269 212
RT-PCR for MMP-8 and -12, Cathepsins B, D and C, Cystatin C, hprt and tfrc was performed with the Applied Biosystems Assays-on-Demand Gene Ex-
pression Products™.
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 Immunohistochemistry for Cathepsin D Protein on 
Lung Tissue 
 The presence of Cathepsin D protein was examined by 
immunohistochemistry on parafﬁ n-embedded lung sec-
tions of mice exposed to cigarette smoke or control air for 
1 month. While there was no Cathepsin D protein detect-
able in the lungs of air-exposed mice ( ﬁ g. 5 B), there was 
a strong staining for Cathepsin D protein in the alveolar 
macrophages of the smoke-exposed animals ( ﬁ g. 5 C, D). 
 MMP-12 and Cathepsin D mRNA Expression in DCs 
and Macrophages Isolated from Lung Tissue 
 Mice were exposed to cigarette smoke or control air 
for 1, 3 and 6 months. Smoke exposure induced a sig-
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 Fig. 1. Morphometric quantiﬁ cation of emphysema.  A Representa-
tive photomicrographs of hematoxylin and eosin stained lung tissue 
of air-exposed ( a ) and smoke-exposed ( b ) mice.  B Mean linear in-
tercept (L m ) values of mice exposed to cigarette smoke for 6 months, 
compared to air-exposed mice. n = 6 animals per group. * p  ! 
0.05. 
 Fig. 2. RT-PCR for the expression of MMP-12 mRNA ( A ) and 
Cathepsin D mRNA ( B ) in lung tissue of mice exposed to cigarette 
smoke for 1, 3 and 6 months, compared to air-exposed mice. Re-
sults are expressed as a ratio with hrpt mRNA (mean  8 SD). n = 
5 animals per group. * p  ! 0.05. hprt = Hypoxanthine guanine phos-
phoribosyltransferase.  1 
 2 
73
 Bracke/Cataldo/Maes/Gueders/Noël/
Foidart/Brusselle/Pauwels 
 
 Int Arch Allergy Immunol 2005;138:169–179 174
niﬁ cant increase in DCs and macrophages in BAL ﬂ uid 
(total number of DCs at 6 months: smoke 50.6  8 2.6  ! 
10 3  vs. air 10.2  8 1.5  ! 10 3 , p  ! 0.001; total number of 
macrophages at 6 months: smoke 11.5  8 1.1  ! 10 5  vs. 
air 4.1  8 0.4  ! 10 5 , p  ! 0.001). Also in lung parenchyma, 
the total number of DCs and macrophages increased sig-
niﬁ cantly upon smoke exposure (DCs at 6 months: smoke 
2.9  8 0.3  ! 10 5  vs. air 1.9  8 0.2  ! 10 5 , p  ! 0.05; mac-
rophages at 6 months: smoke 8.7  8 0.8  ! 10 5  vs. air 4.8 
 8 0.8  ! 10 5 , p  ! 0.01). 
 DCs and macrophages were isolated from total non-
lavaged lung tissue by FACS cell sorting. The MMP-12 
and Cathepsin D mRNA expression was examined by 
quantitative RT-PCR in DCs (CD11c + /low-autoﬂ uores-
cent/MHCII +  cells), in macrophages (CD11c + /high-auto-
ﬂ uorescent cells) and in the CD11c –  population  [24] . 
 We found MMP-12 mRNA expression not only in mac-
rophages, but also in DCs ( ﬁ g. 6 A). In both cell populations 
there was a strong increase in MMP-12 expression after 1, 
3 and 6 months’ smoke exposure. Only a faint expression 
of MMP-12 was detected in the CD11c –  population that 
was depleted from DCs and macrophages ( ﬁ g. 6 A). 
 Cathepsin D mRNA was expressed predominantly in 
macrophages, with only very low levels of mRNA expres-
sion in the DC and CD11c –  populations ( ﬁ g. 6 B). After 
1, 3 and 6 months’ smoke exposure there was a strong 
increase in Cathepsin D mRNA in the macrophage pop-
ulation ( ﬁ g. 6 B). 
 Effects of CSE on Bone Marrow-Derived DCs 
 Expression of MMP-12 mRNA in in vitro cultured, 
bone marrow-derived DCs was examined by quantitative 
RT-PCR. Expression was compared between immature 
DCs (harvested on days 8 and 9) and LPS- or CSE-stim-
ulated DCs (harvested on day 9). 
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 Fig. 4. Western blot for the presence of MMP-12 protein in the 
lungs of mice exposed to cigarette smoke for 1 month, compared 
to air-exposed mice. Results are expressed as OD/mm 2  (mean  8 
SD). n = 7 animals per group. * p  ! 0.05. 
 Fig. 3. RT-PCR for the expression of MMP-12 mRNA ( A ) and 
Cathepsin D mRNA ( B ) in bronchoalveolar (BAL) cells of mice 
exposed to cigarette smoke for 1 month, compared to air-exposed 
mice. Results are expressed as a ratio with hrpt mRNA (mean  8 
SD). n = 8 animals per group. * p  ! 0.05. hprt = Hypoxanthine gua-
nine phosphoribosyltransferase. 
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 Fig. 5. Immunohistochemistry for Cathepsin D protein on lung tissue of mice exposed to cigarette smoke or con-
trol air for 1 month:  A isotype control,  B air-exposed mice,  C smoke-exposed mice on a 20 ! magniﬁ cation and 
 D smoke-exposed mice on a 40 ! magniﬁ cation. 
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 MMP-12 expression was detected in all DC popula-
tions, with a signiﬁ cantly higher expression in the LPS- 
and CSE-stimulated populations ( ﬁ g. 7 ). 
 For Cathepsin D, there was no signiﬁ cant difference 
in expression between the DC populations (data not 
shown). 
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 Fig. 6. MMP-12 ( A ) and Cathepsin D mRNA ( B ) expression in dendritic cells (DCs) and macrophages (Mph) ob-
tained by cell sorting of non-lavaged lung tissue from mice-exposed to cigarette smoke for 1, 3 and 6 months, com-
pared to air-exposed mice, and the MMP-12 and Cathepsin D mRNA expression in the CD11c –  population that 
is depleted from DCs and macrophages. Results are expressed as a ratio with tfrc mRNA. Data are representative 
of three independent experiments. * p  ! 0.05. tfrc = Transferrin receptor. 
 Fig. 7. MMP-12 mRNA expression in bone marrow-derived DCs, 
harvested at days 8 and 9 after LPS or CSE stimulation. Results are 
expressed as a ratio with hprt mRNA (mean  8 SD). n = 5 cultures 
of bone marrow-derived DCs. Data are representative of three in-
dependent experiments. * p  ! 0.05. LPS = Lipopolysaccharide; 
CSE = cigarette smoke extract; hprt = hypoxanthine guanine phos-
phoribosyltransferase. 
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 Discussion 
 Airﬂ ow limitation in COPD is largely due to airway 
inﬂ ammation and loss of elastic recoil due to destruction 
of lung parenchyma (emphysema). An imbalance be-
tween proteinases and their inhibitors is believed to play 
an essential role in the development of pulmonary em-
physema. To elucidate which proteinases play a key role 
in this process, we examined the mRNA expression of 
several proteinases and antiproteinases in the lungs of 
mice either exposed to cigarette smoke or to control air. 
Histological analysis of the lungs of these mice showed 
clear signs of pulmonary emphysema after 6 months of 
smoke exposure, in contrast to air-exposed mice. 
 In both lung tissue and BAL cells there was a strong 
increase in MMP-12 mRNA expression after smoke ex-
posure, while there was no difference in the expression 
levels of the inhibitors TIMP-1 and -2. Therefore, the 
MMP-12/TIMP ratio will be increased, contributing to 
the proteinase/antiproteinase imbalance. Western blot 
analysis revealed a signiﬁ cant increase in MMP-12 pro-
tein in lung extracts of smoke-exposed mice. Taken to-
gether with the fact that MMP-12-deﬁ cient mice do not 
develop emphysema in response to long-term cigarette 
smoke  [18] , these ﬁ ndings further establish the involve-
ment of MMP-12 in the development of pulmonary em-
physema. Moreover, it has been described that the devel-
opment of age-related emphysema in Itg  6-deﬁ cient mice 
is accompanied by a marked induction of MMP-12  [29] . 
It should however be noted that, to date, the involvement 
of MMP-12 in pulmonary emphysema has only been 
demonstrated in mice, and not yet in humans. This could 
point to species-speciﬁ c effects, although it has recently 
been described that human bronchial epithelial cells may 
be an important source of MMP-12 in COPD and tissue 
remodelling  [30] . 
 Lung inﬂ ammation in COPD is characterized by the 
recruitment of several inﬂ ammatory cells such as macro-
phages, neutrophils and DCs. In our mouse model of 
COPD, these cell types are increased in mice exposed to 
cigarette smoke, compared to air-exposed mice  [21] . To 
determine the cellular sources of MMP-12, we examined 
the mRNA expression in DCs and macrophages isolated 
from the lungs of mice either exposed to cigarette smoke 
or to control air. We found MMP-12 expression in simi-
lar amounts in both DC and macrophage populations. 
Since we found almost no MMP-12 expression in the pop-
ulation that was depleted from DCs and macrophages, it 
is likely that DCs and macrophages are among the main 
sources for MMP-12 in the lungs of mice. In both DC and 
macrophage populations, there was a strong increase in 
MMP-12 expression after 1, 3 and 6 months’ smoke ex-
posure, compared to air exposure. The higher MMP-12 
levels in the lungs of smoking mice can thus be attributed 
to the combination of increased numbers of macrophages 
and DCs, and a higher expression of MMP-12 in these 
cells. 
 We conﬁ rmed expression of MMP-12 in DCs derived 
from bone marrow. According to Lutz et al.  [25] , cells 
harvested at day 8 were mostly immature DCs. After 
overnight stimulation of bone marrow-derived DCs with 
LPS or CSE, there was a signiﬁ cant increase in MMP-12 
mRNA expression. This indicates that MMP-12 expres-
sion increases with LPS- or CSE-induced maturation of 
DCs, and correlates with the increased MMP-12 expres-
sion in the in vivo DCs isolated from lungs of mice after 
smoke exposure. Moreover, this increased expression of 
MMP-12 in bone marrow-derived DCs clearly shows a 
direct inﬂ uence of CSE on DCs. The expression of MMP-
12 by DCs has also been described in human blood mono-
cyte-derived DCs  [31] . 
 Although the relative numbers of macrophages are 
higher than those of DCs, the observation that MMP-12 
(also called macrophage metalloelastase) is not only pro-
duced by macrophages but also by DCs, could be of par-
ticular importance, since DCs are migratory cells. In 
steady-state conditions, respiratory DCs are continuous-
ly replenished by a fast recruitment of DC precursors 
from the circulation  [32] . In response to environmental 
stimuli (e.g. antigen) or stress signals, respiratory DCs 
emigrate from the airways towards thoracic lymph nodes 
 [33] . This airway trafﬁ cking is further accelerated in 
mouse models of ongoing allergic airway inﬂ ammation 
 [34] . During their recruitment from the circulation into 
the lungs, or during their emigration from the respiratory 
tract, DCs could thus harm the surrounding tissue and 
degrade cross-linked elastin networks by releasing MMP-
12. Moreover, MMPs not only degrade components of 
the ECM, but also have several cytokines and chemokines 
among their substrates  [35] . MMP-12 in particular, acts 
as a TNF-  -converting enzyme, releasing active TNF-  
 [36] . It has been shown that TNF-  plays an important 
role in the pathogenesis of cigarette smoke-induced em-
physema  [37] . 
 Besides the important role of MMP-12, there are most 
certainly other proteinases involved in the development 
of pulmonary emphysema. We showed an increase in Ca-
thepsin D mRNA expression after 1, 3 and 6 months’ 
smoke exposure, while the Cathepsin inhibitor Cystatin 
C was not inﬂ uenced by the smoke exposure. The in-
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creased ratio of Cathepsin D to Cystatin C adds further 
to the imbalance between proteinases and antiprotein-
ases. We found Cathepsin D mRNA and protein to be 
predominantly expressed by macrophages, as evidenced 
by RT-PCR and immunohistochemistry respectively. 
Again, the increase in Cathepsin D mRNA in the lungs 
of smoking mice can be attributed to both the higher num-
ber of macrophages and their higher expression of Ca-
thepsin D per cell. It has been described earlier that in-
duction of emphysema by IFN-  is accompanied by an 
increased expression of Cathepsin D  [20] . 
 We also found a slight increase in MMP-2 expression 
after 6 months of smoke exposure, but no difference in 
the mRNA expression of MMP-8 and -9 and Cathepsins 
B and L could be detected. Next to the MMPs and ca-
thepsins, there is evidence that neutrophil elastase is im-
portant, as neutrophil elastase-deﬁ cient mice are signiﬁ -
cantly protected from the development of pulmonary em-
physema in response to cigarette smoke  [38] . 
 In conclusion, we have demonstrated an increase in 
MMP-12 and Cathepsin D – both at the mRNA and pro-
tein level – in cigarette smoke-exposed mice. Moreover, 
we have shown that MMP-12 is not only produced by 
macrophages, but also by pulmonary DCs. Our results 
further support the hypothesis that MMP-12 plays a cen-
tral role in the cascade of events leading to perpetuated 
inﬂ ammation and pulmonary emphysema related to cig-
arette smoke exposure. 
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lower MCP-1 and TNF-  levels in BAL fluid compared to 
 Tlr4  WT  animals. After chronic CS exposure, however, the dif-
ference in pulmonary inflammation between  Tlr4  WT  and 
 Tlr4  defective  mice was less pronounced and both strains 
showed similar MCP-1 and TNF-  levels in BAL and similar 
pulmonary MMP-12, TLR4 and TLR2 expression.  Conclu-
sions: We demonstrated that the TLR4 mutation in C3H/HeJ 
mice is protective against CS-induced pulmonary influx of 
neutrophils, DCs and lymphocytes upon subacute CS expo-
sure. However, TLR4 is only of minor importance in chronic 
CS-induced inflammation in mice. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 The major risk factor for the development of chronic 
obstructive pulmonary disease (COPD)  is the exposure 
to cigarette smoke (CS). COPD is a major cause of death 
and disability worldwide and it is predicted to become
the most important disability-producing illness by 2020 
 [1, 2] . The disease is characterized by chronic inflamma-
tion and obstruction in the small airways and by destruc-
tion of lung parenchyma causing an enlargement of air-
spaces (emphysema)  [1–4] . Although the morphological 
changes in COPD are well defined, the mechanisms of 
the inflammation and the importance of the different cell 
types in the development of the airway narrowing and 
emphysema are not well understood.
 Key Words 
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 Abstract 
 Background: Chronic obstructive pulmonary disease (COPD) 
is associated with an abnormal inflammatory response of 
the lungs to noxious particles or gases. We investigated 
whether Toll-like receptor 4 (TLR4) is implicated in cigarette 
smoke (CS)-induced pulmonary inflammation in a murine 
model of COPD.  Methods: C3H/HeOuJ  (Tlr4  WT  ) and C3H/HeJ 
 (Tlr4  defective  )  mice were exposed to air or CS for 5 weeks (sub-
acute) and 26 weeks (chronic), and pulmonary inflammation 
was evaluated.  Results: In  Tlr4  WT  mice, subacute and chronic 
CS exposure induced a substantial pulmonary infiltration of 
macrophages, neutrophils, lymphocytes and dendritic cells 
(DCs), that was absent in air-exposed mice. CS exposure in-
creased the costimulatory marker expression on DCs, the 
levels of monocyte chemoattractant protein-1 (MCP-1) and 
tumor necrosis factor-  (TNF-  ) in bronchoalveolar lavage 
(BAL) fluid and induced the pulmonary expression of matrix 
metalloproteinase-12 (MMP-12), TLR4 and TLR2. In contrast, 
after subacute CS exposure,  Tlr4  defective  mice showed a limit-
ed (5-fold lower) increase of DCs and lymphocytes in BAL 
fluid, lower costimulatory marker expression on DCs and 
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 Multiple inflammatory and immune cells belonging 
to the innate and adaptive immune system may contrib-
ute to the pathogenesis of COPD  [4] . The numbers of neu-
trophils and macrophages, two prototypic inflammatory 
cells of the innate immune system, are increased in bron-
choalveolar lavage (BAL) fluid, sputum, airways and lung 
biopsies from COPD patients  [4] . Also the numbers of T 
lymphocytes and B lymphocytes, two cell types with pre-
dominantly adaptive immune functions, are increased in 
airways and lungs of COPD patients  [4–6] . Finally, the 
numbers of dendritic cells (DCs), professional antigen-
presenting cells that link both the innate and adaptive 
immune responses, are increased in smokers  [7] , suggest-
ing that these cells could play a role in the COPD pathol-
ogy  [4] . For several of the above-mentioned immune 
cells, clear correlations were found between the cell num-
bers in COPD patients and the severity of the disease. 
Indeed, a positive correlation was found between the 
amount of macrophages and lymphocytes in lung tissue 
and the degree of lung destruction  [5] , whereas the neu-
trophil and lymphocyte numbers in bronchial biopsies 
and induced sputum correlate with the degree of airway 
obstruction  [4, 6, 8] .
 Toll-like receptors (TLR) are a family of proteins – 
originally identified in  Drosophila – that recognize 
‘pathogen-associated molecular patterns’ such as endo-
toxin, flagellin and double-stranded RNA. This recogni-
tion of pathogenic components is crucial for the initiation 
of a whole range of host defense mechanisms  [9, 10] . Re-
cently, several researchers have reported on the impor-
tance of TLR4 signaling in pulmonary disease  [11–15] . 
The TLR4 was originally identified as the receptor for li-
popolysaccharide (LPS), a Gram-negative bacterial cell 
wall component. C3H/HeJ  (Tlr4  defective  )  mice that carry a 
missense mutation, resulting in a defective TLR4, are hy-
poresponsive to LPS  [16] . In both mice and humans, 
TLR4 is mainly expressed on myeloid cells such as mono-
cytes, macrophages, myeloid DCs, mast cells and granu-
locytes  [9, 17] . Recently, TLR4 expression was also report-
ed on structural cells such as primary human alveolar 
type II epithelial cells, human bronchial epithelial cells 
and endothelial cells from murine lung  [18–20] .
 Interestingly, CS exposure could lead to the presence 
of several endogenous and exogenous ligands that bind 
the TLR4. Tissue stress and damage by CS could release 
endogenous ligands such as heat shock proteins,   -defen-
sins or breakdown products of extracellular matrix (hy-
aluronan, fibronectin)  [21–24] , whereas LPS from tobac-
co  [25] is an exogenous ligand that could play a role in the 
CS-induced inflammation. Moreover, the lower airways 
of patients with severe COPD are often colonized by 
Gram-negative bacteria  [26, 27] , which could activate the 
TLR4 pathway.
 Given the importance of TLR4 in several lung pathol-
ogies  [11–15] , combined with the latter findings, we were 
interested in establishing if TLR4 is implicated in the pul-
monary inflammation in a mouse smoke exposure mod-
el  [28] . Therefore, we exposed TLR4-defective (C3H/HeJ) 
and control mice (C3H/HeOuJ) to CS for 5 weeks (sub-
acute model) and 26 weeks (chronic model) and evalu-
ated the pulmonary inflammation. We also monitored 
the levels of the proinflammatory cytokine tumor necro-
sis factor-  (TNF-  ) and the chemokine monocyte che-
moattractant protein-1 (MCP-1) in the BAL fluid, since 
TNF-  and MCP-1 release can be affected by TLR4 sig-
naling  [16, 29] and since these compounds are increased 
in sputum and BAL of COPD patients  [4] and are impli-
cated in smoke-induced pulmonary inflammation and 
development of emphysema  [30–32] .
 Materials and Methods 
 Mice 
 Male inbred C3H/HeJ ( Tlr4  defective , endotoxin-tolerant) and 
C3H/HeOuJ ( Tlr4  WT , endotoxin-sensitive) of 6–8 weeks of age 
were purchased from The Jackson Laboratory (Bar Harbor, Me., 
USA). The inbred C3H/HeJ and C3H/HeOuJ substrains of C3H 
were separated in 1952 and are genetically very similar. However, 
a spontaneous mutation occurred in the C3H/HeJ strain at the 
LPS response locus, making C3H/HeJ mice endotoxin-resistant 
whereas the C3H/HeOuJ strain is endotoxin-sensitive (http://jax-
mice.jax.org). The C3H/HeOuJ mice can thus be used as a control 
strain when studying effects of TLR4 deficiency  [12] . The mice 
were maintained in a pathogen-free animal facility. The local Eth-
ics Committee of the Ghent University (Ghent, Belgium) ap-
proved all in vivo manipulations.
 CS Exposure 
 Mice were placed in a chamber (7,500 cm 3 , whole body expo-
sure) and exposed to CS using a smoking apparatus (purchased 
from D. Kobayashi, Washington University Medical Center, USA). 
The animals received mainstream CS of 5 reference cigarettes 
(1R3, University of Kentucky, Lexington, Ky., USA) per exposure, 
4 exposures a day for 5 days a week  [28] . The smoke:air ratio was 
1:  12  [33] . Control groups were exposed to air. Directly after smoke 
exposure, carbon monoxide in blood reached a nontoxic level of 
8.29  8 1.4% (compared to 1.02  8 0.22% in air-exposed animals, 
p = 0.003, n = 7 for both groups), which is similar to the carboxy-
hemoglobin blood concentrations in human smokers  [34] .
 After 5 or 26 weeks and 24 h after the last exposure, mice were 
sacrificed by an intraperitoneal injection of pentobarbital (Sano-
fi, Libourne, France). Numbers of mice used in the experiments 
were n = 8 and n = 15 per group in the subacute (5 week) and 
chronic (26 week) experiments, respectively.
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 Buffers and Media for the Preparation of Single-Cell 
Suspensions and Immunofluorescent Labeling 
 RPMI 1640 medium, supplemented with 2 m M  L -glutamine, 
10   g/ml streptomycin, 100 U/ml penicillin, 5% FCS, 1 mg/ml 
collagenase type 2 (Worthington Biochemical Corporation, 
 Lakewood, N.J., USA), and 0.02 mg/ml DNAse I (grade II from 
bovine pancreas; Boehringer, Brussels, Belgium) were used as 
lung digestion medium. PBS without ionized calcium and mag-
nesium, supplemented with 0.1% azide, 5% EDTA-treated FCS 
and 5 m M EDTA was used as FACS-EDTA buffer. 
 BAL and Preparation of Lung Single-Cell Suspensions 
 Lungs were lavaged via the tracheal cannula using 4 times 1 ml 
of Hanks balanced salt solution (HBSS) free of Ca 2+  and Mg 2+ , 
supplemented with 0.05 m M sodium EDTA. Typical BAL cell re-
covery/mouse was between 2!10 5  and 5!10 5  cells for air-ex-
posed mice and between 8!10 5  and 1.5!10 6  for smoke-exposed 
mice. The recovered cells from BAL fluid were treated with NH 4 Cl 
to remove red blood cells, washed and resuspended in 1 ml of 
HBSS. Total cell counts were obtained using a Bürker chamber. 
Cytocentrifuged preparations (Cytospin 2; Shandon Ltd., Run-
corn, UK) stained with May-Grünwald-Giemsa were used to per-
form a blinded differential cell count based on standard morpho-
logical criteria, enabling the discrimination of monocytes/mac-
rophages, lymphocytes and neutrophils. Flow-cytometric analysis 
of BAL cells was also performed for the detection of DCs  [28, 
35] .
 Following BAL, the pulmonary and systemic circulation was 
perfused with saline/EDTA. Single-cell suspensions were pre-
pared from the right lung as previously described  [36] . Briefly, the 
lung was thoroughly minced, digested, subjected to red blood cell 
lysis, passed through a 50-  m cell strainer and kept on ice until 
labeling. Cell counting occurred with a Z2 particle counter (Beck-
man-Coulter, Ghent, Belgium).
 Labeling of Single-Cell Suspension for Flow Cytometry 
 All staining reactions were performed on ice, in the dark and 
in FACS-EDTA buffer. To reduce nonspecific binding of mono-
clonal antibodies (mAbs), cells were preincubated with anti-
CD16/CD32 (2.4G2). The myeloid DC population was identified 
using 2 immunofluorescent criteria, which were low autofluores-
cence and intermediate-to-high levels of CD11c  [28, 35] . For this, 
we used biotinylated anti-CD11c (N418). Additional PE-conju-
gated markers for DC phenotyping were anti-IA k  (14.4.4S), CD40 
(3/23), CD86/B7-2 (GL1), whereas isotype control was rat IgG 2a,K . 
Mouse T cell subpopulations in lung single-cell suspensions were 
identified by biotinylated anti-CD3e (145-2C11), FITC-conjugat-
ed anti-CD4 (L3T4), FITC-conjugated anti-CD8a (Ly-2) and T 
cell activation marker anti-CD69 (H1.2F3). Activated helper T 
lymphocytes were defined as CD3+CD4+CD69+  and activated 
cytotoxic T lymphocytes as CD3+CD8+CD69+. Binding of bio-
tinylated mAbs was revealed by incubation with streptavidin-
 allophycocyanin (Sav-APC). All mAbs were obtained from BD 
Pharmingen (San Diego, Calif., USA), except anti-CD11c (N418 
hybridoma; a gift from Prof. M. Moser, Brussels Free University, 
Belgium). Before analysis, samples were incubated with 7-amino-
actinomycin (7-AAD or Viaprobe; BD Pharmingen) for dead cell 
exclusion.
 Flow cytometry data acquisition was performed on a FACS 
Vantage TM  flow cytometer running CellQuest TM  software (BD 
Biosciences, San Diego, Calif., USA). FlowJo software (Tree Star 
Inc., Ashland, Oreg., USA) was used for data analysis.
 Measurement of Cytokines and Chemokines 
 Cytokines and chemokines from BAL were determined with 
ELISA (kits for MCP-1 and IL-13; R  D Systems Europe, Abing-
don, UK) or by FACS using the cytometric bead array (CBA, 
mouse inflammation kit; BD Biosciences, Pharmingen, San Di-
ego, Calif., USA), following the manufacturer’s instructions. For 
the CBA, we prepared a mixture of 6 capture bead populations 
with distinct fluorescence intensities (detected in FL3, using a 
FACSCalibur TM  flow cytometer, BD Biosciences) that were coated 
with antibodies specific for IL-6, IL-10, MCP-1, IFN-  , TNF-  
and IL-12p70 proteins. Test samples or recombinant standards 
were incubated together with the CBA capture beads and PE-con-
jugated detection antibodies to form sandwich complexes. Fol-
lowing acquisition of sample data using the flow cytometer, the 
sample results were generated in graphical and tabular format us-
ing CBA analysis software (BD Biosciences).
 RNA Preparation and RT-PCR 
 RNA from lung tissue was extracted using the Qiagen RNeasy 
Midi Kit (Qiagen, Valencia, Calif., USA) with an additional 
 DNAse step. Reverse transcription was performed at 48  °  C for 
30 min followed by 12 min of incubation at 95  °  C for the denatur-
ation of RNA-DNA heteroduplexes and a DNA amplification 
with 50 cycles at 95  °  C for 15 s and 60  °  C for 60 s. RT-PCR was 
performed starting from 10 ng of total RNA, using an ABI PRISM 
7700 sequence detection system (Applied Biosystems, Foster City, 
Calif., USA). Expression of  MMP-12, TLR2  and TLR4 mRNA rel-
ative to hypoxanthine guanine phosphoribosyl transferase  (hprt) 
mRNA, was analyzed with the Assays-on-Demand TM  gene 
 expression products (Applied Biosystems). Monitoring of the
RT-PCR occurred in real time using an FAM/TAMRA probe.
 Immunohistochemistry 
 The left lung was fixated by gentle infusion of fixative (4% 
paraformaldehyde) through the tracheal cannula  [28] . After exci-
sion, the lung was immersed in fresh fixative during 2 h. The lung 
lobe was embedded in paraffin and cut in 3-  m transversal sec-
tions.
 For the detection of CD11c, after blocking, sections were 
stained with anti-CD11c (N418 hybridoma) or isotype hamster 
IgG (BD 15554D) followed by a goat anti-hamster IgG biotin 
(Star79b, Serotec, Oxford, UK). Then, slides were incubated with 
streptavidin horseradish peroxidase (K0377; DakoCytomation, 
Heverlee, Belgium) and colored with diaminobenzidine (DAB, 
K3466; DakoCytomation).
 For the detection of lymphoid follicles, lung sections were sub-
jected to CD3/B220 staining  [37] : First, sections were incubated 
with Boehringer blocking agent with triton and primary antibody 
anti-CD3 (A0452) or isotype rabbit Ig (X0936), followed by goat 
anti-rabbit biotin (E0432). Then, slides were incubated with strep-
tavidin horseradish peroxidase (K0377) and colored with DAB 
(K3466). All reagents were obtained from DakoCytomation 
(Heverlee, Belgium). In a second step, sections were stained with 
anti-B220 biotin or isotype IgG2a biotin (553086 and 11022C; BD 
Pharmingen) after Boehringer blocking with triton. Finally, slides 
were incubated with streptavidin alkaline phosphatase (K0391, 
DakoCytomation) and colored with Vector Blue (SK-5300; Vector 
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Laboratories Inc., Burlingame, Calif., USA). Lymphoid follicles, 
defined as dense areas with CD3/B220 double staining, were 
counted in a blinded fashion in the tissue area surrounding the 
airways. Results were expressed as counts relative to the numbers 
of airways per lung section. The values are the average of 15 mice 
per group.
 For the detection of matrix metalloproteinase-12 (MMP-12), 
TLR4 and TLR2, lung sections were subjected to the following 
immunological staining sequences: blocking agent, goat anti-
mouse antibody [for MMP-12: M-19 (sc-8893); for TLR4: M-16 
(sc-12511), for TLR2: S-16 (sc-16237); Santa Cruz Biotechnology, 
Santa Cruz, Calif., USA] or goat IgG isotype control and detection 
with Vectastain Elite Goat IgG ABC Kit (PK-6105; Vector Labo-
ratories Inc.) and DAB substrate (K-3466; DAKO, Glostrup, Den-
mark). Sections were counterstained with hematoxylin.
 To evaluate and compare TLR4 and TLR2 expression in the 
subacute and chronic experiment, lung sections from the 5-week 
and 26-week experiment were simultaneously stained. Semi-
quantitative scoring was performed on lung sections of each ani-
mal (8 animals/group in the subacute and 9 animals/group in the 
chronic experiment). The degree of expression in macrophages 
was defined with a score between 0 and 2 (0: no or very faint stain-
ing, 1: positive staining, 2: strongly positive staining).
 Representative images for each group were captured at a mag-
nification of 200 ! or 400 ! using a Zeiss KS400 image analyzer 
platform (Zeiss, Oberkochen, Germany).
 Statistical Analysis 
 Statistical analysis was performed with Sigma Stat software 
(SPSS Inc., Chicago, Ill., USA) using nonparametrical tests (Krus-
kal-Wallis; Mann-Whitney U test). p  ! 0.05 was considered sig-
nificant.
 Results 
 Tlr4 defective  Mice Are Partly Protected against
CS-Induced Pulmonary Recruitment of Neutrophils, 
Lymphocytes and DCs 
 The importance of TLR4 in CS-induced pulmonary 
inflammation was evaluated using control  Tlr4  WT  (C3H/
HeOuJ) and  Tlr4  defective  (C3H/HeJ) mice. To that end, the 
different cell types from BAL fluid and lung single-cell 
suspensions were determined in both strains after air or 
CS exposure. 
 Results from BAL 
 After subacute and chronic CS exposure (5 and 26 
weeks, respectively), the total cell number in the BAL flu-
id of both the  Tlr4  WT  and  Tlr4  defective  strain increased 2- to 
3-fold compared to air-exposed control animals (p  ! 
0.001,  fig. 1 a). More specifically, there was an accumula-
tion of macrophages, neutrophils, lymphocytes and my-
eloid DCs in CS-exposed  Tlr4  WT  mice compared to air-
exposed  Tlr4  WT  animals (p  ! 0.001 for all cell types, 
 fig. 1 b–e). Although the total cell numbers in the BAL 
fluid did not differ significantly between the CS-exposed 
 Tlr4  WT  and  Tlr4  defective  animals, the distribution of the 
inflammatory cells from the BAL fluid was clearly differ-
ent between the 2 strains: in the subacute model of 
5 weeks, the influx of neutrophils, lymphocytes and DCs 
was clearly impaired in CS-exposed  Tlr4  defective  mice 
compared to CS-exposed  Tlr4  WT  animals. In contrast, 
subacute CS exposure resulted in a 2-fold increase in the 
number of macrophages in both  strains ( fig. 1 b). 
 After chronic exposure for 26 weeks, the CS-induced 
pulmonary inflammation was sustained in both strains. 
At this time point, lymphocyte and DC numbers in the 
BAL fluid of CS-exposed  Tlr4  defective  animals were sig-
nificantly lower compared to CS-exposed  Tlr4  WT  ani-
mals (p  ! 0.05), but the differences were less pronounced 
than after 5 weeks. The CS-induced increase in BAL 
 neutrophils and macrophages did not differ between 
the 2 strains after chronic exposure during 26 weeks 
( fig. 1 b, c).
 Results from Lung Single-Cell Suspensions 
 Also in lung single-cell suspensions, subacute CS ex-
posure increased the numbers of DCs in  Tlr4  WT  animals 
compared to air-exposed  Tlr4  WT  controls ( fig. 2 a). This 
CS-induced increase in lung DCs did not occur in CS-
exposed  Tlr4  defective  animals upon subacute CS exposure, 
indicating it was TLR4-dependent. In contrast, upon 
chronic CS exposure, the percentages of lung DCs in-
creased in both the  Tlr4  WT  and  Tlr4  defective  animals 
( fig. 2 a).
 CS exposure also increased the numbers of CD4+
CD69+ T lymphocytes in the lungs in both the  Tlr4  WT 
 and  Tlr4  defective  animals at both time points. At 26 weeks, 
the CS-induced numbers of CD4+CD69+ T lymphocytes 
in Tlr4  defective  animals were significantly lower than in 
CS-exposed  Tlr4  WT  animals (p  ! 0.01,  fig. 2 b).
 Results from Immunological Stainings of Lung 
Tissue 
 Immunohistological staining for CD11c (which visual-
izes macrophages and DCs) on lung tissue sections of
the chronic experiment revealed increased amounts of 
CD11c+  cells upon CS exposure compared to air expo-
sure, with no evident differences between the  Tlr4  WT  and 
 Tlr4  defective  animals ( fig. 3 a–d). Moreover, CS exposure 
clearly led to the presence of enlarged cells within the al-
veolar spaces, suggesting alveolar macrophage activation.
 Immunohistochemistry using anti-CD3 and anti-B220 
mAbs to stain T lymphocytes and B lymphocytes, respec-
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 Fig. 1. Effect of CS on total number and cell differentiation in BAL fluid. BAL cell counts in  Tlr4  WT  and  Tlr4  defective  
mice upon subacute (5 weeks) or chronic (26 weeks) exposure to air or CS. Average number of cells/mouse re-
covered from BAL of  Tlr4  WT  and  Tlr4  defective  mice after air or CS exposure ( a ), average number of monocytes/
macrophages ( b ), neutrophils ( c ), lymphocytes ( d ) and DCs ( e ). Monocytes/macrophages, neutrophils and lym-
phocytes were determined based on morphological criteria (cytospin), whereas DCs were counted using flow 
cytometry. Data are expressed as mean  8 SEM. The mean value is the average/mouse obtained from 8 or 15 
individual mice/group for the 5- and 26-week experiment, respectively.  * p  ! 0.05;  * * p  ! 0.01;  * * * p  ! 0.001. 
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tively, revealed no or few peribronchial lymphoid follicles 
in the air-exposed  Tlr4  WT  and  Tlr4  defective  animals of the 
chronic experiment (number of lymphoid follicles/air-
way: 0.05  8 0.01 and 0.07  8 0.02, respectively). Upon 
chronic CS exposure, however, the number of peribron-
chial lymphoid follicles increased significantly in both 
 Tlr4  WT  and  Tlr4  defective  animals (number of lymphoid fol-
licles/airway: 0.38  8 0.07 and 0.28  8 0.04, respectively; 
p  ! 0.01 vs. the corresponding air-exposed controls) 
( fig. 3 e–h). There were no significant differences in the 
number of lymphoid follicles between the CS-exposed 
 Tlr4  WT  and CS-exposed  Tlr4  defective  animals (p = 0.436).
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 Fig. 2. Effect of CS on number of DCs and activated T helper
cells in the lung. Lung cell percentages in  Tlr4  WT  and  Tlr4  defective  
mice upon subacute (5 weeks) or chronic (26 weeks) exposure
to air or CS.  a Percentage of lung DCs.  b Percentage of lung 
CD3+CD4+CD69+ cells. Data are expressed as mean  8 SEM.
n = 8 or n = 15 per group for the 5- and 26-week experiment, re-
spectively.  * p  ! 0.05;  * * p  ! 0.01;  * * * p  ! 0.001. 
 Fig. 3. CD11c+ cells and lymphoid follicles upon air or CS expo-
sure. Lung tissue sections of  Tlr4  WT  and  Tlr4  defective  mice upon 
chronic (26 weeks) exposure to air or CS.  a – d CD11c staining for 
macrophages and DCs (brown = CD11c+ cells).  e – h CD3/B220 
staining for T cells and B cells (brown = CD3+ cells; blue = B220+ 
 cells). The scale bars represent 100   m.  a ,  e Air-exposed  Tlr4  WT . 
 b ,  f CS-exposed  Tlr4  WT .  c ,  g Air-exposed  Tlr4  defective .  d ,  h CS-ex-
posed  Tlr4  defective . 
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 Fig. 4. Effect of CS on the expression of DC activation/maturation 
markers in BAL. DC activation/maturation in  Tlr4  WT  and 
 Tlr4  defective  mice upon subacute (5 weeks) or chronic (26 weeks) 
exposure to air or CS.  a Expression of MHCII, CD40 and CD86 
on DCs in the subacute experiment.  b Expression of MHCII on 
DCs in the chronic experiment. Dark grey line: Specific marker 
staining; light grey line: isotype control staining. A shift of the 
histogram to the right indicates that the proportion of DCs (low 
autofluorescent, CD11c+) with expression of the specific marker 
is increased. Each histogram is representative for the expression 
pattern in 8 or 15 individual mice per group for the 5- and 26-week 
experiment, respectively. The mean percentage of DCs staining 
positive for the specific marker is indicated. Upon CS exposure 
for 5 and 26 weeks, BAL DCs showed increased expression of all 
tested markers compared to air exposure, both in  Tlr4  WT  and 
 Tlr4  defective  animals (p  ! 0.001 for all markers). But the mean per-
centage of positive DCs was significantly lower in CS-exposed 
 Tlr4  defective  vs. CS-exposed  Tlr4  WT  animals at both time points for 
all tested markers (p  ! 0.001). The MHCII expression in CS-ex-
posed  Tlr4  defective  animals was substantially higher after 26 weeks 
(52.0  8 1.7%) compared to 5 weeks (20.6  8 1.4%). 
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 CS Induces DC Activation and Maturation 
 Since DCs are one of the primary cells that respond to 
danger signals  [10, 38] , we assessed their activation status 
by examining the cell surface expression of MHCII and 
the costimulatory markers CD86 (B7.2) and CD40. In 
 Tlr4  WT  animals, the expression of MHCII, CD86 and 
CD40 on BAL DCs increased upon subacute CS exposure 
compared to air exposure ( fig. 4 a).
 DCs of the lung tissue showed elevated expression of 
MHCII and CD86 upon subacute CS exposure [MHCII-
positive DCs: 41.1  8 1.4% vs. 31.9  8 0.9% for smoke-ex-
posed vs. air-exposed, p  ! 0.001; n = 8 per group; data are 
similar for CD86 (data not shown)].
 Also, upon chronic CS exposure of  Tlr4  WT  mice, BAL 
DCs had elevated levels of MHCII (p  ! 0.001,  fig. 4 b).
 Attenuation of DC Activation and Maturation upon 
CS Exposure in Tlr4 defective  Mice 
 In the subacute experiment, the MHCII, CD86 and 
CD40 expression levels on BAL DCs in CS-exposed 
 Tlr4  defective  mice were significantly lower than in CS-ex-
posed  Tlr4  WT  mice (p  ! 0.001) ( fig. 4 a). Also in lung tis-
sue, the CS-induced expression of MHCII on DCs was 
significantly lower in  Tlr4  defective  animals than in  Tlr4  WT 
 animals (MHCII-positive DCs: 36.3  8 1.5% vs. 41.1  8 
1.4% for CS-exposed  Tlr4  defective  vs. CS-exposed  Tlr4  WT , 
p  ! 0.05, n = 8 per group).
 Upon chronic CS exposure, BAL DCs from both the 
 Tlr4  WT  mice and  Tlr4  defective  animals had elevated levels of 
MHCII ( fig. 4 b). 
 Increase in MCP-1 and TNF-  in BAL after Subacute 
CS Exposure Is TLR4-Dependent 
 Protein levels of cytokines and chemokines in BAL 
were determined using CBA and ELISA. Subacute CS ex-
posure during 5 weeks resulted in a significant increase 
of MCP-1 in BAL in both strains. However, the MCP-1 
levels in the  Tlr4  defective  animals were 6 times lower than 
in  Tlr4  WT  animals (p  ! 0.001). After chronic CS exposure, 
the increase in MCP-1 levels in BAL was similar in both 
strains, indicating it was no longer TLR4-dependent 
( fig. 5 a). 
 CS exposure also increased TNF-  levels in BAL in 
both strains, especially in the chronic experiment ( fig. 5 b). 
Similar to the results for MCP-1, the CS-induced TNF-  
levels in BAL were lower in CS-exposed  Tlr4  defective  ani-
mals compared to CS-exposed  Tlr4  WT  animals in the sub-
acute experiment (p  ! 0.05), whereas the TNF-  levels 
upon chronic CS exposure did not differ between both 
strains. Interestingly, TNF-  levels in BAL were signifi-
cantly lower in air-exposed  Tlr4  defective  animals compared 
to air-exposed  Tlr4  WT  animals at both time points (p  ! 
0.01) ( fig. 5 b).
 The levels of IL-10 in BAL did not change significant-
ly upon CS exposure and were similar in the 2 strains at 
both time points (data not shown). BAL levels of IL-12p70, 
IFN-  , IL-6 and IL-13 were below the detection limit 
(data not shown).
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 Fig. 5. Effect of CS on cytokines and chemokines in BAL. BAL 
cytokines/chemokines in  Tlr4  WT  and  Tlr4  defective  mice upon sub-
acute (5 weeks) or chronic (26 weeks) exposure to air or CS (n = 
8 or n = 15 per group, respectively).  a MCP-1.  b TNF-  . Data are 
expressed as mean  8 SEM.  * p  ! 0.05;  * * p  ! 0.01;  * * * p  ! 0.001. 
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 MMP-12 Expression Is Induced in both Tlr4 WT  and 
Tlr4 defective  Animals after CS Exposure 
 MMP-12 has been shown to be crucial for the develop-
ment of emphysema  [32] . We evaluated the expression of 
MMP-12 in lung tissue of the subacute experiment using 
RT-PCR on total lung RNA. MMP-12 mRNA expression 
levels in air-exposed  Tlr4  WT  mice and  Tlr4  defective  mice 
were similar ( fig. 6 a). CS exposure resulted in a signifi-
cant induction of MMP-12 expression (22-fold in  Tlr4  WT 
 mice and 11-fold in  Tlr4  defective  mice compared to air-ex-
posed littermates). The MMP-12 expression levels ap-
peared to be lower in CS-exposed  Tlr4  defective  animals, but 
the difference was not significant (p = 0.111 for CS-ex-
posed Tlr4  WT  vs. CS-exposed Tlr4  defective  mice). Immuno-
histological staining for MMP-12 protein on lung tissue 
sections of the chronic experiment demonstrated that 
macrophages of both  Tlr4  WT  and  Tlr4  defective  animals 
showed a clear increase in MMP-12 expression upon CS 
exposure, with no obvious difference between the 2 
strains ( fig. 6 b–e).
 TLR4 Expression Is Induced upon Subacute and 
Chronic CS Exposure 
 We monitored TLR4 expression in  Tlr4  WT   animals 
upon CS exposure with RT-PCR, but observed no sig-
nificant difference in lung TLR4 mRNA expression in the 
subacute experiment of 5 weeks ( fig. 7 a).
 Immunohistochemistry on lung tissue sections of 
both the subacute and chronic experiment showed an in-
creased TLR4 protein expression in macrophages of CS-
exposed animals compared to air-exposed animals at 
both time points (p  ! 0.001,  fig. 7 b–f), with a trend to-
wards a more pronounced expression in the chronic ex-
periment (p = 0.074,  fig. 7 b–f).
 TLR2 Expression Is Induced in both Tlr4 WT  and 
Tlr4 defective  Animals after CS Exposure, and Increases 
with Time 
 We monitored the TLR2 expression upon CS exposure 
with RT-PCR. There was a limited, though significant 
increase in lung TLR2 mRNA expression in both  Tlr4  WT  
 and  Tlr4  defective  animals upon CS exposure in the sub-
acute experiment of 5 weeks ( fig. 8 a), with no significant 
difference between the CS-exposed  Tlr4  WT   and CS-ex-
posed  Tlr4  defective  animals.
 Immunohistochemistry on lung tissue sections of 
both the subacute and chronic experiment showed an in-
creased TLR2 protein expression in macrophages of CS-
exposed animals compared to air-exposed animals at 
both time points (p  ! 0.001,  fig. 8 b–j). The CS-induced 
TLR2 expression was similar in  Tlr4  WT   and  Tlr4  defective  
animals. Interestingly, the TLR2 expression was clearly 
more pronounced in the chronic experiment compared 
to the subacute experiment (p  ! 0.05,  fig. 8 b–j).
 Discussion 
 In this work, we clearly demonstrated that the TLR4 
defect significantly affects the pulmonary response to-
wards a subacute CS exposure of 5 weeks. Indeed, the CS-
induced pulmonary recruitment of neutrophils, lympho-
cytes and DCs, the CS-induced DC activation/matura-
tion and CS-induced increase of TNF-  and MCP-1 in 
BAL were lower in TLR4-defective C3H/HeJ mice com-
pared to control Tlr4  WT  animals. After chronic CS expo-
sure, however, the difference in pulmonary inflamma-
tion between  Tlr4  WT  and  Tlr4  defective  mice was less pro-
nounced and both strains showed similar MCP-1 and 
TNF-  levels in BAL and similar pulmonary MMP-12, 
TLR4 and TLR2 expression. 
 Several TLR4-dependent mechanisms are likely to be 
involved in the CS-induced pulmonary inflammation. 
CS could – directly or indirectly – activate TLR4 signal-
ing on pulmonary epithelial cells and transmigrated res-
ident cells such as macrophages that act as the first line 
of defense against external threats, resulting in the pro-
duction of chemokines that attract inflammatory cells 
 [10] . Another possible mechanism is the CS-induced 
TLR4 activation on mast cells and DCs that are interlaced 
at lung mucosal surfaces  [10] .
 In our model, CS exposure induced an impressive pul-
monary inflammation in  Tlr4  WT  animals, characterized 
by increased numbers of neutrophils, lymphocytes, mac-
 Fig. 6. Effect of CS on MMP-12 expression in lung tissue. MMP-
12 expression in  Tlr4  WT  and  Tlr4  defective  mice upon subacute (5 
weeks) or chronic (26 weeks) exposure to air or CS.  a Subacute 
experiment: RNA was prepared from lung tissue to monitor 
 MMP-12  mRNA expression. RT-PCR results are expressed as a 
ratio of  MMP-12  mRNA to  hprt mRNA (mean  8 SEM, n = 4–5 
animals per group,  * p  ! 0.05). One representative of 2 indepen-
dent experiments is shown.  b – e Chronic experiment: MMP-12 
protein detected with immunohistochemistry (brown = MMP-
12+ cells). The scale bars represent 10   m.  b Air-exposed  Tlr4  WT . 
 c CS-exposed  Tlr4  WT .  d Air-exposed  Tlr4  defective .  e CS-exposed 
 Tlr4  defective . The MMP12 protein expression is induced upon CS 
exposure in both strains. 
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 Fig. 7. Effect of CS on TLR4 expression in lung tissue. TLR4 ex-
pression in  Tlr4  WT  mice upon subacute (5 weeks) or chronic (26 
weeks) exposure to air or CS.  a Subacute experiment: RNA was 
prepared from lung tissue to monitor  TLR4  mRNA expression. 
RT-PCR results are expressed as a ratio of  TLR4  mRNA with  hprt 
mRNA (mean  8 SEM, n = 8 animals per group).  b Semiquantita-
tive scoring of TLR4 expression on lung tissue sections stained 
with immunohistochemistry. The degree of expression in mono-
cytes/macrophages was defined with a score between 0 and 2 (0: 
no or very faint staining, 1: positive staining, 2: strongly positive 
staining;  * * * p  ! 0.001).  c – f Photographs of TLR4 expression on 
lung tissue sections of  Tlr4  WT  mice (brown = TLR4+ cells). The 
scale bars represent 10   m.  c 5 weeks air-exposed.  d 5 weeks CS-
exposed.  e 26 weeks air-exposed.  f 26 weeks CS-exposed. The 
TLR4 expression is induced upon CS exposure. 
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 Fig. 8. Effect of CS on TLR2 expression in lung tissue. TLR2 ex-
pression in  Tlr4  WT  and  Tlr4  defective  mice upon subacute (5 weeks) 
or chronic (26 weeks) exposure to air or CS.  a Subacute experi-
ment: RNA was prepared from lung tissue to monitor  TLR2 
mRNA expression. RT-PCR results are expressed as a ratio of 
 TLR2  mRNA with  hprt mRNA (mean  8 SEM, n = 8 animals per 
group;  * * p  ! 0.01;  * * * p  ! 0.001).  b Semiquantitative scoring of 
TLR2 expression on lung tissue sections stained with immuno-
histochemistry in the subacute and chronic experiment. The de-
gree of expression in monocytes/macrophages was defined with 
a score between 0 and 2 (0: no or very faint staining, 1: positive 
staining, 2: strongly positive staining;  * p  ! 0.05;  * * * p  ! 0.001). 
Photographs of TLR2 expression in lung tissue sections of the 
subacute ( c–f ) and the chronic ( g–j ) experiment (brown = TLR2+ 
cells). The scale bars represent 10   m.  c ,  g Air-exposed  Tlr4  WT . 
 d ,  h CS-exposed  Tlr4  WT .  e ,  i Air-exposed  Tlr4  defective .  f ,  j CS-ex-
posed  Tlr4  defective . The TLR2 protein expression is induced upon 
CS exposure in both strains and increases with time. 
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rophages and DCs. In humans, clear correlations have 
been found between the numbers of neutrophils, lym-
phocytes and macrophages in COPD patients and sever-
ity of disease  [4, 6, 8] . In contrast, there are currently only 
limited reports that suggest a role for DCs in the COPD 
pathology. Soler et al.  [7] reported the presence of in-
creased pulmonary DCs in human smokers. Recently, it 
was described that an accumulation of DCs in the small 
conducting airways of the lungs correlates with a decline 
in FEV 1  through the Global Initiative for Obstructive 
Lung Disease (GOLD) classification of COPD  [39] . In 
mouse models, several authors reported increased num-
bers of pulmonary DCs upon smoke exposure  [28, 33, 37, 
40] , whereas Robbins et al.  [41] described the opposite. 
Possibly, the intensity and dose of smoke exposure ac-
counts for these divergent results. In any case, DCs resid-
ing in the mucosal surfaces of the airways are ideally lo-
cated for sensing and responding towards toxic inhal-
ants.
 DCs act as the bridge between innate and adaptive im-
mune responses by capturing antigen and presenting it to 
cells of the adaptive immune system  [10, 38] . Antigen up-
take by DCs induces their maturation, with the upregula-
tion of MHCII and costimulatory molecules, which en-
able them to activate T lymphocytes. Our group recently 
reported in a C57/Bl6 model that smoke-induced DCs are 
in an activated state with elevated expression of MHCII 
and the costimulatory molecules CD40 and CD86  [28] . 
Also in this paper, the pulmonary DCs of CS-exposed 
 Tlr4  WT  mice were in an activated state both upon sub-
acute and chronic CS exposure. Correspondingly, the 
numbers of activated CD4+ T lymphocytes in lung tissue 
were increased upon CS exposure in our model. 
 The pro-inflammatory cytokine TNF-  and chemo-
kine MCP-1 are increased in sputum and BAL of COPD 
patients  [4] and are implicated in smoke-induced pulmo-
nary inflammation and the development of emphysema 
 [30–32] . We also observed increased concentrations of 
TNF-  and MCP-1 in the BAL fluid of CS-exposed mice. 
TNF-  activates endothelial cells, facilitating neutrophil 
and monocyte adhesion and extravascular migration 
 [31] . CS can, directly or indirectly via TNF-  , induce the 
release of the chemoattractant MCP-1 by alveolar epithe-
lial type II cells, endothelial cells, lung fibroblasts and 
alveolar macrophages  [42–45] , which can lead to a pul-
monary infiltration of macrophages/monocytes, T lym-
phocytes and DCs  [31, 32, 46, 47] .
 Evaluation of the inflammatory parameters in the CS-
exposed Tlr4  defective  mice suggests that TLR4 plays a role 
in the immune response towards CS. Especially in BAL 
fluid and after a relatively short subacute exposure time 
(5 weeks), the absence of a functional TLR4 partly pro-
tects against the CS-induced pulmonary inflammation. 
The attenuated levels of TNF-  and MCP-1 in the BAL 
compartment  Tlr4  defective  mice – resulting from defective 
TLR4 signaling – can explain the reduced recruitment of 
neutrophils, T lymphocytes and DCs to the lungs of CS-
exposed  Tlr4  defective  mice compared to  Tlr4  WT  mice in the 
subacute experiment. The reduced DC activation in the 
CS-exposed  Tlr4  defective  animals in combination with the 
limited influx of lymphocytes in BAL fluid and lungs 
suggests that the DC response is impaired or delayed in 
these  Tlr4  defective  mice during subacute CS exposure. This 
is in line with earlier reports of impaired cytokine (TNF-
  ) production and impaired maturation (CD40 expres-
sion) of bone marrow-derived DCs from  Tlr4  defective  C3H/
HeJ mice  [48] .
 Importantly, with time, differences in inflammation 
between the CS-exposed  Tlr4  WT  and  Tlr4  defective  mice be-
came less pronounced, suggesting that TLR4 signaling 
predominantly plays a role in the subacute inflammatory 
response towards CS. 
 The limited differences between the 2 mouse strains 
in the chronic experiment could suggest a tolerance 
mechanism or downregulation of TLR4 signaling in the 
chronic CS exposure model in the Tlr4  WT  mice. TLR sig-
naling can be negatively regulated by reducing TLR ex-
pression or by blocking downstream TLR signaling path-
ways  [49–51] . This occurs for example in LPS-exposed 
monocytes/macrophages, which become refractory to a 
subsequent stimulation with LPS (called LPS or endotox-
in tolerance)  [51] . Since LPS is one of the components of 
CS and repetitive exposure to LPS could lead to endo-
toxin tolerance, we analyzed if the TLR4 expression pat-
tern in the lungs is affected by CS exposure. Interestingly, 
the TLR4 expression in macrophages increased upon CS 
exposure compared to air-exposed animals, at both time 
points. This suggests that downregulation of TLR4 ex-
pression in the  Tlr4  WT  mice cannot explain the limited 
differences we observed between the 2 strains in the 
chronic experiment. Recently, it has been demonstrated 
that tolerance to endotoxin is compartmentalized and 
that bronchoalveolar cells are less likely to develop toler-
ance to endotoxin than splenocytes, peritoneal cells and 
bone marrow cells  [52] . However, downregulation of 
TLR4 signaling can also occur by inhibition of expression 
or function of intracellular mediators downstream of 
TLR4 and can thus not be excluded in our chronic mod-
el  [49, 50] . 
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 Besides TLR4, TLR2 expression in lung macrophages 
also increased upon CS exposure in both strains at both 
time points and was clearly more pronounced in the 
chronic experiment compared to the subacute experi-
ment. Despite the latter observation, we did not detect 
increased CS-induced inflammation in the chronic ex-
periment compared to the subacute experiment, suggest-
ing that a certain ‘plateau’ is reached. It is thus difficult to 
assess the relative importance of both pathways in the 
pathogenesis of CS-induced inflammation. This could be 
further unraveled by evaluating the CS-induced inflam-
mation in TLR2-defective and TLR4/TLR2-defective an-
imals. 
 It has recently been described that TLR2 surface ex-
pression is decreased on alveolar macrophages of ciga-
rette smokers and COPD patients  [53] . These results dif-
fer strongly from the increased TLR2 expression that we 
observed in macrophages in our CS exposure model in 
mice. Important differences between the regulation of 
murine and human TLR2 expression have been previ-
ously described and probably result from a different ge-
nomic organization of the TLR2 gene in the two species 
 [17] . This stresses that we should be cautious when ex-
trapolating results from murine models to human dis-
eases.
 Macrophages and neutrophils release proteolytic en-
zymes, such as MMPs and neutrophil elastase, which are 
believed to result in a proteinase-antiproteinase imbal-
ance and subsequent tissue destruction and airspace en-
largement in COPD  [32, 54, 55] . Recently, it was reported 
that also DCs are capable of inducing MMP-12 upon CS 
exposure  [40] . In an acute smoke exposure model, MMP-
12 mediates smoke-induced inflammation by releasing 
TNF-  from macrophages  [31] . We have demonstrated 
that both  Tlr4  WT  and  Tlr4  defective  mice have increased 
MMP-12 mRNA expression in the lungs upon subacute 
CS exposure, with a tendency for lower MMP-12 mRNA 
levels in the  Tlr4  defective  mice, which corresponds with 
lower TNF-  levels in BAL of CS-exposed  Tlr4  defective  
mice. In the chronic experiment, however, the CS-in-
duced protein levels of MMP-12 in lung macrophages 
were similar in Tlr4  WT  and  Tlr4  defective  mice. MMP-12 re-
lease can result in emphysema. Yet, in this model it was 
impossible to compare the development of emphysema, 
because at baseline the  Tlr4  defective  mice have enlarged air-
spaces compared to the control  Tlr4  WT  strain (data not 
shown). Similar observations were obtained by Soutiere 
et al.  [56] who reported that C3H/HeJ  (Tlr4  defective  ) mice 
have enlarged alveolar spaces, with a 30% larger mean 
linear intercept compared to C57/Bl6 mice.
 Considering the similarities in CS-induced pulmo-
nary inflammation in the  Tlr4  WT   and  Tlr4  defective  animals 
in the chronic experiment, the putative importance of 
TLR4 in human COPD pathogenesis may be questioned. 
However, in our chronic model, some limited differences 
remain, such as the number of lymphocytes and DCs in 
the lungs. It remains to be determined if these limited 
differences are relevant in the pathogenesis of COPD, but 
positive correlations between COPD disease severity and 
the numbers of lymphocytes and DCs in the lungs have 
been made previously  [6, 39] . The importance of  TLR4 
gene polymorphisms and their association with human 
COPD is still controversial. Whereas one study reported 
that the Asp299Gly  TLR4  polymorphism did not have 
any significant impact on lung function  [57] , another one 
described that the Gly299 allele was decreased in COPD 
patients and even absent in COPD patients who never 
smoked  [58] . However, further and much larger cohorts 
are required to draw final conclusions on the importance 
of this  TLR4  polymorphism in COPD  [58] .
 In conclusion, using a mouse model of COPD, we 
demonstrated for the first time that part of the CS-in-
duced pulmonary inflammation occurs through the 
TLR4 signaling pathway. Indeed, after subacute CS expo-
sure for 5 weeks, the absence of TLR4 partly protects 
against CS-induced pulmonary influx of DCs, lympho-
cytes and neutrophils and against the CS-induced in-
crease of TNF-  and MCP-1 in BAL. However, chronic 
CS exposure for 26 weeks results in limited differences in 
inflammatory parameters between Tlr4  WT  and  Tlr4  defective  
mice, suggesting that TLR4 signaling is of minor impor-
tance in chronic CS-induced inflammation in mice.
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5.3. ‘Cigarette smoke-induced pulmonary inflammation and emphysema are 
attenuated in CCR6-deficient mice’ 
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Chemokines are assumed to contribute to the recruitment of inflammatory cells in COPD by 
binding to their respective chemokine receptors. We investigated the possible involvement of 
CCR6 in the pathogenesis of COPD by using CCR6 deficient mice in our smoke-model, and 
studying the effects of this deletion on pulmonary inflammation, emphysema and airway wall 
remodeling. 
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Cigarette Smoke-Induced Pulmonary Inflammation and
Emphysema Are Attenuated in CCR6-Deficient Mice1
Ken R. Bracke,* An I. D’hulst,* Tania Maes,* Katrien B. Moerloose,* Ingel K. Demedts,*
Serge Lebecque,† Guy F. Joos,* and Guy G. Brusselle2*
Chronic obstructive pulmonary disease (COPD) is mainly caused by cigarette smoking, and is characterized by an increase in
inflammatory cells in the airways and pulmonary tissue. The chemokine receptor CCR6 and its ligand MIP-3/CCL20 may be
involved in the recruitment of these inflammatory cells. To investigate the role of CCR6 in the pathogenesis of COPD, we analyzed
the inflammatory responses of CCR6 knockout (KO) and wild-type mice upon cigarette smoke (CS) exposure. Both subacute and
chronic exposure to CS induced an increase in cells of the innate and adaptive immune system in the bronchoalveolar lavage, both
in CCR6 KO and wild-type mice. However, the accumulation of dendritic cells, neutrophils, and T lymphocytes, which express
CCR6, was significantly attenuated in the CCR6 KO mice, compared with their wild-type littermates. In the lung tissue of CCR6
KO mice, there was an impaired increase in dendritic cells, activated CD8 T lymphocytes, and granulocytes. Moreover, this
attenuated inflammatory response in CCR6 KO mice offered a partial protection against pulmonary emphysema, which correlated
with an impaired production of MMP-12. Importantly, protein levels of MIP-3/CCL20, the only chemokine ligand of the CCR6
receptor, and MCP-1/CCL2 were significantly increased upon CS exposure in wild-type, but not in CCR6 KO mice. In contrast,
CCR6 deficiency had no effect on the development of airway wall remodeling upon chronic CS exposure. These results indicate
that the interaction of CCR6 with its ligand MIP-3 contributes to the pathogenesis of CS-induced pulmonary inflammation and
emphysema in this murine model of COPD. The Journal of Immunology, 2006, 177: 4350–4359.
C hronic obstructive pulmonary disease (COPD)3 is one ofthe leading causes of mortality and morbidity in theworld, and its prevalence is expected to increase in the
next decades (1, 2). The disease is characterized by a slowly pro-
gressive development of airflow limitation that is poorly revers-
ible. The airflow limitation is due to chronic obstructive bronchi-
olitis and loss of elastic recoil caused by destruction of lung
parenchyma (emphysema) (3). Patients with COPD also display
pathologically distinct structural alterations of the small airways
(airway remodeling) (4), as well as systemic inflammation (5, 6).
The molecular and cellular mechanisms that are responsible for the
development of COPD are not well understood. Cigarette smoking
is the major risk factor for the development of COPD, and it has
been shown that chronic exposure to cigarette smoke (CS) leads to
lung inflammation with an increase of inflammatory cells such as
macrophages (7, 8), neutrophils (9, 10), dendritic cells (DCs) (11,
12), and CD8 T lymphocytes (13). These cells are capable of
releasing inflammatory mediators and proteinases, such as matrix
metalloproteinases (MMPs) or neutrophil elastase, which are believed
to play a role in the progressive lung destruction in COPD (14–16).
Several cytokines and chemokines are assumed to regulate the
activation and recruitment of these inflammatory cells into the air-
ways and pulmonary tissue of COPD patients. For example, it has
been described that binding of MCP-1 to its receptor CCR2 leads
to recruitment of DCs and monocytes from the blood to the tissue
(17) and that IL-8 (or the mouse homolog KC) is chemotactic for
neutrophils (18). In recent papers, some investigators suggested
that COPD is an autoimmune disease triggered by CS (19, 20),
which would then depend heavily on the presence of T lympho-
cytes and DCs. Moreover, in patients with severe COPD (Global
Initiative for Obstructive Lung Disease stages 3 and 4), lymphoid
follicles containing T and B lymphocytes are present in the peri-
bronchial wall (21). Recently, in a murine model of CS-induced
COPD (22), we and others (23, 24) have described a significant
increase in the number and size of peribronchial follicles upon
chronic CS exposure.
Chemokines are a family of structurally related chemotactic pro-
teins, whose primary role is to direct the migration of leukocytes
throughout the body, both under physiological and inflammatory
conditions. Moreover, they have broad-reaching effects on other
fundamental aspects of immunology, including the development,
homeostasis, and function of the immune system. Generally, che-
mokines exert their biological functions by interaction with spe-
cific chemokine receptors on their target cells (25).
Chemokine receptor CCR6, a seven-transmembrane-domain G
protein-coupled receptor, is a receptor that, unlike most of its fam-
ily members, has only one chemokine ligand, namely MIP-3
(CCL20). It has, however, been described that certain members of
the -defensin family also bind CCR6, but with lower affinity (26).
CCR6 is expressed on immature DCs (27), B lymphocytes (28),
memory T cells (29), cytokine-activated neutrophils (30), and at
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low levels on endothelial cells (31). The MIP-3/CCR6 interaction
functions as one of the most potent mechanisms for recruitment of
immature DC (32, 33). MIP-3 is expressed predominantly in in-
flamed epithelial surfaces, including the airway epithelium (34),
and could thus regulate the migration of immature DCs to the
airways for subsequent Ag presentation. It has also been reported
that MIP-3 is chemotactic for T lymphocytes (35). Moreover,
MIP-3 expression can be up-regulated by a broad spectrum of
proinflammatory cytokines (e.g., TNF-) and by ambient particles
(34), making it an ideal candidate for a role in chronic inflamma-
tory airway diseases such as COPD. CCR6 has also been impli-
cated in asthma, in which it has been shown that CCR6 knockout
(KO) mice have a reduced allergic pulmonary inflammation in
response to cockroach Ag (36).
These data suggest that CCR6 and its ligand MIP-3 may play
a role in the inflammatory cell recruitment in COPD. To elucidate
the functional role of CCR6 in the pathogenesis of COPD, we
tested CCR6 KO and wild-type mice in a model of CS-induced
pulmonary inflammation and emphysema (22). We analyzed the
inflammatory responses in both bronchoalveolar lavage (BAL) and
lung tissue after subacute (4-wk) or chronic (24-wk) exposure to
CS. Second, we quantified the extent of pulmonary emphysema,
airway wall remodeling, and peribronchial aggregates in both
CCR6 KO and wild-type mice upon chronic CS exposure.
Materials and Methods
Animals
A breeding pair of mice with disruption of the CCR6 gene was obtained
from S. Lebecque (Service de Pneumologie, Centre Hospitalier Universi-
taire-Lyon, France). The CCR6 KO mice were backcrossed 10 generations
onto the C57BL/6 background (37). Male CCR6 KO mice were bred (8 wk
old) and male C57BL/6 wild-type mice (8 wk old) were used as control
mice (Charles River Laboratories). The local ethics committee for animal
experimentation of the faculty of Medicine and Health Sciences (Ghent,
Belgium) approved all in vivo manipulations.
CS exposure
Mice (n  8) were exposed whole body to CS, as described previously
(22). Briefly, groups of eight mice were exposed to the tobacco smoke of
five cigarettes (Reference Cigarette 2R4F without filter; University of Ken-
tucky) four times per day with a 30-min smoke-free interval, 5 days per
week for 4 wk (subacute exposure) or 24 wk (chronic exposure). An op-
timal smoke:air ratio of 1:6 was obtained. The control groups were exposed
to air. Carboxyhemoglobin in serum of smoke-exposed mice reached a
nontoxic level of 8.3  1.4% (compared with 1.0  0.2% in air-exposed
mice (n  7 for both groups)), which is similar to carboxyhemoglobin
blood concentrations of human smokers (38).
Bronchoalveolar lavage
Twenty-four hours after the last exposure, mice were weighed and sacri-
ficed with an overdose of pentobarbital (Sanofi-Synthelabo), and a tracheal
cannula was inserted. A total of 3  300 l, followed by 3  1 ml of
HBSS, free of ionized calcium and magnesium, but supplemented with
0.05 mM sodium EDTA, was instilled via the tracheal cannula and recov-
ered by gentle manual aspiration. The six lavage fractions were pooled and
centrifuged, and the cell pellet was washed twice and finally resuspended
in 1 ml of HBSS. A total cell count was performed in a Bu¨rcker chamber,
and the differential cell counts (on at least 400 cells) were performed on
cytocentrifuged preparations using standard morphologic criteria after
May-Gru¨nwald-Giemsa staining. Flow cytometric analysis of BAL cells
was performed to enumerate DCs and CD4 and CD8 T lymphocytes.
Collection of blood leukocytes
Following BAL, blood was drawn by cardiac puncture and collected in
EDTA-coated tubes. The blood was subjected to RBC lysis and labeled for
differential leukocyte counts by flow cytometry.
Preparation of lung single-cell suspensions
Following cardiac puncture, the pulmonary and systemic circulation was
rinsed. The left lung was used for histology, and the right lung for the
preparation of a cell suspension, as detailed previously (39). Briefly, the
lung was thoroughly minced, digested, subjected to RBC lysis, passed
through a 50-m cell strainer, and kept on ice until labeling. Cell counting
was performed with a Z2 Beckman Coulter particle counter (Beckman
Coulter).
FIGURE 1. Measurement of MIP-3 in BAL fluid and lung tissue. A,
Protein levels of MIP-3/CCL20 in the BAL fluid of wild-type and CCR6
KO mice after subacute (4-wk) exposure to air or CS, as measured by
ELISA. Results are expressed as pg/ml (mean  SEM). n  8 animals/
group; , p  0.05. B, mRNA levels of MIP-3/CCL20 in total lung tissue
of wild-type and CCR6 KO mice after subacute (4-wk) exposure to air or
CS, as measured by RT-PCR. Results are expressed as a ratio with hprt
mRNA (mean  SEM). n  5 animals/group; , p  0.05.
FIGURE 2. CCR6-expressing DCs (A) and T lymphocytes (B) in BAL
fluid and lung digests of wild-type mice after subacute (4-wk) exposure to
air or CS, enumerated by flow cytometry. Results are expressed as per-
centage of total cells (means  SEM). n  8 animals/group; , p  0.05.
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Labeling of BAL cells, lung single-cell suspensions, and blood
leukocytes for flow cytometry
Cells were preincubated with FcR blocking Ab (anti-CD16/CD32, clone
2.4G2) to reduce nonspecific binding. The following mAbs were used to
identify mouse DC populations: biotinylated anti-CD11c (N418) and PE-
conjugated anti-I-Ab (AF6-120.1). We discriminated between macro-
phages and DCs using the methodology described by Vermaelen and Pau-
wels (40). After gating on the CD11c-bright population, two peaks of
autofluorescence can be distinguished. Macrophages are identified as the
CD11c-bright, high autofluorescent population, and do not express MHC
class II. DCs are identified as CD11c-bright, low autofluorescent cells,
which strongly express MHC class II. DCs enumerated by these criteria
correspond with myeloid DCs. The following Abs were used to stain
mouse T cell subpopulations: FITC-conjugated anti-CD4 (L3T4), FITC-
conjugated anti-CD8 (Ly-2), and biotinylated anti-CD3 (145-2C11) mAbs.
The additional marker used for T cell activation was PE-conjugated anti-
CD69 (H1.2F3). PE-conjugated anti-CD19 (1D3) and anti-CD11c were
used to characterize B lymphocytes. PE-conjugated anti-GR1 (Ly-6G) and
biotinylated anti-CD11c Abs were used to characterize pulmonary granu-
locytes. The following Abs were used to differentiate blood leukocytes:
FITC-conjugated anti-CD11b (M1/70), PE-conjugated anti-CD45 (Ly-5),
allophycocyanin-conjugated anti-CD3, and biotinylated anti-CD19. CCR6
expression was revealed with PE-conjugated anti-CCR6 (140706). Biotin-
ylated anti-CD11c and anti-CD3 were revealed by incubation with strepta-
vidin-allophycocyanin. Biotinylated anti-CD19 was revealed by incubation
with streptavidin-PerCP. All mAbs were obtained from BD Pharmingen,
except anti-CD11c (N418 hybridoma; a gift from M. Moser, Brussels Free
University, Brussels, Belgium) and anti-CCR6 (R&D Systems).
As a last step before analysis, cells were incubated with 7-aminoacti-
nomycin D (or viaprobe; BD Pharmingen) for dead cell exclusion. All
labeling reactions were performed on ice in FACS-EDTA buffer.
Flow cytometry data acquisition was performed on a dual-laser FACS-
Vantage flow cytometer running CellQuest software (BD Biosciences).
FlowJo software (www.Treestar.com) was used for data analysis.
Histology
The left lung was fixated by gentle infusion of fixative (4% paraformal-
dehyde) through the tracheal cannula (22). After excision, the lung was
immersed in fresh fixative during 2 h. The lung lobe was embedded in
paraffin and cut in 3-m transversal sections. Lung tissue samples were
stained with H&E and examined by light microscopy for histological sec-
tions. For each animal, 10 fields at a magnification of 200 were captured
in a blinded fashion using a Zeiss KS400 image analyzer platform (KS400;
Zeiss).
Quantification of emphysema
Emphysema is a structural disorder characterized by destruction of the
alveolar walls and enlargement of the alveolar spaces. We determined de-
struction of alveolar walls by measuring the destructive index (DI) (41) and
FIGURE 3. Total BAL cells and
cell differentiation in BAL fluid of
wild-type and CCR6 KO mice after
subacute (4-wk) or chronic (24-wk)
exposure to air or CS: A, total BAL
cells; B, macrophages; C, DCs; D,
neutrophils; E, lymphocytes; F,
CD4 T lymphocytes; and G, CD8
T lymphocytes (A, B, D, and E were
calculated on cytospins; C, F, and G
were enumerated by flow cytometry).
Results are expressed as means 
SEM. n  8 animals/group; , p 
0.05.
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enlargement of alveolar spaces by quantifying the mean linear intercept
(Lm) (42), as described previously (22, 23).
Quantification of airspace enlargement was determined after 6-mo air or
CS exposure by measuring the Lm using image analysis software (Image J
1.33). The Lm was measured by placing a 100  100-m grid over each
field. The total length of each line of the grid divided by the number of
alveolar intercepts gives the average distance between alveolated surfaces,
or the Lm (42).
The destruction of alveolar walls was quantified by the DI (41). A grid
with 42 points that were at the center of hairline crosses was superimposed
on the lung field. Structures lying under these points were classified as
normal (N) or destroyed (D) alveolar and/or duct spaces. Points falling over
other structures, such as duct walls, alveolar walls, etc., did not enter into
the calculations. The DI was calculated from the formula: DI  D/(D 
N)  100.
Morphometric quantification of lymphoid aggregates
To evaluate the presence of lymphoid aggregates in lung tissue after 6-mo
air or CS exposure, lung sections obtained from Formalin-fixed, paraffin-
embedded lung lobes were subjected to an immunohistological CD3 stain-
ing: at first, sections were incubated with Boehringer blocking reagent with
Triton X-100 and primary Ab anti-CD3, followed by goat anti-rabbit biotin
(both obtained from DakoCytomation). Then, slides were incubated with
streptavidin HRP and colored with diaminobenzidine (both obtained from
DakoCytomation). Lymphoid aggregates were defined as accumulations of
at least 50 cells and counted in the tissue area surrounding the airways
(airway perimeter 0–2000 m). Results were expressed as counts relative
to the numbers of airways per lung section.
Measurement of chemokines and cytokines
Using a commercially available ELISA kit (R&D Systems), MIP-3 pro-
tein level was determined in BAL fluid after 4 and 24 wk of air or CS
exposure.
At the same time points, cytokines and chemokines in BAL fluid were
determined by FACS using the cytometric bead array (CBA; BD Bio-
sciences), following the manufacturer’s instructions. A mixture of three
capture bead populations, each with distinct fluorescence intensities and
coated with Abs specific for TNF-, MCP-1, and KC, was prepared. The
CBA capture beads were incubated together with PE-conjugated detection
Abs and test samples or standards, to form sandwich complexes. Following
acquisition of sample data using the flow cytometer (FACSCalibur flow
cytometer; BD Biosciences), the sample results were generated in graphical
and tabular format using the CBA Analysis Software (BD Biosciences).
Immunohistochemistry for MMP-12
Sections obtained from Formalin-fixed, paraffin-embedded lung lobes were
subjected to the following immunohistological staining sequences: block-
ing reagent, goat anti-mouse MMP-12 (Santa Cruz Biotechnology), or goat
IgG isotype control, and detection with Vectastain Elite Goat IgG ABC Kit
(Vector Laboratories) and diaminobenzidine substrate (DakoCytomation).
Sections were counterstained with hematoxylin.
RT-PCR analysis
Total lung RNA was extracted with the RNeasy Midi Kit (Qiagen). Ex-
pression of MIP-3, MMP-12, and TNF- mRNA, relative to hypoxan-
thine guanine phosphoribosyltransferase (hprt) mRNA, was analyzed with
the Assays-on-Demand Gene Expression Products (Applied Biosystems).
FIGURE 4. Cell differentiation in the lungs of
wild-type and CCR6 KO mice after subacute (4-
wk) or chronic (24-wk) exposure to air or CS: A,
macrophages; B, DCs; C, activated CD4 T lym-
phocytes; D, activated CD8 T lymphocytes; and
E, granulocytes (all cell types were enumerated by
flow cytometry). Results are expressed as means 
SEM. n  8 animals/group; , p  0.05.
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RT-PCR was performed on an ABI PRISM 7700 Sequence Detection Sys-
tem with murine leukemia virus RTase (Applied Biosystems). Reverse
transcription was performed at 48°C for 30 min, followed by 12-min in-
cubation at 95°C for denaturation of RNA-DNA heteroduplexes, and 50
cycles of 95°C for 15 s and 60°C for 60 s. Monitoring of the RT-PCR
occurred in real time using a FAM/TAMRA probe. All reactions were
performed starting from 10 ng of total RNA.
Airway remodeling
Collagen in the airway wall was stained using Sirius Red, and the amount
of fibronectin with a goat anti-rat fibronectin Ab (Calbiochem) using the
streptavidin-biotin peroxidase method (43). For each experimental group,
three lung sections per animal were examined. Morphometrical parameters
(44) were marked manually on the digital representation of the airway: the
length of the basement membrane (Pbm), the area defined by the basement
membrane (Abm), and the area defined by the total adventitial perimeter
(Ao). The total bronchial wall area (WAt) was calculated (WAt  Ao –
Abm) and normalized to the squared Pbm. For the quantification of colla-
gen and fibronectin deposition, the area in the airway wall covered by the
stain was determined by the software (KS400; Zeiss) and its value was
calculated, as described previously (43). The area of collagen or fibronectin
deposition was normalized to Pbm. All airways with a Pbm smaller than
2000 m and cut in reasonable cross sections (defined by a ratio of min-
imal to maximal internal diameter 0.5) were included.
Statistical analysis
Reported values are expressed as mean  SEM. Statistical analysis was
performed with Sigma Stat software (SPSS) using nonparametric tests
(Kruskall-Wallis; Mann-Whitney U). A p value 0.05 was considered
significant.
Results
Increased MIP-3/CCL20 levels in the BAL fluid and lungs
upon subacute CS exposure
Because MIP-3 is the only known chemokine ligand for CCR6,
we examined the presence of MIP-3 protein in the BAL fluid of
wild-type and CCR6 KO mice by ELISA. Subacute (4-wk) expo-
sure to CS significantly increased the levels of MIP-3 in the BAL
fluid of wild-type mice, compared with air-exposed littermates. In
contrast, we did not observe a CS-induced up-regulation of
MIP-3 protein in CCR6 KO mice (Fig. 1A). Moreover, the
amounts of MIP-3 were significantly lower in both air- and CS-
exposed CCR6 KO mice, compared with wild-type animals
(Fig. 1A).
RT-PCR analysis on RNA extracted from total lung tissue also
revealed a significant increase of MIP-3 expression upon CS ex-
posure. Again, this time on the mRNA level, there was signifi-
cantly less expression in the CS-exposed CCR6 KO mice, com-
pared with wild-type mice (Fig. 1B).
Subacute CS-induced increase of CCR6-expressing DCs and T
lymphocytes
FACS analysis using an anti-CCR6 mAb clearly revealed CCR6
expression on DCs and T lymphocytes of wild-type mice. Upon
subacute CS exposure, there was, in both BAL and lung tissue, a
significant increase in CCR6-expressing DCs and T lymphocytes,
measured as percentage of total cells (Fig. 2). The CCR6 expres-
sion within the DC population also increased upon CS exposure in
both BAL (air, 5.52  0.70% vs smoke, 8.20  0.85%) and lung
tissue (air, 22.41  1.30% vs smoke, 27.07  2.68%), but this did
not reach statistical significance (data not shown). The CCR6 ex-
pression within the T lymphocyte population did not change in
lung tissue (air, 48.60  3.49% vs smoke, 48.70  3.96%) and
even tended to decrease in BAL (air, 43.74  3.15% vs smoke,
32.83  2.42%) (data not shown).
CS-induced increase of inflammatory cells in the BAL fluid
Subacute and chronic exposure to CS increased the absolute num-
bers of total cells, alveolar macrophages, DCs, lymphocytes, and
neutrophils in the BAL fluid of both wild-type and CCR6 KO
mice, compared with air-exposed animals (Fig. 3). There were no
significant differences in total numbers of BAL cells and alveolar
macrophages between wild-type and CCR6 KO mice upon CS
exposure (Fig. 3, A and B). In contrast, at both time points (4 and
24 wk), the numbers of DCs, lymphocytes, and neutrophils were
significantly lower in the CS-exposed CCR6 KO mice, compared
with wild-type animals (Fig. 3, C–E). Within the lymphocyte pop-
ulation, the CS-induced accumulation of both CD4 and CD8
cells was attenuated in CCR6 KO mice (Fig. 3, F and G).
Moreover, baseline levels of BAL DCs and lymphocytes were
significantly lower in air-exposed CCR6 KO mice, compared with
their wild-type littermates (Fig. 3, C and E).
CS-induced increase of inflammatory cells in the lungs
In lung single-cell suspensions, subacute and chronic exposure to
CS induced an increase in interstitial macrophages, DCs, activated
CD4 and CD8 T lymphocytes, and granulocytes in both wild-
type and CCR6 KO mice, compared with air-exposed littermates
(Fig. 4). In the lung compartment, there were no significant dif-
ferences between wild-type and CCR6 KO animals, except for the
significantly lower numbers of DCs (upon subacute CS exposure)
and activated CD8 T lymphocytes and granulocytes (upon
chronic CS exposure) in the CCR6 KO mice (Fig. 4, B and E). The
FIGURE 5. Quantification of pulmonary lymphoid aggregates. A, Lym-
phoid aggregates around the airways in lung tissue of wild-type and CCR6
KO mice after chronic (24-wk) exposure to CS, compared with air-exposed
mice. Results are expressed as means SEM. n 8 animals/group; , p
0.05. Photomicrographs of lymphoid aggregates in CD3-stained lung tissue
of air- and smoke-exposed wild-type and CCR6 KO mice at 24 wk (mag-
nification, 100). B, Air-exposed wild-type mice; C, CS-exposed wild-
type mice; D, air-exposed CCR6 KO mice; and E, CS-exposed CCR6 KO
mice.
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number of B lymphocytes did not change significantly upon smoke
exposure (data not shown).
Chronic CS-induced increase in pulmonary lymphoid aggregates
Immunohistochemistry using an anti-CD3 mAb to stain T lym-
phocytes revealed hardly any lymphoid aggregates in the lung ar-
eas surrounding the airways or blood vessels of air-exposed wild-
type and CCR6 KO mice. Chronic CS exposure significantly
increased the number of peribronchial lymphoid aggregates (which
also occur perivascularly) in the lungs of both wild-type and CCR6
KO mice (Fig. 5). However, there was a trend toward less aggre-
gates in the CS-exposed CCR6 KO mice, compared with the wild-
type littermates ( p  0.077) (Fig. 5A). No pulmonary aggregates
could be detected in the lungs after subacute CS exposure.
Partial protection against emphysema in CCR6 KO mice upon
chronic CS exposure
Pulmonary emphysema is characterized by destruction of alveolar
walls due to damage to the lung parenchyma, leading to enlarge-
ment of alveolar spaces. Therefore, to quantify emphysematous
lesions, it is recommended to evaluate both the airspace enlarge-
ment (quantified by the measurement of the Lm) and the destruc-
tion of the alveolar walls (quantified by the measurement of
the DI).
Chronic CS exposure clearly induced pulmonary emphysema in
wild-type mice, evidenced by a significant increase in Lm (air,
41.08  0.33 m vs smoke, 49.91  0.72 m; 14.2% increase)
and DI (air, 28.12  1.03 vs smoke, 41.92  1.42; 49.1% in-
crease). Also, in CCR6 KO animals, chronic CS exposure led to an
induction of emphysema, evidenced by a significant increase in Lm
(air, 42.19 0.51 m vs smoke, 44.19 0.33 m; 4.7% increase)
and DI (air, 27.51  1.44 vs smoke, 33.67  1.64; 22.4% in-
crease). However, the Lm and DI of the smoke-exposed CCR6 KO
mice were significantly lower compared with the smoke-exposed
wild-type mice (Fig. 6, A and B), indicating a partial protection
against pulmonary emphysema in CCR6 KO mice. The significant
airspace enlargement due to chronic CS exposure in wild-type
mice and the attenuated emphysema in CCR6 KO mice is illus-
trated with H&E-stained lung tissue sections (Fig. 6, C–F).
Impaired increase in MMP-12 expression in CCR6 KO mice
upon CS exposure
MMP-12 is one of the key proteinases implicated in the develop-
ment of pulmonary emphysema (45). Because CS-induced emphy-
sema is attenuated in CCR6 KO mice, we analyzed the pulmonary
expression of MMP-12 by RT-PCR and immunohistochemistry.
Subacute CS exposure induced a significant increase in MMP-12
mRNA in both wild-type and CCR6 KO mice, compared with
air-exposed littermates. However, the CS-induced increase in
MMP-12 mRNA expression was significantly attenuated in the
CCR6 KO mice, compared with wild-type animals (Fig. 7A). Im-
munohistochemistry clearly revealed MMP-12 staining in macro-
phages and DCs of chronic CS-exposed wild-type and CCR6 KO
mice, compared with the absence of MMP-12 staining in air-ex-
posed littermates (Fig. 7, B–E). Again, the MMP-12 induction
seemed attenuated in the CCR6 KO mice, as evidenced by a fainter
staining, compared with wild-type mice.
FIGURE 6. Quantification of pul-
monary emphysema. Morphometry of
the lungs after chronic (24-wk) air or
CS exposure: A, Lm and B, DI values
of wild-type and CCR6 KO mice. Re-
sults are expressed as means  SEM.
n  8 animals/group; , p  0.05.
Photomicrographs of H&E-stained
lung tissue of air- and smoke-exposed
wild-type and CCR6 KO mice at 24
wk (magnification, 200). C, Air-ex-
posed wild-type mice; D, CS-exposed
wild-type mice; E, air-exposed CCR6
KO mice; and F, CS-exposed CCR6
KO mice.
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Subacute CS-induced increase of inflammatory chemokines and
cytokines
To gain further insight in the molecular mechanisms of the atten-
uated inflammation and emphysema in CCR6 KO mice, we mea-
sured protein levels of MCP-1, KC, and TNF- in the BAL fluid
by CBA, as well as the TNF- mRNA expression in total lung
tissue by RT-PCR.
Subacute exposure to CS induced a strong increase in MCP-1
protein in the BAL fluid of wild-type mice, while there was no
up-regulation in the CCR6 KO mice (Fig. 8A). KC (mouse ho-
molog for IL-8) was increased in BAL fluid of both wild-type and
CCR6 KO mice upon subacute CS exposure (Fig. 8B).
The levels of TNF- protein were below detection limit in al-
most all BAL fluid samples (data not shown), while subacute ex-
posure to CS induced a significant increase in TNF- mRNA in
total lung tissue of wild-type mice, which was significantly atten-
uated in the CCR6 KO mice (Fig. 8C).
Chronic CS-induced airway wall remodeling
To investigate the effects of chronic CS exposure on the deposition
of extracellular matrix in the airway wall, lung sections were
stained with antifibronectin or Sirius Red to reveal fibronectin and
collagen, respectively. In both wild-type and CCR6 KO mice,
chronic CS exposure induced a significant increase in peribron-
chial fibronectin deposition (Fig. 9, A–E). Similarly, chronic CS
exposure significantly increased the amount of collagen present in
the peribronchial area of both wild-type and CCR6 KO mice (Fig.
9, F–J). Moreover, this increased deposition of fibronectin and
collagen resulted in a significant thickening of the airway wall
upon chronic CS exposure in both genotypes (Fig. 9K).
Differential cell counts on blood leukocytes upon subacute CS
exposure
Because COPD is also characterized by systemic inflammation, we
performed differential cell counts on blood leukocytes, distinguish-
ing monocytes, granulocytes, and B and T lymphocytes. Subacute
CS exposure significantly increased blood granulocytes (measured
as percentage of total blood leukocytes), in both wild-type and
CCR6 KO mice (wild type  air, 8.52  1.30% vs CS, 16.16 
2.57%, p  0.05; CCR6 KO  air, 8.92%  1.91 vs CS, 15.45 
1.88%, p  0.05). In contrast, subacute CS exposure did not
change the percentage of blood monocytes and B lymphocytes
(monocytes: wild type  air, 4.92  0.42% vs CS, 5.33  0.64%,
FIGURE 7. Measurement of MMP-12 in lung tissue. A, RT-PCR for the
expression of MMP-12 mRNA in total lung tissue of wild-type and CCR6
KO mice after subacute (4-wk) exposure to air or CS. Results are expressed
as a ratio with hprt mRNA (mean  SEM). n  5 animals/group; , p 
0.05. Immunohistochemistry for MMP-12 protein on lung tissue of wild-
type and CCR6 KO mice exposed to air or CS for 24 wk (chronic exposure)
(magnification,400). MMP-12 is expressed by macrophages and DCs. B,
Air-exposed wild-type mice; C, CS-exposed wild-type mice; D, air-ex-
posed CCR6 KO mice; and E, CS-exposed CCR6 KO mice. Photomicro-
graphs are representative of eight animals per group.
FIGURE 8. Effect of subacute (4-wk) exposure to air or CS on the pro-
tein levels of MCP-1 (A) and KC (mouse IL-8) (B) in BAL fluid of wild-
type and CCR6 KO mice, as measured by CBA. Results are expressed as
pg/ml (mean  SEM). n  8 animals/group; , p  0.05. C, RT-PCR for
the expression of TNF- mRNA in total lung tissue of wild-type and
CCR6 KO mice after subacute (4-wk) exposure to air or CS. Results are
expressed as a ratio with hprt mRNA (mean  SEM). n  5 animals/
group; , p  0.05.
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NS; CCR6 KO  air, 4.62  0.52% vs CS, 4.06  0.58%, NS; B
lymphocytes: wild type  air, 49.41  5.83% vs CS, 51.24 
1.53%, NS; CCR6 KO  air, 49.58  2.68% vs CS, 44.33 
2.85%, NS). Also, on the numbers of T lymphocytes, there was no
effect of CS exposure. However, the percentage of T lymphocytes
was significantly higher in CCR6 KO mice, compared with wild-
type mice (air  wild type, 19.41  1.83% vs CCR6 KO, 29.74 
1.51%, p  0.01; smoke  wild type, 19.69  1.19% vs CCR6
KO, 28.97  2.73%, p  0.01).
Discussion
COPD is mainly caused by cigarette smoking, and is characterized
by a pulmonary inflammation with an increase in cells of both the
innate and the adaptive immune system. In this study, we have
demonstrated that the CS-induced pulmonary inflammation is
partly impaired in CCR6 KO mice, resulting in an attenuated in-
crease of DCs, T lymphocytes, and neutrophils in the BAL fluid
and an impaired increase in DCs, activated CD8 T lymphocytes,
and granulocytes in the lungs of CCR6 KO mice, compared with
wild-type littermates. Importantly, upon chronic CS exposure,
there was a partial protection against pulmonary emphysema in the
CCR6 KO mice. In contrast, CCR6 deficiency had no effect on the
development of airway wall remodeling and systemic inflammation.
We have shown that both mRNA and protein levels of MIP-3/
CCL20, the unique chemokine ligand for the CCR6 receptor, are
significantly increased upon CS exposure in wild-type mice. This
can be due to activation of the lung epithelium, either directly by
CS or indirectly via inflammatory mediators such as TNF- or
IFN- (34), which are released in the ongoing process of COPD.
MIP-3 is known to attract CCR6-expressing cells from the tissue
to the site of pathogen invasion (17), and may contribute to the
CS-induced pulmonary inflammation. Indeed, in CCR6 KO mice,
we observed an attenuated increase in the numbers of DCs and T
lymphocytes (cell types that clearly showed CCR6 expression in
wild-type mice), whereas the numbers of macrophages (that are
not expressing CCR6) were comparable to the wild-type animals.
Moreover, in CCR6 KO mice, we observed significantly lower
levels of MIP-3. This can be a downstream effect of the CCR6
deficiency, in which the impaired pulmonary inflammation leads to
a reduced release of inflammatory mediators such as TNF- or
IFN-, thereby hampering the activation of airway epithelial cells
to release MIP-3.
We also found the chemokine MCP-1 to be strongly induced in
CS-exposed wild-type mice. MCP-1 binds to CCR2, a receptor
that is highly expressed on circulating blood DCs and monocytes,
and thus primarily controls their recruitment from the blood ves-
sels to the tissue (17). In contrast to wild-type mice, there was no
increase in MCP-1 levels in CCR6 KO mice upon CS exposure,
again probably a downstream effect of the CCR6 deficiency in
which the impaired pulmonary inflammation leads to less MCP-1
release.
CS-exposed CCR6 KO mice also showed a significant attenu-
ation in neutrophil influx. This can be due to a direct effect of the
FIGURE 9. Quantification of airway
wall remodeling. A, Peribronchial fi-
bronectin deposition in lung tissue of
wild-type and CCR6 KO mice after
chronic (24-wk) exposure to air or CS.
Results are expressed as means SEM.
n  8 animals/group; , p  0.05. Pho-
tomicrographs of peribronchial fi-
bronectin deposition (magnification,
100): B, air-exposed wild-type mice;
C, CS-exposed wild-type mice; D, air-
exposed CCR6 KO mice; and E, CS-
exposed CCR6 KO mice. F, Peribron-
chial collagen deposition in lung tissue
of wild-type and CCR6 KO mice after
chronic (24-wk) exposure to air or CS.
Results are expressed as means SEM.
n  8 animals/group; , p  0.05. Pho-
tomicrographs of peribronchial collagen
deposition (magnification, 100): G,
air-exposed wild-type mice; H, CS-ex-
posed wild-type mice; I, air-exposed
CCR6 KO mice; and J, CS-exposed
CCR6 KO mice. K, Airway wall thick-
ness of wild-type and CCR6 KO mice
upon chronic (24-wk) exposure to air or
CS. Results are expressed as means 
SEM. n 8 animals/group; , p 0.05.
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lack of CCR6, which is described to be present on certain cyto-
kine-activated neutrophils (30), or indirectly via the release of
other inflammatory mediators. One neutrophil-attracting chemo-
kine that we found to be significantly induced upon CS exposure
is KC (the mouse homolog for IL-8), but there were no differences
between wild-type and CCR6 KO mice.
The remaining recruitment of DCs, neutrophils, and T lympho-
cytes to the airways of CCR6 KO mice can be explained by the
release of other chemokines, such as MIP-1/CCL3 or I-TAC/
CXCL11, which are also chemotactic for a variety of inflammatory
cells by binding to chemokine receptors like CCR5 (46) or CXCR3
(47–49), respectively. Also, elastin fragments, generated as a re-
sult of proteolysis of elastin fibers by neutrophil elastase or MMP-
12, are chemotactic for monocytes (50). The fact that baseline
levels of BAL DCs and lymphocytes were lower in the air-exposed
CCR6 KO mice compared with wild-type littermates suggests that
the CCR6 pathway is not only important in CS-induced inflam-
mation, but also in the homeostatic recruitment of inflammatory
cells to the airways.
The reduced accumulation of DCs in CCR6-deficient mice upon
CS exposure supports the findings by Osterholzer et al. (51), who
described the contribution of CCR6 to DC migration into alveolar
spaces of allergen-challenged mice. In the same respect, Le
Borgne et al. (52) showed that recruitment of DCs into epithelial
tissues for CD8 T lymphocyte priming depends on the CCR6/
MIP-3 pathway.
The alveolar destruction in pulmonary emphysema is believed
to originate mainly from an imbalance between proteinases and
their inhibitors. Macrophages are an important source of protein-
ases, especially MMP-12, which has been implicated in the devel-
opment of pulmonary emphysema upon long-term CS exposure in
mice (45). We have shown recently that not only macrophages, but
also DCs are capable of releasing MMP-12 in response to CS (53).
The impaired production of MMP-12 that we observed in CS-
exposed CCR6 KO mice can be the result of the lower numbers of
DCs, or can be due to an attenuated activation of DCs and mac-
rophages in these mice. Either way, these lower levels of MMP-12
can be a possible explanation for the partial protection against
alveolar destruction and emphysema in CCR6 KO mice.
Several additional mechanisms might explain why CCR6 KO
mice are partially protected against CS-induced pulmonary em-
physema. First, neutrophils are another important source of pro-
teinases, releasing serine proteinases such as neutrophil elastase,
which is also implicated in the pathogenesis of pulmonary emphy-
sema (15). The lower number of neutrophils in CCR6 KO mice
will lead to less neutrophil elastase, further influencing the pro-
teinase/antiproteinase imbalance in CCR6 KO mice. Second, the
attenuated smoke-induced increase of T lymphocytes in CCR6 KO
mice might also contribute to the partial protection against CS-
induced pulmonary emphysema. Indeed, cytotoxic CD8 T lym-
phocytes have the capacity to cause cytolysis and apoptosis of
alveolar epithelial cells through the release of perforins and gran-
zyme B (19, 54).
Contrary to the clear influence of the CCR6 deficiency on CS-
induced pulmonary inflammation and airspace enlargement, it had
no effect on airway wall remodeling, another hallmark of COPD.
This suggests that the peribronchial deposition of fibronectin and
collagen is not a direct downstream effect of the ongoing pulmo-
nary inflammation, but rather occurs through independent pro-
cesses, a theory that has also been proposed for remodeling in
asthma (55, 56). It is not known what exactly drives these pro-
cesses, but there is evidence for the involvement of TGF- (57).
COPD is also characterized by systemic inflammation (5, 6).
Whether this is the result of spillover from the airway inflamma-
tion or not is still controversial. We have shown that the CS-in-
duced increase in blood granulocytes is not influenced by the at-
tenuated pulmonary inflammation in CCR6 KO mice, indicating
that CS can directly produce systemic inflammation, as has also
been evidenced in human smokers (6).
In conclusion, we have demonstrated that CCR6 deficiency
leads to an impaired accumulation of myeloid DCs, neutrophils,
and T lymphocytes upon CS exposure, which is reflected in a
partial protection against the development of pulmonary emphy-
sema. This indicates that the interaction of CCR6 with its ligand
MIP-3 contributes to the pathogenesis of CS-induced pulmonary
inflammation and emphysema.
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There is growing evidence that the recruitment of inflammatory cells in COPD is largely 
orchestrated chemokines binding to their respective chemokine receptors. We investigated 
the role of CCR5 in the pathogenesis of COPD by using CCR5 deficient mice in our smoke-
model, and studying the effects of this deletion on pulmonary inflammation, emphysema and 
airway wall remodeling. 
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 Cigarette smoke-induced pulmonary inflammation, but not airway 
remodeling, is attenuated in CCR5 deficient mice 
 
Ken R. Bracke1#, An I. D’hulst1#, Tania Maes1, Ingel K. Demedts1, Katrien B. 
Moerloose1, William A. Kuziel2, Guy F. Joos1 and Guy G. Brusselle1* 
 
Background: Chronic obstructive pulmonary disease (COPD) is characterized by a chronic inflammatory response of 
the airways and lungs to noxious particles and gases, mostly cigarette smoke (CS). Pathological changes characteristic 
of COPD include airway wall thickening, peribronchial fibrosis, peribronchial lymphoid follicles and destruction of 
lung parenchyma (emphysema). The recruitment of inflammatory cells into the lung in response to CS is thought to 
play an important role in the development of COPD. Objective: Our aim was to study the contribution of chemokine 
receptor CCR5 to the pathogenesis of COPD and specifically whether the development of airway remodeling is a 
direct result of airway inflammation or rather occurs through an independent mechanism. Methods: In this study 
C57BL/6 wild type mice and CCR5 deficient mice were subjected to sub acute (4 weeks) and chronic (24 weeks) CS-
exposure. Results: Both sub acute and chronic CS-exposure significantly increased CCR5 mRNA expression and 
protein levels of CCR5-ligands (MIP-1α, MIP-1β and RANTES), and induced the recruitment of neutrophils, 
macrophages, dendritic cells and lymphocytes to the bronchoalveolar lavage (BAL) of wild type mice. Chronic CS-
exposure also increased the number and extent of peribronchial lymphoid follicles. In CCR5 KO mice, these CS-
induced increases in CCR5-ligands, inflammatory cells in BAL and peribronchial lymphoid follicles were all 
significantly attenuated compared to wild type animals. Importantly, chronic CS-exposure induced airspace 
enlargement in wild type mice, while CCR5 KO mice were partially protected against the development of emphysema. 
However, CCR5-deficiency did not affect CS-induced airway wall remodeling, since chronic CS-exposure induced a 
similar increase in airway wall thickness, smooth muscle mass and peribronchial deposition of collagen and 
fibronectin in both wild type and CCR5 KO mice. Conclusion: Our data suggest that CCR5 contributes to pulmonary 
inflammation and to the development of emphysema in response to CS. CCR5 is however not implicated in CS-
induced airway wall remodeling, suggesting that the mechanisms that lead to airway inflammation are distinct to 
those responsible for airway remodeling. 
 
Chronic obstructive pulmonary disease (COPD) is the 
fifth leading cause of death worldwide and an important 
cause of chronic disability1,2. Further increases in its 
prevalence and mortality are expected in the coming 
decades. The disease is characterized by a chronic 
inflammation as well as obstruction of small airways and 
destruction of lung parenchyma, causing enlargement of 
alveolar spaces (emphysema)3. Patients with COPD also 
show pathologically distinct structural alterations of the 
small airways, referred to as airway wall remodeling4. 
______________________________________________ 
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Cigarette smoking is by far the most important risk factor 
for COPD. However, the molecular and cellular 
mechanisms involved in cigarette smoke (CS)-induced 
inflammation, pulmonary emphysema and airway 
remodeling in COPD are still unclear. 
The chronic inflammation in COPD is characterized by 
increased numbers of macrophages, dendritic cells, 
neutrophils and CD8+ T-lymphocytes3-6. Several 
cytokines and chemokines (e.g. TNF-α and IL-8) may 
play a key role in recruiting and activating inflammatory 
cells in the lungs of COPD patients7-8. Furthermore, 
smokers who develop COPD show increased amounts of 
interstitial collagen in the small airways, referred to as 
airway wall fibrosis4. The excess deposition of 
connective tissue in the smaller conducting airways in 
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 COPD occurs preferentially in the adventitial 
compartment9. This peribronchiolar fibrosis might 
contribute to fixed airway obstruction by restricting the 
enlargement of airway calibre that occurs with lung 
inflation. It is still open to debate whether this airway 
remodelling occurs as a consequence of the chonic 
inflammation in COPD, or rather through direct induction 
of growth factors by CS and thus independently of 
inflammation. 
CC chemokines are thought to be involved in COPD. 
MIP-1α/CCL3 and MIP-1β/CCL4 are markedly elevated 
in bronchoalveolar lavage (BAL) and sputum of COPD 
patients10.  MIP-1α mRNA levels are higher in the 
bronchial epithelium of smokers with airflow limitation 
than in smokers without airflow limitation or in never-
smokers11. Strong gene expression of RANTES/CCL5, 
also belonging to the CC chemokine family, was 
observed in bronchial biopsies of COPD patients12. 
Chemokine receptor CCR5, a seven-transmembrane, G-
protein-coupled receptor, belonging to the β-chemokine 
receptor family, is a receptor for MIP-1α, MIP-1α and 
RANTES. CCR5 is expressed on granulocytes, 
macrophages, immature DCs, CD8+ T-lymphocytes and 
memory CD4+ T-lymphocytes13-14, and is an important 
co-receptor for HIV15. It is well known that CCR5 
influences the recruitment of monocytes/macrophages, 
dendritic cells and T-cells14. Prior studies have shown 
that CCR5 plays an important role in various 
inflammatory processes in the lungs16-18. Schuh et al. 
demonstrated that CCR5-deficiency reduced the 
hallmarks of allergic asthma, including airway 
remodeling19. Importantly, CCR5 was reported to be 
increased in bronchial biopsies of COPD patients with 
mild/moderate disease compared to control smokers20 and 
high levels of T-lymphocytes, expressing CCR5 were 
associated with loss of lung function and emphysema in 
COPD patients21. J. Elias and coworkers elegantly 
demonstrated that IFN-γ is a potent stimulator of CC 
chemokines, and that CCR5 plays an important role in the 
pathogenesis of both IFN-γ and CS-induced inflammation 
and emphysema22. Recently, we demonstrated that CCR6 
and its ligand MIP-3α/CCL20 may be involved in the 
pathogenesis of COPD23. To further elucidate the 
functional role of the CCR5 pathway in COPD, we used 
the murine model of cigarette smoke-induced pulmonary 
inflammation and emphysema6. In the present paper, we 
report the pulmonary effects of sub acute (4 weeks) or 
chronic (24 weeks) exposure to cigarette smoke in wild 
type and CCR5 KO mice. We analyzed the inflammatory 
responses in both the BAL fluid and lungs, and we 
performed morphometric analysis to quantify the extent 
of pulmonary emphysema and airway remodeling after 
chronic exposure to CS. 
 
Material and Methods  
Animals 
Mice with a targeted deletion of the entire CCR5 gene and 
backcrossed for 10 generations to the C57BL/6 genetic 
background were obtained from the Section of Molecular 
Genetics and Microbiology, University of Texas, Austin, Texas24 
and bred in the animal facility at the Ghent University Hospital. 
Males (8 weeks old) were used for the described experiments.  
C57BL/6 wild type males (also 8 weeks old) were used as 
control mice (Harlan, Zeist, The Netherlands). The local Ethics 
Committee for animal experimentation of the faculty of 
Medicine and Health Sciences (Ghent, Belgium) approved all in 
vivo manipulations. 
 
Smoke exposure 
Mice (n=8 per group) were exposed whole body to cigarette 
smoke as described previously6. Briefly, groups of 8 mice were 
exposed to the tobacco smoke of 5 cigarettes (Reference 
Cigarette 2R4F without filter, University of Kentucky, 
Lexington, KY) four times a day with 30 minutes smoke-free 
intervals, 5 days a week for 4 (sub acute exposure) or 24 weeks 
(chronic exposure). An optimal smoke:air ratio of 1:6 was 
obtained. The control groups were exposed to air. 
Carboxyhemoglobin in serum of smoke-exposed mice reached a 
non-toxic level of 8.3 ± 1.4 % (compared to 1.0 ± 0.2 % in air-
exposed mice (n=7 for both groups)), which is similar to 
carboxyhemoglobin blood concentrations of human smokers25. 
 
Bronchoalveolar lavage (BAL) 
Twenty-four hours after the last smoke exposure, mice were 
weighed and sacrificed with an overdose of pentobarbital 
(Sanofi, Libourne, France) and a tracheal cannula was inserted. 3 
times 300 µl followed by 3 times 1 ml of Hank’s balanced salt 
solution (HBSS), free of ionized calcium and magnesium but 
supplemented with 0.05 mM sodium EDTA, was instilled via the 
tracheal cannula and recovered by gentle manual aspiration. The 
6 lavage fractions were pooled, centrifuged and the cell pellet 
was washed twice and finally resuspended in 1 ml of HBSS. A 
total cell count was performed in a Bürcker chamber and the 
differential cell counts (on at least 400 cells) were performed on 
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 cytocentrifuged preparations using standard morphologic criteria 
after May-Grünwald-Giemsa staining. Flow cytometric analysis 
of BAL-cells was performed to enumerate DCs and CD4+ and 
CD8+ T-cells. 
 
Preparation of lung single-cell suspensions 
Following BAL, the pulmonary and systemic circulation was 
rinsed. The left lung was used for histology, the right lung for 
the preparation of a cell suspension as detailed previously26. 
Briefly, the lung was thoroughly minced, digested, subjected to 
red blood cell lysis, passed through a 50 µm cell strainer, and 
kept on ice until labeling. Cell counting was performed with a 
Z2 Beckman-Coulter particle counter (Beckman-Coulter, Ghent, 
Belgium). 
 
Labeling of BAL-cells and lung single-cell suspensions for flow 
cytometry 
Cells were pre-incubated with Fc-receptor blocking antibody 
(anti-CD16/CD32, clone 2.4G2) to reduce non-specific binding. 
Monoclonal antibodies used to identify mouse DC populations 
were: biotinylated anti-CD11c (N418) and phycoerythrin (PE)-
conjugated anti-IAb (AF6-120.1). We discriminated between 
macrophages and DCs using the methodology described by 
Vermaelen et al.27. After gating on the CD11c-bright population, 
two peaks of autofluorescence can be distinguished. 
Macrophages are identified as the CD11c-bright, high 
autofluorescent population, and do not express MHCII. DCs are 
identified as CD11c-bright, low autofluorescent cells, which 
strongly express MHCII. DCs enumerated by these criteria 
correspond with myeloid DCs. The following antibodies were 
used to stain mouse T-cell subpopulations: fluorescein 
isothiocyanate (FITC)-conjugated anti-CD4 (L3T4), FITC-
conjugated anti-CD8 (Ly-2), and biotinylated anti-CD3 (145-
2C11) monoclonal antibodies. The additional marker used for 
activation was PE-conjugated anti-CD69 (H1.2F3). Biotinylated 
anti-CD11c and anti-CD3 were revealed by incubation with 
streptavidine-allophycocyanine (SAv-APC). All monoclonal 
antibodies were obtained from BD Pharmingen, except anti-
CD11c (N418 hybridoma, a gift from Prof. M. Moser, Brussels 
Free University, Belgium). 
As a last step before analysis, cells were incubated with 7-
amino-actinomycin (7-AAD or viaprobe, BD Pharmingen) for 
dead cell exclusion. All labeling reactions were performed on ice 
in FACS-EDTA buffer.  
Flow cytometry data acquisition was performed on a dual-laser 
FACS VantageTM flow cytometer running CELLQuestTM 
software (Becton Dickinson, Mountain View, California). 
FlowJo software (www.Treestar.com) was used for data 
analysis.  
Histology 
The left lung was fixed by gentle infusion of 4% 
paraformaldehyde through the tracheal cannula6. After excision, 
the lung was immersed in fresh fixative for 2 h. The lung lobe 
was embedded in paraffin and cut in 3 µm transverse sections. 
Lung tissue samples were stained with hematoxylin and eosin, 
and examined by light microscopy for histological sections. For 
each animal, 10 fields at a magnification of 200x were captured 
in a blinded fashion using a Zeiss KS400 image analyzer 
platform (KS400, Zeiss, Oberkochen, Germany). 
 
Quantification of emphysema 
Emphysema is a structural disorder characterized by destruction 
of the alveolar walls and enlargement of the alveolar spaces. We 
determined destruction of the alveolar walls by measuring the 
destructive index (DI)28 and enlargement of alveolar spaces by 
quantifying the mean linear intercept (Lm) after 24 weeks of 
smoke exposure, as described previously6;29, using image 
analysis software (Image J 1.33). Only sections without cutting 
artefacts, compression or hilar structures (airway or blood vessel 
with a diameter larger than 50 µm) were used in the analysis. 
The Lm was measured by placing a 100 x 100 µm grid over each 
field. The total length of each line of the grid divided by the 
number of alveolar intercepts gives the average distance between 
alveolated surfaces, or the Lm. The Lm was measured by 2 
independent observers, with a strong positive correlation (R2 = 
0.82, P<0.01). DI was measured by superimposing a grid with 42 
points on the lung field. Structures lying under these points were 
classified as normal (N) or destroyed (D) alveolar and/or duct 
spaces. Points falling over other structures, such as duct walls, 
alveolar walls, etc., did not enter into the calculations. The DI 
was calculated from the formula: DI = D/(D + N) x 100. 
 
Morphometric quantification of lymphoid follicles 
To evaluate the presence of lymphoid follicles in lung tissue 
after 24 weeks of smoke exposure, lung sections obtained from 
formalin-fixed, paraffin-embedded lung lobes were subjected to 
the following immunohistological CD3/B220 double staining: at 
first, sections were incubated with Boehringer blocking reagent 
with triton and primary antibody anti-CD3, followed by goat-
anti-rabbit biotin (both obtained from DakoCytomation). Then, 
slides were incubated with streptavidin horseradish peroxidase 
and colored with DAB. In a second step, sections were stained 
with anti-B220-biotin after Boehringer blocking (with triton). 
Finally, slides were incubated with streptavidin alkaline 
phosphatase (DakoCytomation) and colored with Vector blue 
(Vector Laboratories, Inc., Burlingame, CA). Lymphoid follicles 
were defined as accumulations of at least 50 cells and counted in 
the tissue area surrounding the airways (airway perimeter 0-2000 
µm). Results were expressed as counts relative to the numbers of 
airways per lung section. 
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 Airway remodeling 
Collagen in the airway wall was stained using Sirius Red, and 
the amount of fibronectin with a goat anti-rat fibronectin 
antibody (Calbiochem, BadsSoden, Germany) using the 
streptavidin-biotin peroxidase method30. Airway smooth muscle 
was revealed by staining with a rabbit anti-mouse α-smooth 
muscle actin antibody (Abcam, Cambridge, UK). For each 
experimental group 3 lung sections per animal were examined. 
Morphometrical parameters31 were marked manually on the 
digital representation of the airway: the length of the basement 
membrane (Pbm), the area defined by the basement membrane 
(Abm) and the area defined by the total adventitial perimeter 
(Ao). The total bronchial wall area (WAt) was calculated (WAt 
= Ao – Abm) and normalized to the squared length of the 
basement membrane. For the quantification of collagen and 
fibronectin deposition and smooth muscle hypertrophy, the area 
in the airway wall covered by the stain was determined by the 
software (KS400; Zeiss) and its value calculated as described 
previously30. The area of collagen (WCt), fibronectin (WFt) or 
α-smooth muscle actin (WAc) was normalized to Pbm. All 
airways with a Pbm smaller than 2000 µm and cut in reasonable 
cross sections (defined by a ratio of minimal to maximal internal 
diameter greater than 0.5) were included. 
 
Measurement of cytokines and chemokines 
Using commercially available ELISA kits (R&D Systems), MIP-
1α (Macrophage Inflammatory Protein–1α), MIP-1β 
(Macrophage Inflammatory Protein-1β), RANTES (Regulated 
upon Activation, Normal T Expressed and Secreted), MCP-1 
(Macrophage Chemotactic Protein-1), KC (mouse IL-8) and 
Transforming Growth Factor-β (TGF-β) protein levels were 
determined in BAL fluid after 4 and/or 24 weeks of CS-
exposure. 
After 4 weeks of CS-exposure, protein levels of cytokines in 
BAL fluid were determined by FACS using the Cytometric Bead 
Array (CBA - Mouse Th1/Th2 cytokine kit; BD Biosciences, 
San Diego, CA, USA), as described previously31. A mixture of 5 
capture bead populations, each with distinct fluorescence 
intensities and coated with antibodies specific for Interleukin-2 
(IL-2), Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interferon-γ 
(IFNγ) and Tumor Necrosis Factor-α (TNFα), were prepared. 
The CBA capture beads were incubated together with PE-
conjugated detection antibodies, test samples or standards, to 
form sandwich complexes. Following acquisition of sample data 
using the flow cytometer (FACSCaliburTM flow cytometer, BD 
Biosciences), the sample results were generated in graphical and 
tabular format using the CBA Analysis Software (BD 
Biosciences, San Diego, CA, USA).  
 
 
RT-PCR analysis 
Total lung RNA was extracted with the RNeasy Midi Kit 
(Qiagen, Hilden, Germany). Expression of CCR5 mRNA, 
relative to hypoxanthine guanine phosphoribosyltransferase 
(hprt) mRNA, was analysed with the Assays-on-Demand™ Gene 
Expression Products (Applied Biosystems, USA). RT-PCR was 
performed on a LightCycler 480 system (Roche, USA) with 
MuLV RTase (Applied Biosystems, USA). Reverse transcription 
was performed at 48°C for 30 min followed by 10 min 
incubation at 95°C for denaturation of RNA-DNA 
heteroduplexes, and 50 cycles of 95°C for 10 sec and 60°C for 
15 sec. Monitoring of the RT-PCR occurred in real time using a 
FAM/TAMRA probe. All reactions were performed starting 
from 10 ng of total RNA. 
 
Statistical analysis 
Reported values are expressed as mean ± standard error of the 
mean (SEM). Statistical analysis was performed with Sigma Stat 
software (SPSS 11.0 Inc, Chicago, IL, USA) using non-
parametric tests (Kruskall-Wallis, Mann-Whitney U). P-values 
under 0.05 were considered as significant. 
 
RESULTS 
Increased CCR5 mRNA expression in lung tissue upon 
cigarette smoke exposure 
RT-PCR analysis on mRNA extracted from total lung 
tissue of wild type mice revealed a significant increase in 
CCR5 expression upon both sub acute (4 weeks) and 
chronic (24 weeks) exposure to CS, compared with air-
exposed littermates (Fig. 1). 
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Figure 1 – Effect of cigarette smoke exposure on CCR5 
mRNA expression in total lung tissue 
mRNA levels of CCR5 in total lung tissue of wild type mice 
upon sub acute (4 weeks) and chronic (24 weeks) exposure to 
air or cigarette smoke, as measured by RT-PCR. Results are 
expressed as a ratio with hprt mRNA (mean ± SEM). N = 5 
animals per group (* p<0.05). (Hprt: hypoxanthine guanine 
phosphoribosyltransferase) 
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 Chemokine expression in the bronchoalveolar lavage 
fluid following cigarette smoke exposure is CCR5 
dependent 
Since the levels of the CCR5 ligands (MIP-1α/CCL3, 
MIP-1β/CCL4 and RANTES/CCL5), MCP-1/CCL2 and 
IL-8 are augmented in sputum and BAL of COPD-
patients, we determined the protein levels of these 
chemokines in BAL-fluid of wild type and CCR5 KO 
mice.  
Sub acute (4 weeks) and chronic (24 weeks) exposure to 
CS clearly induced the levels of MIP-1α, MIP-1β, MCP-
1 and KC (mouse IL-8) in BAL-fluid of both wild type 
and CCR5 KO mice, compared to air-exposed littermates 
(Fig. 2). However, significantly smaller increases of 
MIP-1α, MIP-1β, MCP-1 and KC were observed in CS-
exposed CCR5 KO mice versus CS-exposed wild type 
animals (Fig. 2). The protein levels of RANTES were 
significantly augmented in BAL-fluid of wild type 
animals upon chronic (24 weeks) CS-exposure. In 
contrast, no differences in RANTES levels were observed 
in chronic CS-exposed CCR5 KO mice versus air-
exposed CCR5 KO littermates (Fig 2C). 
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Figure 2 – Effect of cigarette smoke exposure on the protein levels of chemokines in bronchoalveolar lavage fluid 
Protein levels of chemokines in the bronchoalveolar lavage fluid of wild type and CCR5 KO mice upon sub acute (4 weeks) and chronic 
(24 weeks) exposure to air or cigarette smoke, as measured by ELISA: (A) MIP-1α, (B) MIP-1β, (C) RANTES, (D) MCP-1 and (E) KC. 
Results are expressed as pg/ml (mean ± SEM). N = 8 animals per group (* p<0.05 and ** p<0.01). (MIP-1α: Macrophage Inflammatory 
Protein-1α; MIP-1β: Macrophage Inflammatory Protein-1β; RANTES: Regulated Upon Activation, Normal T Expressed; MCP-1: 
Monocyte Chemotactic Protein-1; KC: mouse interleukin-8) 
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Figure 3 – Effect of cigarette smoke exposure on cell differentiation in bronchoalveolar lavage fluid 
Total bronchoalveolar lavage (BAL) cells and cell differentiation in BAL fluid of wild type and CCR5 KO mice upon sub acute (4 weeks) 
and chronic (24 weeks) exposure to air or cigarette smoke: (A) Total BAL cells, (B) neutrophils, (C) macrophages, (D) dendritic cells, (E) 
lymphocytes, (F) CD4+ T-lymphocytes and (G) CD8+ T-lymphocytes. Results are expressed as means ± SEM. N = 8 animals per group (* 
p<0.05, ** p<0.01). 
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 Cigarette smoke-induced increase of inflammatory cells 
in bronchoalveolar lavage fluid and lungs is CCR5 
dependent 
In both wild type and CCR5 KO mice, sub acute (4 
weeks) or chronic (24 weeks) exposure to CS caused a 
significant increase in absolute numbers of total BAL 
fluid cells, including neutrophils, monocytes/ 
macrophages, DCs and lymphocytes (Fig. 3A-E). 
However, at both timepoints, these increases in 
inflammatory cells were significantly smaller in CS-
exposed CCR5 KO mice, compared to wild type animals 
(Fig. 3A-E). In more detail, exposure to CS significantly 
increased the number of both CD4+ and CD8+ T-
lymphocytes in wild type and CCR5 KO mice, compared 
to air-exposed control mice (Fig. 3F-G). Again, these 
increases were significantly impaired in CCR5 KO mice 
versus wild type littermates (Fig. 3F-G). 
In lung homogenates, chronic CS exposure induced – 
similarly to the BAL compartment – a significant 
increase in the numbers of DCs, macrophages and 
activated CD4+ and CD8+ T-cells in both wild type and 
CCR5 KO mice (data not shown). However, the CS-
induced increase in the numbers of activated CD4+ and 
CD8+ T-lymphocytes in the lung was smaller in CCR5 
KO mice compared to wild type mice (p<0.05).  
 
Cigarette smoke-induced increase of cytokines in BAL 
fluid of wild type and CCR5 KO mice 
To decipher whether cigarette smoke exposure modifies 
the Th1/Th2 balance, several cytokines were measured in 
the BAL fluid by Cytometric Bead Array. Sub acute (4 
weeks) CS-exposure significantly increased the BAL 
levels of TNFα and IL-2 in wild type mice compared to 
air-exposure (Fig. 4A-B). In contrast, no differences in 
the protein levels of TNFα and IL-2 were found between 
BAL fluid of air- and CS-exposed CCR5 KO animals. 
IFNγ-levels tended to increase in BAL fluid of wild type 
and CCR5 KO animals upon CS exposure (Fig. 4C). The 
levels of IL-4 and IL-5 were below the detection limit in 
almost all BAL fluid samples, irrespective of mouse 
genotype or exposure regimen (data not shown). 
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Figure 4 – Effect of cigarette smoke exposure on the levels of cytokines in bronchoalveolar lavage fluid 
Protein levels of cytokines in the bronchoalveolar lavage fluid of wild type and CCR5 KO mice upon sub acute (4 weeks) exposure to air or 
cigarette smoke, as measured by cytometric bead array: (A) TNFα, (B) IL-2 and (C) IFNγ. Results are expressed as pg/ml (mean ± SEM). 
N = 8 animals per group (* p<0.05 and ** p<0.01). (TNFα: Tumor Necrosis Factor-α; IFNγ: Interferon-γ; IL-2: Interleukin-2) 
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 Partial protection against emphysema in CCR5 KO mice 
upon chronic cigarette smoke exposure 
Pulmonary emphysema is characterized by destruction of 
alveolar walls due to damage to the lung parenchyma, 
leading to enlargement of alveolar spaces. Therefore, we 
quantified emphysematous lesions by measuring the 
mean linear intercept (Lm) and the destructive index (DI). 
Chronic (24 weeks) exposure to CS clearly induced 
pulmonary emphysema in wild type animals, as 
evidenced by a significant increase in the Lm (air 37.6 ± 
0.3 µm vs. CS 40.0 ± 0.2 µm, p<0.05) and DI (air 25.6 ± 
0.7 vs. CS 33.7 ± 0.4, p<0.05). In CCR5 KO mice, the 
difference in Lm and DI upon chronic CS-exposure did 
not reach statistical significance (air 37.2 ± 0.3 µm vs. CS 
39.0 ± 0.2 µm, NS; DI: air 26.1 ± 0.7 vs. CS 30.9 ± 0.5, 
NS). The significant airspace enlargement due to chronic 
CS exposure in wild type mice and the partial protection 
against emphysema in CCR5 KO mice is demonstrated 
on hematoxylin and eosin-stained lung tissue sections 
(Fig. 5A-D). 
 
Cigarette smoke-induced increase of peribronchial 
lymphoid follicles is CCR5 dependent 
Immunohistochemistry using anti-CD3 and anti-B220 
monoclonal antibodies to stain T-lymphocytes and B-
lymphocytes respectively, revealed the presence of only a 
few small lymphoid follicles in the lung areas 
surrounding the airways of air-exposed wild type and 
CCR5 KO mice (Fig. 6A). Chronic (24 weeks) CS-
exposure significantly augmented the number of 
peribronchial lymphoid follicles in the lungs of both wild 
type and CCR5 KO mice. However, this increase in 
lymphoid follicles was significantly attenuated in the 
CCR5 KO mice (Fig. 6A). Moreover, these peribronchial 
lymphoid follicles appeared to be larger and denser in 
wild type mice, compared to CCR5 KO animals (Fig. 6B-
E). 
 
Cigarette smoke-induced airway remodeling is similar in 
wild type and CCR5 KO mice 
To investigate the effects of chronic (24 weeks) CS-
exposure on the deposition of extracellular matrix in the 
airway wall, lung sections were stained with anti-
fibronectin and Sirius Red to reveal fibronectin and 
collagen, respectively. To study smooth muscle 
hypertrophy, lung sections were stained with anti-α-
smooth muscle actin. In wild type animals, chronic (24 
weeks) CS-exposure significantly increased the amount 
of fibronectin present in the peribronchial area (Fig. 7A-
E). CCR5 deficiency did not affect the CS-induced 
increase in peribronchial fibronectin deposition (Fig. 7A-
E). Similarly, chronic CS-exposure induced a significant 
increase in peribronchial collagen deposition in both wild 
type and CCR5 KO mice (Fig. 7F-J). Smooth muscle 
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Figure 5 – Pulmonary emphysema upon chronic cigarette smoke exposure 
Photomicrographs of hematoxylin and eosin stained lung tissue of air- and cigarette smoke (CS)-exposed wild type and CCR5 KO mice at 
24 weeks (chronic exposure; magnification x200): (A) air-exposed wild type mice, (B) CS-exposed wild type mice, (C) air-exposed CCR5 
KO mice and (D) CS-exposed CCR5 KO mice. 
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 mass was significantly increased in the airways of 
chronic CS-exposed wild type and CCR5 KO mice (Fig 
7K-O), but again there was no influence of the CCR5 
deletion. Importantly, the increased peribronchial 
deposition of collagen and fibronectin and the smooth 
muscle hypertrophy contributed to a significant increase 
in the airway wall thickness upon chronic CS-exposure in 
both genotypes (Fig. 7P). 
 
Cigarette smoke-induced increase of activated TGF-β1  
in BAL fluid of wild type and CCR5 KO mice 
To obtain a mechanistic explanation for the observed 
airway wall remodeling in wild type and CCR5 KO mice, 
we measured the protein levels of activated Transforming 
Growth Factor-β1 (TGF-β1) in BAL fluid by ELISA. 
Sub acute exposure to CS significantly increased the 
protein levels of TGF-β, in both wild type and CCR5 KO 
mice (Fig. 8). 
 
DISCUSSION 
Exposure to CS is the main risk factor for the 
development of COPD, a disease that is characterized by 
pulmonary inflammation, destruction of lung parenchyma 
and remodeling of the small airways. In this study we 
show that CCR5 deficiency attenuates the CS-induced 
increase in inflammatory cells of both the innate and the 
adaptive immune system, and offers a partial protection 
against the development of pulmonary emphysema. In 
contrast, CCR5 deficiency does not affect airway wall 
remodeling, induced by chronic CS-exposure. 
CS can activate lung resident cells, including epithelial 
cells, macrophages, and DCs, which then release several 
inflammatory mediators that are capable of recruiting 
inflammatory cells3;33-36. After both sub acute and chronic 
CS-exposure, increased protein levels of MIP-1α/CCL3, 
MIP-1β/CCL4 and RANTES/CCL5 in the BAL-fluid of 
wild type mice were associated with a high influx into the 
BAL and lungs of monocytes/macrophages, DCs and T-
lymphocytes, which all express the corresponding 
chemokine receptor CCR513-14;20. Expression of the 
CCR5 receptor in lung homogenates of wild type mice 
was significantly increased upon both sub acute and 
chronic CS-exposure. In contrast, smaller numbers of 
macrophages, DCs and T-lymphocytes were observed in 
the BAL and lungs of CS-exposed CCR5 KO mice. 
Moreover, in these CCR5 deficient mice we observed a 
significantly impaired increase of all three CCR5 ligands 
upon CS-exposure. This was also documented by Ma et 
al.22 and can be explained as a downstream effect of the 
CCR5 deficiency, where the impaired pulmonary 
inflammation leads to a reduced release of inflammatory 
mediators.  
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Figure 6 – Quantification of pulmonary lymphoid follicles 
upon chronic cigarette smoke exposure 
Peribronchial lymphoid follicles in lung tissue of wild type and 
CCR5 KO mice upon chronic (24 weeks) exposure to air or 
cigarette smoke (CS) (A). Results are expressed as means ± SEM. 
N = 8 animals per group (* p<0.05, ** p<0.01). 
Photomicrographs of peribronchial lymphoid follicles in lung 
tissue of air- and CS-exposed wild type and CCR5 KO mice at 24 
weeks (chronic exposure; magnification x200): (B) air-exposed 
wild type mice, (C) CS-exposed wild type mice, (D) air-exposed 
CCR5 KO mice and (E) CS-exposed CCR5 KO mice. 
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Figure 7 – Quantification of airway wall remodeling upon chronic cigarette smoke exposure 
Peribronchial fibronectin deposition in lung tissue of wild type and CCR5 KO mice upon chronic (24 weeks) exposure to air or cigarette 
smoke (CS) (A). Results are expressed as means ± SEM. N = 8 animals per group (* p<0.05, ** p<0.01). Photomicrographs of 
peribronchial fibronectin deposition in lung tissue of air- and CS-exposed wild type and CCR5 KO mice at 24 weeks (magnification x100): 
(B) air-exposed wild type mice, (C) CS-exposed wild type mice, (D) air-exposed CCR5 KO mice and (E) CS-exposed CCR5 KO mice. 
(Pbm: lenght of basement membrane) 
Peribronchial collagen deposition in lung tissue of wild type and CCR5 KO mice upon chronic (24 weeks) exposure to air or cigarette 
smoke (CS) (F). Results are expressed as means ± SEM. N = 8 animals per group (** p<0.01). Photomicrographs of peribronchial collagen 
deposition in lung tissue of air- and CS-exposed wild type and CCR5 KO mice at 24 weeks (magnification x100): (G) air-exposed wild 
type mice, (H) CS-exposed wild type mice, (I) air-exposed CCR5 KO mice and (J) CS-exposed CCR5 KO mice. 
Airway smooth muscle mass in lung tissue of wild type and CCR5 KO mice upon chronic (24 weeks) exposure to air or cigarette smoke 
(CS) (K). Results are expressed as means ± SEM. N = 8 animals per group (* p<0.05, ** p<0.01). Photomicrographs of smooth muscle in 
the airways of air- and CS-exposed wild type and CCR5 KO mice at 24 weeks (magnification x100): (L) air-exposed wild type mice, (M) 
CS-exposed wild type mice, (N) air-exposed CCR5 KO mice and (O) CS-exposed CCR5 KO mice. 
Airway wall thickness (WAt) of wild type and CCR5 KO mice upon chronic (24 weeks) exposure to air or CS (P). Results are expressed as 
means ± SEM. N = 8 animals per group (** p<0.01). (WAt: total bronchial wall area)
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 Indeed, the CS-induced increase in production of 
chemokines MCP-1 and KC and cytokines TNFα and IL-
2 that we observed in wild type mice, was significantly 
attenuated in CCR5 KO mice. As a consequence of this 
attenuated inflammation, CCR5 KO mice were partially 
protected against the development of pulmonary 
emphysema, which also confirms the observations of Ma 
et al. A logical explanation would be that the reduced 
numbers of MMP-12 releasing macrophages or DCs37-38, 
and neutrophil elastase producing neutrophils3 in CCR5 
KO mice, influences the proteinase/antiproteinase 
balance in favor of antiproteolytic activity. 
We demonstrated that chronic CS-exposure leads to an 
increase in peribronchial lymphoid follicles. This 
correlates with human COPD patients, where Hogg et al. 
demonstrated that progression of COPD is associated 
with increasing percentages of airways that contained 
lymphoid follicles39. CCR5 KO mice had significantly 
less of these lymphoid accumulations around the airways 
upon CS-exposure. Interestingly, Castellino et al. showed 
in a recent study that inflammation increases the 
expression of CCR5 on CD8+ T-cells, permitting them to 
be attracted to sites of CD4+ T-cell-DC interaction40. 
Together with the reduced numbers of lymphocytes and 
more specific activated CD4+ and CD8+ T-cells in the 
airways and lungs, this underscores the contribution of 
CCR5 in T-cell migration and activation.  
Airway wall remodeling is another hallmark of COPD, 
and contributes to the airflow obstruction. Our group has 
shown for the first time that exposure to CS leads to 
airway wall remodeling in a mouse model of COPD. 
Although, compared to asthma, the structural alterations 
of the airways in COPD are less pronounced41, we were 
able to measure several features of the remodeling 
process. Firstly, we observed an increase in peribronchial 
deposition of collagen and fibronectin upon chronic CS-
exposure. Secondly, we showed an increase in airway 
smooth muscle mass upon CS-exposure. And thirdly, this 
smoke-induced deposition of fibronectin and collagen 
and smooth muscle hypertrophy resulted in a significant 
thickening of the airway walls. Interestingly, we 
demonstrated that although the CCR5 deletion had a 
significant effect on CS-induced pulmonary 
inflammation, it had no effect on airway wall remodeling. 
This suggests that smooth muscle hypertrophy and the 
peribronchial deposition of collagen and fibronectin is 
not a downstream effect of the ongoing pulmonary 
inflammation, but rather occurs through independent 
processes. This has also been proposed in asthma, where 
activation of the epithelial-mesenchymal trophic unit 
leads to release of growth factors, resulting in airway 
remodeling42-43. 
We provided a similar mechanistic explanation for the 
observed airway wall remodeling in COPD by 
demonstrating an increase in activated TGF-β1 protein 
levels in BAL fluid of both CS-exposed wild type and 
CCR5 KO mice. It has been described that TGF-β1 
drives airway remodeling in CS-exposed tracheal 
explants44 and recently Churg and colleagues presented 
data on increased TGF-β1 gene expression in airway 
walls isolated from lungs of mice upon a single CS-
exposure45. This last observation confirms the ability of 
CS to directly induce the release of growth factors, 
independent of the pulmonary inflammation. 
Interestingly, we have also observed this development of 
airway wall remodeling regardless of the degree of 
inflammation in CCR6 deficient mice23. 
Therapy for COPD and emphysema is currently limited 
to pharmacologic bronchodilation or treatment with 
inhaled glucocorticosteroids, but these drugs do not affect 
the natural history of the disease (e.g. accelerated decline 
in lung function). Therapeutic interventions that target 
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Figure 8 – Effect of cigarette smoke exposure on the protein 
levels of activated TGF-β1 in bronchoalveolar lavage fluid 
Protein levels of activated TGF-β1 in the bronchoalveolar lavage 
fluid of wild type and CCR5 KO mice upon sub acute (4 weeks) 
exposure to air or cigarette smoke, as measured by ELISA. Results 
are expressed as pg/ml (mean ± SEM). N = 8 animals per group 
(** p < 0.01). (TGF-β1: Transforming Growth Factor-β1) 
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 chemokines and chemokine receptors are now in clinical 
development for a variety of pathological inflammatory 
processes and some of these might be effective in 
blocking the influx of inflammatory cells into the airways 
and lung parenchyma in COPD. Our experimental 
findings suggest that CCR5 antagonists, currently in 
development as HIV entry inhibitors, might be useful for 
the treatment of COPD46. However, one caveat when 
applying this approach is the absence of an effect of 
CCR5 deficiency on airway wall remodeling. Therefore, 
it would be interesting to determine whether the 
incidence, onset and severity of COPD are altered in 
individuals who are naturally deficient in CCR5. 
In conclusion, we have demonstrated that CCR5 
deficiency leads to an impaired recruitment of 
inflammatory cells into the lungs and a partial protection 
against emphysema following chronic CS exposure. Our 
in vivo studies in this murine model of COPD indicate 
that CCR5 contributes to the pathogenesis of CS-induced 
pulmonary inflammation, peribronchial lymphoid follicle 
formation and emphysema, but is not implicated in 
airway wall remodeling. 
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In this review we assembled the available literature on the role of chemokine receptors in the 
pathogenesis of COPD, focussing mainly on the receptors that have an affinity for the CC-
family of chemokines. 
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Abstract: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and disability in the 
world, with a prevalence that is expected to increase in the next decades. The disease is characterized by a chronic in-
flammatory response of the airways and lungs to noxious particles and gases, mostly cigarette smoke. The molecular and 
cellular mechanisms that lead to this exaggerated influx of cells belonging to both the innate and adaptive immune system 
are not yet completely unravelled. However, there is now growing evidence that the recruitment of these inflammatory 
cells in response to cigarette smoke is largely regulated by chemokines acting as ligands for chemokine receptors. Several 
of these receptors, which fall mainly in the CC- or CXC-category, have been implicated in the pathogenesis of COPD. In 
this review we will focus mainly on the CC-family, as the involvement of CXC-receptors in COPD has already been ex-
tensively reviewed. In patients with COPD, several CC-chemokines like MIP-1, MIP-3, RANTES and MCP-1 are 
upregulated, suggesting the contribution of their respective receptor in the pathogenesis of the disease. Using knock out 
mice, this contribution has been further confirmed for CCR5 and CCR6, evidenced by an attenuated accumulation of in-
flammatory cells like macrophages, dendritic cells, neutrophils and CD8+ T-lymphocytes upon cigarette smoke-exposure. 
Moreover, mice deficient for CCR5 or CCR6 are partially protected from the development of pulmonary emphysema, an-
other hallmark of COPD. These data suggest that chemokine receptors are potential therapeutic targets to reduce the 
chronic inflammation and parenchymal destruction in COPD. 
INTRODUCTION 
 Chronic obstructive pulmonary disease (COPD) is the 
fifth leading cause of death worldwide and a major burden 
on healthcare systems. Moreover, its prevalence and mortal-
ity are expected to escalate in the coming decades [1]. COPD 
is a chronic respiratory disease that is characterized by an 
abnormal inflammatory response of the lungs to noxious 
particles and gases. This leads to obstruction of the small 
airways and destruction of the lung parenchyma (emphy-
sema), resulting in a slowly progressive development of air-
flow limitation that is not fully reversible [2;3]. 
 Cigarette smoke is the major risk factor for the develop-
ment of COPD, and it has been shown that smoking leads to 
airway inflammation with an increase of inflammatory cells 
of both the innate and adaptive immune system. Indeed, an 
exaggerated accumulation of macrophages [4;5], neutrophils 
[6;7], dendritic cells [8;9] and CD8+ T-lymphocytes [10] has 
been observed in lungs of COPD patients. 
 Aside from smoking cessation, current therapies for 
COPD are limited to pharmacologic bronchodilatation or 
treatment with inhaled corticosteroids and are directed 
against the clinical symptoms. However, these drugs neither 
affect the natural history of the disease (e.g. accelerated de-
cline in lung function) nor prevent the underlying inflamma-
tory process. Effective treatment depends on further elucida-
tion of the molecular and cellular mechanisms that are re-
sponsible for the development of COPD. There is now grow-
ing evidence that the recruitment of inflammatory cells in 
COPD is largely orchestrated by chemokines binding to their 
respective chemokine receptors, making these interactions 
possible drug targets. 
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 Chemokines are a family of small, structurally related 
peptides that regulate trafficking of various types of leuko-
cytes, both under physiological and inflammatory conditions 
[11]. In addition, they have broad-reaching effect on other 
fundamental aspects of immunology, including the develop-
ment, homeostasis and function of the immune system. 
Chemokines have been divided into four subfamilies based 
on the arrangement of amino acids surrounding conserved 
cysteine residues (CXC, CC, C and CX3C), with most of the 
chemokines belonging to the CXC- and CC-families. Gener-
ally, chemokines exert their biological functions by interac-
tions with specific receptors on the surface of their target 
cells [12]. These chemokine receptors are members of a 
large subfamily within the 7-transmembrane, G-protein cou-
pled receptors and are classified according to their affinity 
for one of the chemokine subfamilies: CXCR, CCR, XCR 
and CX3CR. There is extensive redundancy in this receptor-
ligand binding, as an individual chemokine receptor may 
have an affinity for several chemokines, and a single 
chemokine may bind to multiple receptors. 
 Several CXC- and CC-chemokine receptors are found to 
be expressed on inflammatory cells associated with COPD. 
As Panina et al. have recently reviewed in depth the role of 
CXC-chemokine receptors in COPD [13], we will limit this 
discussion to the CC-chemokine receptors. An overview of 
this family of receptors is given in Table 1. 
CCR1 
 CCR1 was the first CC chemokine receptor identified and 
is expressed on a variety of cells, including T-lymphocytes, 
macrophages, immature dendritic cells and neutrophils. While 
no clear indications for the involvement of CCR1 in COPD 
have been described, CCR1 has an affinity for multiple 
chemokines, including macrophage inflammatory protein-1 
(MIP-1/CCL3) and regulated on activation, normal T-cell 
expressed and secreted (RANTES/CCL5), which are both 
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elevated in lungs of COPD patients [14;15]. Thus, CCR1 
could participate in the increased recruitment of inflammatory 
cells to the airways of patients with COPD. Several CCR1 
antagonists have been developed and are in clinical trials for 
autoimmune diseases [16]. 
CCR2 
 CCR2 is expressed on many cell types including mono-
cytes, immature dendritic cells and T-lymphocytes and is the 
only chemokine receptor for monocyte chemoattractant pro-
tein-1 (MCP-1/CCL2). It also binds other nonselective 
members of the MCP chemokine subfamily (MCP-3/CCL7, 
MCP-2/CCL8 and MCP-4/CCL13). CCR2 is involved in 
recruitment of monocytes/macrophages and immature den-
dritic cells to sites of inflammation [17], and it has been 
demonstrated that activated neutrophils can migrate in re-
sponse to MCP-1/CCL2 [18]. These cell types are all impli-
cated in the pathology of COPD, making the CCR2/MCP-1 
axis an interesting target. Indeed, Capelli et al. reported in-
creased concentrations of MCP-1/CCL2 in BAL fluid from 
smokers [19]. On the other hand, Traves et al. could not con-
firm the elevated MCP-1/CCL2 levels in BAL, but found 
increased MCP-1/CCL2 concentrations in induced sputum of 
patients with COPD [20]. Moreover, they reported a negative 
correlation between sputum MCP-1/CCL2 levels and FEV1 
% predicted and a positive correlation between sputum 
MCP-1/CCL2 levels and sputum neutrophil numbers. The 
latter could be the result of enhanced monocyte recruitment, 
followed by secretion of neutrophil chemoattractants like IL-
8 or GRO. In addition, elevated levels of both CCR2 and 
MCP-1/CCL2 mRNA were observed in bronchial epithelium 
of COPD patients [21]. 
 Increased MCP-1/CCL2 production upon cigarette smoke 
exposure has also been described in a mouse model of 
COPD [22], further underscribing the role of CCR2 in the 
inflammatory process of COPD. 
 Monoclonal antibodies and small molecule antagonists 
for CCR2 have been developed and are used in clinical trials 
for treatment of inflammatory disorders like rheumatoid ar-
thritis. 
CCR3 
 CCR3 is highly expressed on eosinophils [23], but has 
also been found on dendritic cells [24], on a subpopulation 
of Th2 lymphocytes [25] and on structural cells such as 
epithelial cells [26], endothelial cells [27], smooth muscle 
cells [28] and fibroblasts [29]. It has an affinity for multiple 
chemokines, including eotaxin-1 (CCL11) and RAN-
TES/CCL5. CCR3 is mainly involved in eosinophil recruit-
ment, and has therefore been strongly implicated in allergic 
airway inflammation [30;31]. Although eosinophils are not 
elevated in stable COPD, patients with mild to moderate 
COPD exacerbations show increased numbers of eosinophils 
in their bronchial mucosa [32;33]. Exacerbations are charac-
terized by an acute worsening of the airway inflammation 
and are triggered by a variety of factors including viruses, 
bacteria and air pollutants. The eosinophilia during these 
exacerbations is paralleled by an up-regulation of both CCR3 
and its ligands eotaxin-1/CCL11 and RANTES/CCL5 
[33;34]. Moreover, a positive correlation between CCR3+ 
Table 1. CC-Chemokine Receptors 
 
Name Cell-Type Expression Chemokine Ligands 
CCR1 NK cells, T-lymphocytes, macrophages, immature dendritic cells, baso-
phils, eosinophils, neutrophils 
MIP-1/CCL3, RANTES/CCL5, MCP-2/CCL8, MCP-
3/CCL7, MCP-4/CCL13 
CCR2 monocytes, immature dendritic cells, T-lymphocytes, B-lymphocytes, 
basophils, neutrophils 
MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13 
CCR3 eosinophils, Th2 lymphocytes, dendritic cells, mast cells, epithelial cells, 
endothelial cells, smooth muscle cells, fibroblasts 
Eotaxin-1/CCL11, Eotaxin-2/CCL24, Eotaxin-3/CCL26, 
RANTES/CCL5, MCP-2/CCL8, MCP-3/CCL7, MCP-
4/CCL13, MIP-1/CCL15 
CCR4 Th2 lymphocytes, NK cells, epithelial cells, dendritic cells TARC/CCL17, MDC/CCL22 
CCR5 monocytes, immature dendritic cells, granulocytes, CD8+ T-lymphocytes, 
memory CD4+ T-lymphocytes 
MIP-1/CCL3, MIP-1/CCL4, RANTES/CCL5, MCP-
2/CCL8 
CCR6 immature dendritic cells, B-lymphocytes, memory T-lymphocytes, neutro-
phils, endothelial cells 
MIP-3/CCL20 
CCR7 mature dendritic cells, T-lymphocytes, B-lymphocytes, NK cells MIP-3/CCL19, SLC/CCL21 
CCR8 Th2 lymphocytes, monocytes, B-lymphocytes, NK cells, endothelial cells TCA3/CCL1, HCC4/CCL16 
CCR9 T-lymphocytes TECK/CCL25 
CCR10 T-lymphocytes, Langerhans cells, melanocytes CTACK/CCL27, MEC/CCL28 
CCR11 astrocytes MIP-3/CCL19, SLC/CCL21, TECK/CCL25 
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cells and eosinophils has been described, further supporting 
the role of CCR3 in the recruitment of eosinophils during 
COPD exacerbations. 
CCR4 
 CCR4 is expressed predominantly on Th2 lymphocytes 
and is up-regulated by T-cell receptor activation [35;36]. It 
binds only two selective chemokines: thymus and activation-
regulated chemokine (TARC/CCL17) and monocyte derived 
chemokine (MDC/CCL21). Both chemokines are considered 
to be key players in Th2 lymphocyte recruitment in allergic 
diseases like asthma [37;38], but have also been implicated 
in trafficking of monocytes and dendritic cells [39;40]. The 
hypothesis that CCR4 and its ligands could also contribute to 
the pathogenesis of COPD is suggested by the elevated ex-
pression of both TARC/CCL17 and MDC/CCL21 in ciga-
rette smoke-induced inflammation in rats [41]. However, no 
increase in CCR4 expression or elevated numbers of CCR4+ 
cells could be detected in the lung of these smoking rats. On 
the other hand, the bronchial epithelial cells displayed a con-
stitutive expression of CCR4, indicating that they are major 
targets for TARC/CCL17 and MDC/CCL21 in cigarette 
smoke-induced inflammation. Interestingly, CCR4 is not the 
only chemokine receptor that is expressed on lung residential 
cells. The function of those receptors is still poorly under-
stood, but it is easily speculated that they are involved in 
several functions of the epithelium, including cell migration, 
activation, proliferation and apoptosis. 
 A clinical trial with an anti-CCR4 monoclonal antibody 
is currently being conducted in patients with CCR4+ T-cell 
leukemia/lymphoma [42]. 
CCR5 
 CCR5 is a receptor for MIP-1/CCL3, MIP-1/CCL4 
and RANTES/CCL5, and is expressed on granulocytes, 
macrophages, immature dendritic cells, CD8+ T-lymphocytes 
and memory CD4+ T-lymphocytes [43;44]. CCR5 is known 
to influence the recruitment of monocytes/macrophages, 
dendritic cells and T-lymphocytes [44], and also acts as a co-
receptor for HIV [45]. In bronchial biopsies from COPD 
patients with mild to moderate disease, increased levels of 
CCR5+ T-lymphocytes have been reported [46], and Gru-
melli et al. associated high percentages of CCR5-expressing 
T-lymphocytes with loss of lung function and pulmonary 
emphysema [47]. Moreover, the CCR5 ligands MIP-
1/CCL3, MIP-1/CCL4 and RANTES/CCL5 are all sig-
nificantly elevated in the lungs of COPD patients [14;15;19]. 
These data suggest a prominent role of CCR5 in the patho-
genesis of COPD, a hypothesis that has been supported by 
experiments with CCR5 deficient mice. In wild type mice, 
exposure to cigarette smoke induces increased protein levels 
of CCR5 chemokine ligands in the BAL fluid, leading to 
pulmonary inflammation and development of emphysema 
[48]. In CCR5 deficient mice, the accumulation of macro-
phages, dendritic cells, T-lymphocytes and neutrophils is 
significantly attenuated. As a consequence, these mice seem 
to be partially protected against the development of pulmo-
nary emphysema [48] [Bracke et al., unpublished data], 
probably because lower numbers of inflammatory cells re-
sults in less release of proteolytic enzymes like MMP-12. 
Moreover, the cigarette smoke-induced increase of MIP- 
 
1/CCL3, MIP-1/CCL4 and RANTES/CCL5 is impaired in 
CCR5 deficient mice, suggesting the ability of CCR5 to con-
tribute to the autoinduction of its own ligands [48]. Indeed, 
these experimental data in a murine model of COPD suggest 
that the CCR5 driven accumulation of inflammatory cells 
leads to an enhanced release of inflammatory mediators like 
TNF- or IFN-, who in their turn stimulate the additional 
release of CCR5 ligands. This suggests a positive feedback 
loop that can sustain the inflammatory response to cigarette 
smoke (Fig. 1). 
 There are a lot of data that make CCR5 an ideal drug 
target, not only for COPD but also for asthma or HIV. How-
ever, recent publications describe antimicrobial functions for 
CCR5 [49;50]. This would make blocking of the CCR5 re-
ceptor a double-edged sword, as it could at the same time 
benefit and harm treated persons. Nevertheless, several 
CCR5 antagonists are in late stage clinical trials for treat-
ment of HIV (http://clinicaltrials. gov). 
CCR6 
 CCR6 has, unlike most of its family members, only one 
chemokine ligand, namely macrophage inflammatory pro-
tein-3 (MIP-3/CCL20). However, certain members of the 
-defensin family also bind CCR6, but with a lower affinity 
[51]. This receptor is expressed on immature DCs [52], B-
lymphocytes [53], memory T-lymphocytes [54], cytokine 
activated neutrophils [55] and endothelial cells [56]. The 
interaction of CCR6 with MIP-3/CCL20 is described as 
one of the most potent mechanisms for recruitment of imma-
ture dendritic cells [57;58] and is also known to be chemo-
tactic for T-lymphocytes [59], making CCR6 another possi-
ble player in the inflammatory process of COPD. Its 
chemokine ligand MIP-3/CCL20 is expressed predomi-
nantly in inflamed epithelial surfaces, including the airway 
epithelium, and can be upregulated by a broad spectrum of 
pro-inflammatory cytokines that are released in the ongoing 
process of COPD [60]. Our group has recently shown that 
MIP-3/CCL20 is increased in the airways of patients with 
COPD and that pulmonary dendritic cells express its receptor 
CCR6 [Demedts et al., unpublished data]. We also showed 
that the numbers of dendritic cells in the lungs of these 
COPD patients increase along with disease severity. These 
findings are supported by observations we made in CCR6 
deficient mice. Upon cigarette smoke-exposure these knock-
out mice show an attenuated inflammatory response with 
significantly reduced accumulation of the CCR6 expressing 
dendritic cells, T-lymphocytes and neutrophils [61]. This 
impaired inflammatory response significantly protects the 
mice against the development of pulmonary emphysema. 
Moreover, CCR6 seems to regulate the production of its own 
ligand by a feedback loop that is comparable to the one in 
the CCR5 pathway (Fig. 1). Indeed, the impaired pulmonary 
inflammation in CCR6 deficient mice can lead to a reduced 
release of inflammatory mediators like TNF- or IFN-, 
thereby hampering the activation of airway epithelial cells to 
release MIP-3/CCL20. Interestingly, while cigarette smoke 
induces a strong upregulation of MCP-1/CCL2 in wild type 
mice, we found this to be almost complete abolished in 
CCR6 deficient mice. This could well be another down-
stream effect of the CCR6 deficiency. 
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CCR7 
 The chemokine receptor CCR7 is essential for trafficking 
of T-lymphocytes, B-lymphocytes and dendritic cells across 
high endothelial venules and for their correct positioning in 
T-cell zones of secondary lymphoid tissues [62]. MIP-
3/CCL19 and secondary lymphoid tissue chemokine 
(SLC/CCL21) are the only chemokines that bind to CCR7 
and induce chemotaxis of CCR7-positive cells. There are 
currently no data that suggest a possible role of CCR7 in the 
pathogenesis of COPD. 
CCR8-11 
 The chemokine receptors CCR8 through CCR11 have not 
yet been implicated in the pathogenesis of COPD. 
CONCLUDING REMARKS 
 Interfering with the recruitment of inflammatory cells is 
an appealing strategy for the development of new drugs that 
could ultimately lead to better treatment of COPD. 
Chemokine receptors are therefore interesting targets, as they 
play an important role in the inflammatory process of COPD. 
Chemokine receptor antagonists could be particularly prom- 
ising, because of their specific actions. Indeed, regardless of 
the redundancy in receptor-ligand binding, the expression 
pattern of the chemokine receptors defines the selectivity of 
which cells are recruited to certain sites of inflammation. 
Moreover, these transmembrane G-protein coupled receptors 
make good targets for the development of low-molecular 
weight antagonists or blocking antibodies. 
 Despite these advantages, is has to be taken in account 
that blocking of chemokine receptors will inevitably inter-
rupt specific functions of the immune system, making this 
kind of treatment at the same time possible beneficial and 
harmful for the patient. Moreover, the inflammation in 
COPD is most certainly not regulated by a single chemokine 
receptor. Therefore it would be necessary to inhibit multiple 
receptors in order to obtain therapeutic effects. 
 Several chemokine receptor antagonist are currently un-
der development and have great potential to provide novel 
treatment for COPD. However, there is still need of better 
understanding the pathogenic mechanisms that drive the in-
flammation in this disease. The use of chemokine receptor-
deficient mice in a cigarette smoke model of COPD could be 
a good tool to unravel these processes.  
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 Chapter 6. General discussion and future prospects 
 
Alveolar destruction in COPD is believed 
to originate mainly from an imbalance 
between proteases and antiproteases. Our 
studies have shown a strong increase in 
MMP-12 levels in the lungs of CS-exposed 
mice. Taken together with the fact that 
MMP-12 deficient mice are protected from 
the development of CS-induced pulmonary 
emphysema, these findings clearly 
establish the involvement of MMP-12 in 
alveolar destruction. Interestingly, where it 
was long thought that the effects of MMP-
12 were specific for mice (with MMP-9 
being the major protease in humans), 
there have recently been several 
publications demonstrating an increase in 
MMP-12 in human COPD patients2-4. This 
further underscores the importance of 
MMP-12 in the development of 
emphysema. MMP-12 can directly destroy 
the connective tissue of the lung by 
degrading elastin, the major constituent of 
the alveolar wall. However, it can also 
stimulate neutrophil recruitment by 
activating membrane-bound pro-TNF on 
macrophages, thereby enhancing matrix 
breakdown by neutrophil-derived 
proteases5. Furthermore, we have 
demonstrated that MMP-12 (or 
macrophage metalloelastase) is not only 
produced by macrophages, but also by 
dendritic cells. Although the relative 
numbers of macrophages are higher than 
those of dendritic cells, this observation 
could be of particular importance, since 
dendritic cells are migratory cells6;7. During 
their constant recruitment from the 
circulation into the lungs and their 
emigration towards thoracic lymph nodes, 
dendritic cells could harm the surrounding 
tissue and degrade cross-linked elastin 
networks by releasing MMP-12, thereby 
contributing to the development of 
pulmonary emphysema. While MMP-12 
definitely plays a role, it is most certainly 
not the only protease involved in alveolar 
destruction of COPD lungs. A wide variety 
of proteases, ranging from neutrophil 
elastase over cathepsins to MMPs, have 
been linked in one way or another to 
COPD, making emphysematous lung 
destruction most likely a combined action 
of several proteolytic enzymes. Moreover, 
they have the ability to augment each 
other’s destructive capacity, with for 
example MMPs degrading α1-AT and 
neutrophil elastase degrading TIMPs. 
Pathogen recognition receptors (PRRs) 
may play a role in initiating or even 
maintaining the inflammation in COPD. 
Toll-like receptor (TLR) 4 is a PRR that 
recognizes lipopolysaccharide (LPS), 
which is component of CS and of the cell 
wall of gram negative bacteria (which 
colonise the lower airways of patients with 
severe COPD). We clearly demonstrated 
that a TLR4 defect significantly affects the 
pulmonary response towards sub acute 
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 CS-exposure. Several TLR4 dependent 
mechanisms are likely to be involved in 
the CS-induced pulmonary inflammation. 
CS could directly – throught LPS – or 
indirectly – through released heat shock 
proteins, β-defensins or matrix breakdown 
products – activate TLR4 signalling on 
epithelial cells, macrophages and dendritic 
cells. This can result in production of 
proinflammatory cytokines and 
chemokines that attract inflammatory cells. 
Whether this TLR4 signalling is dependent 
or independent of MyD88 – an important 
molecule in the TLR4 cascade – could be 
determined by using MyD88-deficient mice 
in the CS-driven mouse model. 
Importantly, the effects of the TLR4 defect 
on inflammation became less pronounced 
in the chronic experiment. This could 
suggest downregulation of TLR4 signalling 
or even a tolerance mechanism upon 
chronic CS-exposure. Indeed, is seems 
possible that the repetitive exposure to 
LPS in CS leads to endotoxin tolerance.  
In an attempt to gain some more insight 
into the involvement of chemokine 
receptors in the mechanisms that lead to 
COPD, we studied both CCR5 and CCR6 
deficient mice in our CS-driven COPD 
model. A deletion of either of these 
chemokine receptors leads to a significant 
attenuation of the inflammatory response 
to CS. Indeed, compared to wild type 
animals there is an impaired increase of 
inflammatory cells that normally express 
these chemokine receptors. Interestingly, 
when comparing CS-exposed CCR5 or 
CCR6 knock-out to wild type mice we 
observed lower levels of their respective 
chemokines, suggesting the ability of 
these receptors to contribute to the 
production of their own ligands. This 
mechanism likely operates via a positive 
feedback loop, where the chemokine 
receptor mediated accumulation of 
inflammatory cells leads to an enhanced 
release of inflammatory mediators like 
TNF-α or IFN-γ, who in their turn stimulate 
the additional release of chemokines. 
The reduced inflammatory reaction in CS-
exposed CCR5 and CCR6 deficient mice 
leads to a partial but significant protection 
against the development of pulmonary 
emphysema. The most logical explanation 
would be that lower numbers of 
inflammatory cells, which excessively 
release proteases, results in lower levels 
of these proteases, skewing the 
protease/antiprotease balance in favour of 
antiproteolytic activity. Indeed, we 
observed a significantly impaired 
expression of MMP-12 in CS-exposed 
CCR6 deficient mice.  
In contrast to the clear influence of CCR5 
or CCR6 deficiency on pulmonary 
inflammation and airspace enlargement, it 
had no effect on airway wall remodeling, 
another hallmark of COPD. We observed 
an increase in airway wall thickness and 
peribronchial deposition of collagen and 
fibronectin, that was equal in both CS-
exposed wild type and chemokine receptor 
knockout mice. This suggests that airway 
wall remodeling is not a single 
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 downstream effect of the ongoing 
inflammation, but might rather occur 
through independent mechanisms, a 
theory that has also been proposed for 
remodeling in asthma8;9. In the CCR5 
study we provided a mechanistic 
explanation for the observed remodeling 
by demonstrating an equal increase in the 
growth factor TGF-β in both CS-exposed 
wild type and CCR5 deficient mice. It has 
been described that TGF-β can drive CS-
induced airway wall remodeling10 and a 
recent paper by Churg and colleagues 
confirms the ability of CS to directly induce 
the release of growth factors like TGF-β, 
independently of the pulmonary 
inflammation11. 
Of particular interest, we have recently 
been able to translate the possible 
involvement of CCR6 in COPD 
pathogenesis to the human situation, 
where we demonstrated increased levels 
of the CCR6 chemokine MIP3α/CCL20 in 
both sputum and lung tissue of patients 
with COPD, compared to ‘healthy’ 
smokers and non-smokers (Demedts IK, 
Bracke KR et al, in press12). Moreover, we 
observed CCR6 expression on pulmonary 
dendritic cells and found their numbers in 
the small airways of COPD patients 
increasing along with disease severity. 
In conclusion, by demonstrating that the 
recruitment of inflammatory cells in CS-
exposed mice is largely mediated by 
chemokine receptors CCR5 and CCR6, 
we have added a few pieces to the puzzle 
that will ultimately reveal the mechanisms 
that lead to the pathology of COPD. This 
of course makes these receptors 
interesting targets for new therapies 
against COPD. Chemokine receptor 
antagonists could be particularly 
promising, because of their specific 
actions. Indeed, although there is 
substantial redundancy in receptor-ligand 
binding, the expression pattern of the 
chemokine receptors defines the 
selectivity of which cells are recruited to 
certain sites of inflammation. However, it 
has to be taken in account that blocking of 
chemokine receptors will inevitably 
interrupt specific functions of the immune 
system, making this kind of treatment at 
the same time possible beneficial and 
harmful for the patient. Interestingly, some 
chemokine receptors can also function as 
PRRs, since CCR5 operates as a receptor 
for mycobacterial heat shock protein 
(HSP)7013 and CCR6 has an affinity for β-
defensins14. Studying the expression 
levels of these PAMPs in COPD could 
help to unravel the importance of this 
overlap between chemokine receptors and 
PRRs. Also, the use of HSP70-deficient 
mice in the murine COPD model could be 
of interest. 
The inflammation in COPD is clearly not 
regulated by a single chemokine receptor. 
Therefore it would be necessary to inhibit 
multiple receptors in order to obtain 
therapeutic effects. The same is true if we 
would want to aim therapy at inhibiting 
proteases. Indeed, while we have shown 
in our murine model of COPD that 
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 exposure to CS leads to highly elevated 
levels of MMP-12, the alveolar destruction 
in COPD is most likely the result of a 
combined action of several proteases. And 
again, as with the chemokine receptors, 
inhibiting a protease like MMP-12 needs to 
raise the question why such a destructive 
enzyme is produced in the first place. It 
seems likely that MMP-12 is a double-
edged sword, contributing to tissue 
destruction in a disease as COPD, but at 
the same time playing a role in host 
defence by killing bacteria and inhibiting 
tumour progression. Nevertheless, several 
protease inhibitors have been developed 
and used in clinical trials. Recently, it has 
been described that a dual MMP-9/MMP-
12 inhibitor prevents smoke-induced 
emphysema in guinea pigs15. 
As a general conclusion, it is fair to say 
that despite these and numerous other 
studies in the field of COPD, there is still 
need of better understanding the cellular 
and molecular mechanisms that drive the 
inflammation, alveolar destruction and 
airway wall remodeling in this higly 
prevalent disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic overview of our work: 1) Cigarette smoke induces an exaggerated release of chemokines 
(predominantly by airway epithelium, macrophages, lymphocytes and dendritic cells) 2) The resulting gradient of 
chemokines is chemotactic for a variety of inflammatory cells by interacting with their corresponding chemokine 
receptors. 3) This recruitment leads to an accumulation of inflammatory cells, which subsequently release 
inflammatory mediators like INF-γ or TNF-α. These are in turn capable of stimulating epithelial cells or 
macrophages to an additional release of chemokines, thereby establishing a positive feedback mechanism that 
can perpetuate the inflammation in COPD. 4) Enhanced release of proteases like MMP-12 or neutrophil elastase 
(NE) by inflammatory cells may lead to an imbalance between proteolytic and antiproteolytic activity, contributing 
to the development of pulmonary emphysema. 5) Toll-like receptor (TLR) 4 signalling can be triggered by LPS, 
which is present in cigarette smoke. This can initiate or perpetuate the pulmonary inflammation in COPD 6) 
Cigarette smoke can directly induce release of TGF-β, which can lead to airway wall remodelling, independent of 
the pulmonary inflammation. 
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